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 i 
Zusammenfassung 
Ein Schlüsselprozess in der Immunantwort ist die durch das proinflammatorische 
Zytokin Interferon-??induzierte?transiente Akkumulation von neu synthetisierten 
defekten Proteinen, die durch Anknüpfen von Polymeren des Proteins Ubiquitin 
post-translational modifiziert werden. Die Ubiquitinierung ist Schlüsselsignal für 
den Abbau dieser Proteine. Die Abbauprodukte dienen unter anderem als Quelle 
für die Prozessierung von Antigenen. Um die frühe Immunantwort besser zu 
verstehen, wurden im Rahmen dieser Arbeit die Identität und Charakteristika 
dieser neu synthetisierten Proteine, sowie die Topologie ihrer post-translationalen 
Modifizierung durch Ubiquitin untersucht.
Dazu wurde die massenspektrometrischen Analyse ubiquitinierter Proteine 
weiterentwickelt, indem die experimentellen Konditionen auf deren Analyse 
optimiert wurden. Insbesondere konnte gezeigt werden, dass die kombinierte 
Verdauung der Ubiquitin-Konjugate mittels zweier Peptidasen die Identifizierung 
der Proteinpeptide und der Indikatorpeptide für Ubiquitinierungsstellen 
entscheidend verbessert. Es wurde demonstriert, dass eine selektive 
Isotopenmarkierung der neu synthetisierten Proteine möglich ist. Mit Hilfe dieser 
Methode gelang es, Veränderungen der Ubiquitin Modifikationen bezüglich der 
Topologie sowie quantitative Unterschiede der ubiquitinierten Proteine aus 
humanen HeLa-Zellen in An- und Abwesenheit von Interferon-? zu identifizieren. 
Nach Induktion durch Interferon-? wurden drei polyubiquitinierte, drei mono- 
oder polyubiquitinierte und 111 potentiell ubiquitinierte Proteine identifiziert. 
Diese Proteine zeigten, dass keine generelle Ubiquitinierungspräferenz für die 
durch Interferon-? verstärkt transkribierten Gene besteht. Die Ergebnisse dieser 
Arbeit erweitern das Verständnis der frühen zellulären Immunantwort und tragen 
zum Verständnis von Krebs- und Autoimmunerkrankungen sowie chronischen 
Entzündungsprozessen bei. Möglicherweise bilden sie die Grundlage für die 
Weiterentwicklung entsprechender Therapien. 
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Abstract
A key process within the immune response of organisms is the transient 
accumulation of newly synthesized defective proteins affected by the 
proinflammatory cytokine interferon-?. These proteins are post-translationally 
modified by attachment of polymers of the protein ubiquitin, which represents the 
key signal for targeting them to degradation. The resulting peptides can serve as 
sources for antigen processing. In order to get an insight into the details of the 
cellular early immune response, the identity and characteristics of the newly 
synthesized proteins and the topology of their post-translational modification with 
ubiquitin were investigated. An essential progress of the mass spectrometric 
approach was achieved by optimizing the experimental conditions with regard to 
the requirements of the analysis of the targeted proteins. In particular, it could be 
shown that a combined digestion of ubiquitin conjugates with two peptidases 
leads to an improved detection of protein peptides and also the indicator peptides 
for ubiquitination sites. Further, it was shown that a selective isotopic labeling of 
the newly synthesized proteins was possible. With the help of this method, a 
decisive step forward was made in the understanding of changes of the ubiquitin 
modifications with respect to the topology and in clarifying the quantitative 
differences between ubiquitin conjugates from interferon-? treated and untreated 
human HeLa cells. Three interferon-??induced polyubiquitinated proteins, three 
mono- or poly ubiquitinated as well as 111 potential ubiquitin substrates could be 
identified. These proteins did not show any general ubiquitination preference for 
genes whose transcription is enhanced in presence of interferon-?. The results 
obtained in this work help to broaden and refine the general picture of the early 
cellular immune response. They contribute to the knowledge on molecular 
processes of cancer, autoimmune diseases or chronic inflammation and, 
potentially, can give hints for the continued development of corresponding 
therapies. 
 iv 
 
 
 
 
 
 
 
CHAPTER 1   
 
 
1 Introduction 
The vitality of cells is fundamentally based on the balance of metabolism which 
basically consists of the steady state of a huge number of coupled chemical 
reactions. One example for a process coupled to various biochemical pathways is 
the degradation of proteins. There are two distinct mechanisms of proteolysis in 
eucaryotes namely one via the lysosomes and another one via the adenosine 
triphosphate (ATP) dependent ubiquitin proteasome system (UPS).  
In 2004, the discovery of the controlled ubiquitin-mediated protein degradation 
via the UPS by Aron Ciechanover, Avram Hershko and Irwin Rose was awarded 
with the Nobel Prize in Chemistry (Giles 2004). For this controlled proteolysis, a 
target protein is modified by the successive covalent attachment of the small 
protein ubiquitin (Ub). The process is also termed ubiquitination. Thus, the 
corresponding molecular modification of an ubiquitinated protein serves, beside 
others, as a signal to start its proteolysis via the 26S proteasome, a multi subunit 
protease complex (Giles 2004).  
The 26S proteasome plays a regulatory role in the degradation of short lived 
proteins. In case of resource shortage, it can enhance the supply of energy or 
amino acids and thereby prevent apoptosis. The proteasome protects the cells 
from accumulation of toxic amounts of non-functional proteins by degrading, for 
instance, newly synthesized but non-functional, defective proteins (also called 
defective ribosomal products = DRiPs) (Goldberg 2007; Jung et al. 2008). DRiPs 
are ubiquitous in cells as a consequence of the imperfection of protein synthesis 
and folding resulting in premature terminated or misfolded polypeptides. A large 
fraction (upwards 30%) of proteins are degraded in this way shortly after their 
synthesis (Qian et al. 2006). The amount of DRiPs in the cell can be elevated in 
the case of enhanced protein synthesis. The corresponding increased amount of 
newly synthesized proteins and an accompanying lack of tRNA increases the 
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amount of premature polypeptide termination (Yewdell 2005). In addition, 
oxidative stress increases the amount of DRiPs probably as a result of oxidative 
damage caused by reactive oxygen species (ROS) (Szeto et al. 2006; Seifert et al. 
2010). 
The degradation of DRiPs is closely connected to the immune response as it 
produces precursor peptides for antigen processing. DRiPs are suggested as the 
main source for antigen processing. They guarantee that the cellular immune 
system has early access to viral proteins to minimize the malignant consequences 
of viruses (Yewdell 2005). The released precursor peptides are trimmed by 
cytosolic or endoplasmatic reticulum (ER) peptidases, and they are loaded inside 
the ER lumen onto class one major histocompatibility complexes (MHC class I). 
Finally they are transported to the cell surface where the antigens are presented to 
cytotoxic T-lymphocytes. These cytotoxic T-lymphocytes can distinguish between 
own and foreign antigens and, in case of recognizing the latter, they emit a signal 
for apoptosis (Reits et al. 2000).  
Resulting from the involvement of the proteasome into multiple processes, there 
are numerous malignant diseases which are influenced or caused by its 
dysfunctions, ranging from autoimmune diseases, viral infections, cancer, chronic 
inflammation, muscle degradation to neurodegenerative diseases (Wang et al. 
2006; Dahlmann 2007). Some pharmaceutical therapies of these diseases are 
based on drugs targeting the ubiquitin proteasome system (Armand et al. 2007). 
Besides these diseases, there is also a malignant change in proteasomal function of 
aging cells (Stolzing et al. 2001). 
In this study, the focus lies on the molecular changes in human cells with respect 
to the ubiquitin proteasome system during the early immune response. A 
particular emphasis is devoted to the influence of the proinflammatory cytokine 
interferon-? (IFN?) on the composition of ubiquitinated newly synthesized, 
defective ribosomal products. First, an introduction to the general mechanism of 
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UPS will be given, starting with the definition and function of ubiquitin and 
followed by the ubiquitination process as well as the proteasome complex.  
1.1 Ubiquitination  
1.1.1 Ubiquitin 
Ubiquitin (Ub), a small protein of 76 amino acids with a molecular weight of 
8.6 kDa, serves as a post-translational modificator (PTM). Sequence and structure 
are highly conserved with respect to phylogenetics (Vrana et al. 1996). In 
addition, one can find numerous structurally homologous proteins, called 
ubiquitin-like modifiers and proteins with ubiquitin-like (UbL) domains in 
mammalian cells. A few known ubiquitin-like modifiers also serve as post-
translational modificators, while the ubiquitin-like domains are mostly found in 
ubiquitin adaptor proteins of the ubiquitin proteasome system (described below cf. 
1.3.1). 
Ubiquitin is encoded in four genes and expressed in a precursor form either as a 
monomer with the C-terminus fused to a ribosomal subunit (L40 or S27a) or as a 
linear “head-to-tail” connected polymer with an extension by one amino acid at 
the C-terminus (Baker et al. 1987; Ozkaynak et al. 1987). The precursor fusion 
proteins are activated through C-terminal cleavage by ubiquitin carboxy 
hydrolases (UCHs). This activation results in the liberation of a free C-terminal 
carboxy group which is required for attachment of Ub to a substrate via an 
isopeptide bond (Reyes-Turcu et al. 2009). The formation of this covalent linkage 
occurs for example between an ?-amino-group of a substrate and the C-terminal 
carboxy group of ubiquitin. The reaction is catalyzed by three enzymes in a three 
step ubiquitination reaction (see Figure 1, details in chapter 1.1.2) that takes place 
either in the cytosol or at the endoplasmatic reticulum (ER) membrane, as part of 
the ER associated degradation (cf. chapter 1.1.3, page 8).  
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Figure 1 General mechanism of ubiquitination (also valid for most ubiquitin-like modifiers 
(Hochstrasser 2009)): (I) Ubiquitin is activated by nucleophilic attack of the thiol group of a 
cysteine in the active center of a Ub activating enzyme (E1) accompanied by energy consumption 
from ATP. (II) The activated Ub is transferred to a thiol group of an Ub conjugating enzyme (E2) 
that carries the Ub to an ubiquitin ligation enzyme (E3). (III) The E3 enzyme transfers the 
activated Ub to the substrate. The opponent reaction is the deubiquitination (grey) in which 
deubiquitinases (DUBs) cleave the covalent bond between Ub and its substrate. (Figure adapted 
from (Pickart 2001)).  
 
As Ub itself contains seven lysines (K6, K11, K27, K29, K33, K48, K63), it can 
also be a target for ubiquitination, which leads to the formation of distinct polyUb 
chains connected through isopeptide bonds. Next to the ?-amino-groups, which 
are the conventional Ub-sites (Meierhofer et al. 2008), N-terminal ?-amino-groups 
can be ubiquitinated, too (Bloom et al. 2003). Today it is known that serines, 
threonines and cysteines can form ester or thioester bonds with Ub as well (Tait et 
al. 2007; Ishikura et al. 2010). 
1.1.2 Process of ubiquitination 
In the process of ubiquitination, Ub is first activated (cf. (I) in Figure 1) by an 
ubiquitin activating enzyme, also called E1. This activation requires the acyl-
adenylation of the C-terminus of Ub by adenosine triphosphate (ATP), before it is 
nucleophilically attacked by the cysteines thiol group at the active side of the E1. 
After formation of a thioester bond, the E1 enzyme can adenylate a further Ub. 
Accordingly, it can be loaded asymmetrically with two distinct Ub units at the 
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same time. The human genome encodes two ubiquitin activating enzymes (Haas 
et al. 1982; Ye et al. 2009). 
The activation is followed by the transesterification of the Ub to a thiol group of a 
so called ubiquitin conjugating enzyme or E2 (Figure 1 (II)). This E2 catalyzes a 
more specific reaction by regulating the synthesis of Ub chain linkage specificity 
and the specificity for several E3 enzymes (that catalyze the last step in 
ubiquitination and are described in the following section). In fact, 35 E2 enzymes 
could be identified until today (van Wijk et al. 2010).  
The last reaction step in the ubiquitination cascade is catalyzed by a representative 
of the large heterogeneous family of E3 enzymes which are named ubiquitin 
ligases. These serve as the linker between E2 and the ubiquitination target protein 
transferring the activated Ub from the carrier E2 to the ubiquitination site of the 
substrate (cf. (III) in Figure 1). In fact, hundreds of E3 enzymes are known, each 
of which possessing a particular substrate specificity. The members of the E3 
family are categorized in three classes according to the structure of their catalytic 
domains and to their reaction mechanism (Ardley et al. 2005).  
The first class is called HECT domain E3 ligases. HECT stands for homologous 
to E6-AP (an E3 ligase called E6 associated protein) carboxyl terminus. The 
working mechanism of these HECT E3 enzymes (as schematically presented in 
Figure 2 (A.1) on page 6) is the formation of an intermediary thioester between a 
conserved cysteine in the HECT domain and Ub. This ester reacts then, for 
instance, with a free ?-amino-group of a substrate lysine to build up an isopeptide 
bond (Huibregtse et al. 1995). 
The second and most abundant class of E3 ligases is called RING domain E3 lig-
ases. RING domain stands for “Really Interesting New Gene” domain, and de-
notes a specific zink finger motif. In contrast to the HECT E3-ligases, the RING 
class members do not form intermediary thioesters with Ub, but rather catalyze 
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the direct transfer of Ub from E2 conjugating enzyme to the substrate, thereby 
serving as a scaffold (schematically presented in Figure 2 (A.2)). 
Two mechanisms of Ub chain formation have been described (Figure 2 (B.1) & 
(B.2)) (Komander 2009). One of them concerns the sequential assembly of the Ub 
chains at the substrate, the second the preassembly of Ub chains at an E2 enzyme 
followed by its transfer to the substrate (Deshaies et al. 2009). Furthermore, RING 
ligases can either be cytosolic or membrane associated (as described below 1.1.3). 
Furthermore, they can act either as a complex with only one E2 or as a multi 
subunit complex (cf. Figure 2 (A.3)) (Deshaies 1999). 
 
Figure 2 E3 ligase reaction principles: Working principle of distinct E3 classes (on the left 
side)-- HECT E3 ligases (A.1) first build a thioester intermediate between ubiquitin and its 
cysteine in the active centre, RING and U-box E3 ligases (A.2) as well as the large E3 ligase 
complexes, one representative in (A.3), catalyze the direct transfer of the ubiquitin moiety to the 
substrate and, in this way, serve as a scaffold; Hypotheses about the catalyzation of Ub chain 
formation by E3 RING ligase (on the right side)-- (B.1): the sequential Ub chain formation is 
illustrated; first, transformation occurs of an ubiquitin from an E2 enzyme to the substrate, then, a 
second E2 substrate transfers its Ub unit to the substrate bound Ub; on the right of (B.2): 
preassembly of Ub-chains at the E2 enzyme: one E2 enzyme transfers its Ub to the Ub of another 
E2 resulting in the assembly of a Ub chain which is then transferred to the substrate (figure 
adapted from (Pickart 2001)).  
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Besides the HECT and RING ligases, there is a third class among the E3 ligases, 
the U-box family. Like the RING ligases, the structurally similar U-box proteins 
act as scaffold without forming a thioester intermediate (as illustrated in Figure 2 
(A.2) on page 6) (Ardley et al. 2005). The globular structure of the U-box E3 
ligases is due to electrostatic interactions in contrast to the RING proteins, in 
which it is formed due to metal chelation (Ohi et al. 2003).  
It has been shown that, in some cases, E3 ligases are not required for 
monoubiquitination or for the formation of polyUb (Hoeller et al. 2007). In 
contrast, it has also been reported that sometimes, a fourth enzyme, called E4, is 
required as a conjugation factor for multiUb chain assembly (Koegl et al. 1999). 
The Ub substrate recognition is carried out through specific sequence motifs 
(Wilkinson 2000). One of these recognition motifs can be a sequence rich in 
proline, glutamine, serine and threonine (shortly PEST) serving as a 
phosphorylation site that can enhance or inhibit ubiquitination of mostly short-
lived proteins (Marchal et al. 2000). A second ubiquitination signal underlies the 
mechanism of the so called N-end rule and is based on destabilizing amino acids 
like arginine, lysine, phenylalanine or tryptophan at the N-terminus of proteins. 
Up to now, a few further substrate specific amino acid sequences have been 
confirmed as ubiquitination signals. Additionally, hydrophobic areas at the surface 
of proteins, indicating a misfolding or dissociation of functional protein 
complexes or a membrane-protein interaction can also initiate ubiquitination 
(Wilkinson 2000).  
Also ubiquitin-like modifiers, such as SUMO, NEDD8, and ISG15, have their 
specific recognition sequences. The mechanism of modification, in general, 
consists of the same enzymatic three step reactions as for ubiquitin, but is termed 
sumoylation, neddylation or ISGylation (Schwartz et al. 2003).  
8  1  Introduction 
 
Ubiquitination either takes place in the cytosol or as part of the endoplasmatic 
reticulum associated degradation (ERAD) at the ER membrane as it is described 
in the following section. 
1.1.3 Endoplasmatic reticulum associated degradation system 
The endoplasmatic reticulum associated degradation (ERAD) system (illustrated 
in Figure 3) is a quality control system for newly synthesized proteins. These 
proteins are destined for the endomembrane system, for the plasma membrane or 
for secretion. The newly synthesized amino acid chains targeted for the 
endoplasmatic reticulum (ER) carry the N-terminal signal sequence for their co-
translationally transfer into the ER lumen (Rapoport et al. 1996). Inside the ER 
lumen, the amino acid chains are folded and N-glycosylated by a complex system 
of chaperones in order to reach their functionality (Helenius et al. 2004).  
The functional proteins are then transported to their final destination. But besides 
these functional proteins, there is always a fraction of non-functional proteins. 
This defective proteins result from misfolding, incorrect N-glycosylation or amino 
acid chain disruption during synthesis. To prevent an accumulation of toxic 
amounts of the non-functional proteins and for recovering amino acids and 
energy, they need to be degraded.  
The defective proteins targeted for degradation have to be retro-translocated from 
the ER lumen into the cytosol in order to be ubiquitinated and processed by the 
proteasome. The exact mechanism of retro-translocation is still unknown; perhaps, 
members of a multi protein complex are involved based on a multispanning 
membrane protein called Derlin (Lilley et al. 2005). Derlin assembles with a 
membrane associated E3 RING ligase and a E2 enzyme (Lilley et al. 2005) on the 
cytosolic side of the ER membrane to enable the ubiquitination of the defective 
proteins. The AAA+-ATPase p97, also associated with this complex, might 
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transfer the ubiquitinated proteins directly or via shuttling proteins to the 
proteasome for their proteolysis (Ikeda et al. 2009; Lim et al. 2009). 
 
 
Figure 3 Endoplasmatic reticulum associated protein degradation (ERAD) system. New 
translated amino acid chains carrying a signal sequence are translocated from the cytosol to the ER 
lumen via the membrane protein Sec61. The proteins are folded and, then, N-glycosylated to reach 
functionality. Functional proteins are transported to their final destination, whereas misfolded, 
incorrect deglycosylated or shortened proteins are controlled via chaperones and lectins and either 
refolded or targeted for their proteasomal degradation. Last, the non-functional proteins are retro-
translocated into the cytosol. At the ER membrane, they are ubiquitinated through RING E3 
ligases which associate with a membrane protein called Derlin in presence of an E2 enzyme and an 
AAA+ ATPase complex called p97 and its cofactors. The ubiquitinated ER product is then 
transferred to the 26S proteasome which subsequently degrades the defective protein.  
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Figure 4 Functions of ubiquitin linkages. Metabolic processes targeted by the ubiquitination at 
the respective ?- and ?-amino groups (Komander 2009).  
 
1.1.4 Ubiquitin chains and functions 
The topology of the ubiquitin chains is connected to the different functions (see 
Figure 4) of ubiquitination in eukaryotic cells besides proteasomal degradation. It 
can be differentiated by the chain length, by the linkage type which is specified by 
the position of the lysine/ methionine of Ub carrying the isopeptide/ peptide bond 
to another Ub (M1, K6, K11, K27, K29, K33, K48 or K63), as well as by the 
homogeneity and heterogeneity of the linkage types (Komander 2009). 
It is known that monoUb is involved in virus budding, histone regulation and 
DNA repair. MultimonoUb is involved in endocytosis, but also in regulation of 
polyUb-chain recruiting to the 26S proteasome (Komander 2009). Several 
functions of the distinct linkage types have been identified (see Figure 4 on page 
10). It is known that K48-linked chains with a minimum length of four ubiquitins 
represent the general target signal for proteolysis via the 26S proteasome 
(Thrower et al. 2000). Besides K48-linked chains, it was shown that in some cases 
also K63 (Jacobson et al. 2009), as well as all other linkages (in yeast: K6, K11, 
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K27, K29 and K33 linked Ub-chains) could serve as signal for degradation via the 
proteasome (Xu et al. 2009).  
Another process, in which Ub-chains linked through K63 and also K6 are 
involved, is DNA repair (Sobhian et al. 2007). Cell signaling is influenced by 
K63-linked Ub chains (Skaug et al. 2009) or the interplay between K63- and K48-
linked chain synthesis at a substrate, and also by linear “head-to-tail” Ub-chains 
(Tokunaga et al. 2009). Furthermore, K63-linked chains are also involved in 
endocytosis and lysosomal degradation (Duncan et al. 2006). K33- and K29-
linked Ub chains are found as kinase modifications (Al-Hakim et al. 2008). The 
Ub fusion mediated degradation is influenced by K29 or K48 linkage as the first 
step of Ub chain linkage (Johnson et al. 1995). K11 linkages are connected to the 
endoplasmatic reticulum associated degradation (ERAD) pathway and may also 
play a role in cell cycle regulation (Xu et al. 2009).  
The detection of heterogenically linked Ub chains and the determination of their 
function are currently important research topics. However, this also presents a 
challenge due to technical limitations of their analytical proof. Branched Ub 
chains of adjacent lysines have been identified and were found to poorly bind to 
the 26S proteasome. This suggests that they are not targeting proteasomal 
degradation (Kim et al. 2009). Recently, it could be shown that the viral E3 ligase 
K3 synthesizes branched K11-K63 linked Ub-chains at MHC class I cytosolic tail 
to mediate endocytosis (Boname et al. 2010).  
1.2 Process of deubiquitination  
The process of ubiquitination is opposed to that of deubiquitination. 
Deubiquitination is the enzymatic cleavage of the covalent bond between Ub and 
its target or the bond between Ub and a further Ub. One can distinguish two 
reaction mechanisms (Figure 5 (A)). Deubiquitinases (DUBs) can cleave off the 
Ub chain either sequentially with respect to the single Ub units (exo-cleavage) or 
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polymeric Ub subchains or the entire polymeric Ub chain in one step (endo-
cleavage). DUBs can be specific with regard to the Ub chain linkage or/ and the 
substrate (cf. (B) and (C) in Figure 5). The functions of DUBs are widespread, 
reaching from processing of Ub from its precursor, through recycling of Ub, 
regulation of substrate degradation (antagonizing E3 ligases), regulation of 
substrate activity, up to Ub chain editing (removal of prior chain linkages in order 
to favor the synthesis of special Ub-linkages) (Komander et al. 2009). 
Until today, approximately 80 representatives of deubiquitinating enzymes 
(DUBs) are known which are divided into five families. One is for instance the 
family of ubiquitin carboxy hydrolases (UCHs). Its members selectively cleave 
ubiquitinated ?-NH2-groups and are involved in the activation of Ub precursors as 
well as in the cleavage of linear Ub chains. Another one is the family of JAMM 
motif proteases (JAMMs), metalloproteases, of which two representatives are 26S 
proteasomal subunits (Rpn8 & Rpn11) that deubiquitinate proteasomal targets 
(Komander et al. 2009). 
 
 
Figure 5 General specificities of deubiquitinating enzymes (DUBs): (A) cleavage site specific 
deubiquitination at the distal-end of the Ub chain (sequential or exo-cleavage) or at the proximal 
end of the Ub chain (endo-cleavage); (B) linkage specific deubiquitination (monoUb, isopeptide 
(K6, K11, K27, K29, K33, K48 or K63) or peptide (linear chains, M1)); (C) substrate specific 
deubiquitination. (adapted from (Komander et al. 2009)) 
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1.3 The proteasome and degradation of ubiquitinated proteins 
1.3.1 Recruitment of ubiquitinated proteins to the proteasome 
The ubiquitinated proteasomal targets need to be shuttled to the proteasome for 
their degradation. This process is performed via Ub receptors carrying an Ub-like 
domain for the binding to the proteasome. Additional they also contain an 
ubiquitin binding domain (UBD), which is mostly specific for the particular Ub-
chain lengths and linkages, but can also be specific for ubiquitin-like (UbL) 
domains. UBDs can also be found in ubiquitinating and deubiquitinating enzymes. 
There are sixteen conserved UBD motifs, and most of them have ?-helical 
structures. The known proteasomal adaptors or shuttling proteins carry one or 
more ubiquitin binding domains which belong to one of the following classes: Ub 
interacting motif (UIM) domains, ubiquitin associated (UBA) domains or 
pleckstrin homology ubiquitin binding (PRU) domains (Hurley et al. 2006; Su et 
al. 2009).  
The two UBA domains of the proteasome shuttling protein hHR23 bind to K48-
linked ubiquitin chains and not to monoUb (Raasi et al. 2004), while their 
ubiquitin-like domain seems to interact with the 19S proteasomal subunit Rpn1 as 
was shown for its yeast homologe Rad23 (Elsasser et al. 2002). In yeast, Rad23 
was found to be involved in DNA repair and protection against degradation of 
some Ub substrates (Schauber et al. 1998; Hartmann-Petersen et al. 2003). 
The UBA domain of the proteasomal adaptor protein ubiquilin-1 binds to polyUb 
and polyUb proteins and also to the proteasomal subunit Rpn10 via its UbL 
domain (Ko et al. 2004). Its yeast homolog is also able to bind a proteasome that 
lacks Rpn10 (Matiuhin et al. 2008). Ubiquilins stabilize the tumor surpressor 
protein p53, interfere with the degradation of a transcription factor inhibitor called 
I?B? and are involved in the pathology of neurodegenerative disorders like 
Alzheimer’s disease (Kleijnen et al. 2000; Mah et al. 2000). 
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The facultative proteasomal subunit hRpn10 contains two ubiquitin interacting 
motifs (UIMs). UIM2 exhibits a fivefold higher affinity than UIM1 (Young et al. 
1998). Cytosolic free Rpn10 has been shown to interact with E2/ E3 pairs to 
prevent the formation of non-degradable forked Ub chains in yeast (Kim et al. 
2009). 
The second facultative proteasomal subunit that can bind Ub-conjugates is Rpn13. 
Its ubiquitin binding side, a N-terminal conserved PRU domain, was shown to 
have a high affinity for K48-linked ubiquitin chains. Rpn13 was also revealed to 
interact with the 19S regulatory subunit Rpn2 (Schreiner et al. 2008).  
In conclusion, all these four adaptor proteins bind to the 19S regulatory particle 
that forms the so called 26S proteasome together with the proteolytically active 
20S core particle.  
 
1.3.2 Constitutive proteasome 20S core complex 
The 20S core particle is localized in the cytosol and in the nucleus. It hosts the 
proteolytic activities, has a three-dimensional cylindrical “barrel-like” structure 
with a diameter of around 100 Å and a height of 150 Å, showing a C2 symmetry. 
It is composed of 28 subunits that are assembled in a well organized process in 
four stacked heteroheptameric rings (Groll et al. 1997). Each of the inner ?-rings 
contains seven distinct structural similar ?-subunits, of which three possess a 
proteolytically active site. The ?-rings are enclosed by two ?-rings containing 
seven distinct structurally similar??-subunits. The “barrel-like” structural 
composition of the 20S proteasome leads to two cavities at the entrances that have 
to be surmounted by the substrate to get into the interior catalytic chamber of the 
“barrel”. The six active sites of the caspase-like (?1), the trypsin-like (?2) and 
chymotrypsin-like?protease???5) of both ?-rings are located inside the catalytic 
chamber.  
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With this set of distinct proteases, the proteasome is able to cleave peptide bonds 
at the C-terminus of acidic, neutral and hydrophobic amino acids (Tanaka 2009). 
The ?-subunits are not proteolytically active, but have structural functions, for 
instance, in regulating the entrance or “gating” of substrates into the proteolytic 
chamber. In the structure of the free 20S core particle, the N-termini of the ?-
subunits, especially the N-terminus of the ?3 subunit, block the entrance for 
proteins into the 20S interior (Groll et al. 2000). This entrance can be gated by the 
binding of a 19S regulatory particle or by another activator complex (as described 
below).  
 
1.3.3 Proteasomal activators 
1.3.3.1 19S regulatory complex 
The 19S regulatory complex is responsible for the activation of the 20S 
proteasome and for the degradation of ubiquitinated proteins. It mediates together 
with its associated proteins the binding, deubiquitination, unfolding and 
translocation (into the catalytic chamber) of the proteasomal substrates under 
energy consumption (ATP). With respect to this role, it contains associated 
ubiquitin binding proteins, deubiquitinating enzymes, chaperones and ATPases. 
(Kohler et al. 2001). Due to the confusing and multiple nomenclatures which are 
used for 19S subunits in the literature, the yeast nomenclature was employed here, 
although mainly human cells were investigated in this research project.  
The 19S regulatory particle dissociates in vitro in the presence of high 
concentrations of salt into two sub-complexes that are defined as “lid” and “base” 
(Glickman et al. 1998). Each of the two sub-complexes, the “base” of Rpt1-6 and 
Rpn1&2 and the “lid” Rpn3, Rpn5-9, Rpn11&12, consists of eight subunits 
(Ferrell et al. 2000). Additionally, there are facultative subunits (Rpn10 and 
Rpn13) that are not essential for 19S formation. Besides these facultative 19S 
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subunits, a number of further proteins exist with distinct functions, which are 
known to interact with the 19S particle, such as the Ub adaptors (see 1.3.1 on p. 
13), the deubiquitinating enzymes USP14 and UCHL5, Ub ligases like Parkin, 
Hul5 or E6-AP (Finley 2009). 
The eight “lid” components have no ATPase activity (Ferrell et al. 2000). Rpn11 
and Rpn8 are deubiquitinating enzymes (Cooper et al. 2009) while the exact 
function of the others is not yet well understood.  
The “base” consists of two non-ATPase subunits, namely Rpn1 and Rpn2, 
associated with a heterohexameric ring of six distinct AAA+ ATPases (Rpt1-6). 
Rpn1 and Rpn2 are functioning as binding sites for Ub-receptors (see 1.3.1 on 
page 13). The ATPases act as chaperones and are involved in substrate unfolding, 
as well as in its translocation into the catalytic chamber (Braun et al. 1999). 
The 19S regulatory particle is known to assemble on the 20S core particles, but 
the exact details of this process are still unclear (Funakoshi et al. 2009; Hendil et 
al. 2009; Saeki et al. 2009). The C-terminal residues of the ATPases serve as 
anchors through binding to the pockets formed by the outer ?-rings of the 20S 
core particle. Through this interaction, they induce the 20S proteasome “gate 
opening” for the substrate entrance into the catalytic chamber. It occurs by a 
dislocation of the N-termini of the ?-subunits from the entrance of the 20S 
proteasome (see Figure 6 (A1) & (B) on page 17). The C-termini of Rtp2 and 
Rpt5 are known to be essential for the “gate opening” (Kohler et al. 2001; Smith 
et al. 2007). A decisive role in the “base” is taken over by the subunit Rpt5 which 
binds to ubiquitin chains (Lam et al. 2002). 
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Figure 6   20S gate opening through 19S regulatory particle or PA28 assembly. In a free 20S 
core particle, the entrance to the catalytic chamber is blocked for proteins through the N-termini of 
the ?-subunits (“closed gate”) (A1) and (A2). The binding of the 19S (A1) or PA28 (A2) 
regulatory particle (right) “opens the gate” (B) by a conformational change induced by the binding 
of the C-terminal ends of the 19S regulatory ATPase subunits or of the PA28?/? subunits into the 
pockets formed by the ?-subunits. This results in a dislocation of the N-termini of the ?-subunits 
from the 20S entrance. (C) The 20S core particle can either contain the constitutive proteolytic 
active subunits ?1, ?2 and ?5 (constitutive or standard proteasome) or the respective immuno 
subunits Lmp2 (?1i), Mecl1 (?2i) and Lmp7 (?5i) (immuno proteasome). (D) Distinct proteasome 
formations exist in the cell such as the 30S proteasome (19S-20S-19S), the 26S proteasome (19S-
20S), the immuno proteasome (PA28?/??20S? PA28?/?? and the hybrid proteasome (19S-20S-
PA28?/?? ??
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1.3.3.2 PA28 proteasomal activator 
The 19S regulatory particle is not the only particle that can induce “gate opening”. 
The so called 11S or PA28 regulatory particle is also able to activate the 20S 
proteasome (see Figure 6 (A2) & (B) on page 17,(Stohwasser et al. 2000)). This 
regulator is formed by either seven alternating PA28? and PA28? non-ATPase 
subunits or, in a homopolymeric manner, by an assembly of PA28? non-ATPase 
subunits into a heptameric ring (Zhang et al. 1999).  
PA28? and PA28? are mainly located in the cytoplasm whereas the PA28? is 
predominantly found within the nucleus (Wojcik et al. 1998). PA28 is neither able 
to bind ubiquitinated substrates nor to induce the degradation of large substrates 
(Whitby et al. 2000). It has been shown that PA28 can bind in parallel with a 19S 
regulatory particle to a 20S proteasome to form a so called hybrid proteasome 
(19S-20S-PA28; see Figure 6 (D) on page 17). This hybrid proteasome can 
enhance the effectivity of the degradation of ubiquitinated proteins (Hendil et al. 
1998). The expression of PA28? and PA28? is upregulated in the presence of 
interferon-?? as these proteins belong to the MHC class I antigen presentation 
pathway, which indicates its role for an effective processing of antigen precursors 
(Kloetzel 2001).  
1.3.3.3 Proteasomal activator PA200 
Another proteasome activator of peptide proteolysis is PA200 (in yeast: Blm10) 
which is located predominantly in the nucleus (Ustrell et al. 2002). It can also 
form a hybrid proteasome with 19S regulatory and 20S core particle. It seems to 
be essential in spermatogenesis, DNA repair and genomic stability (Khor et al. 
2006; Blickwedehl et al. 2008). Furthermore, there are hints that Blm10 might be 
involved in the formation of 20S proteasome in yeast (Fehlker et al. 2003). The 
binding of Blm10 to a 20S proteasome core particle in yeast may enhance 
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(Blm10-CP) or repress (Blm10-CP-Blm10) peptide hydrolysis (Lehmann et al. 
2008).  
1.3.4 Proteasome subtypes 
Apart from these distinct activator complexes, there are also subtypes of the 20S 
core particles that differ from the standard or also termed constitutive form. Two 
representatives have already been found and well investigated, namely the 
immuno proteasome and the thymo proteasome (Tanaka 2009). 
The immuno proteasome assembly is induced by interferon-??which enhances the 
expression of the three specific 20S proteasome subunits named ?1i (Lmp2), ?2i 
(Mecl1) and ?5i (Lmp7). They substitute the constitutive subunits with protease 
active sites ?1, ?2 and ?5 in newly assembling proteasomes (Kloetzel 2001) (see 
Figure 6 (C) on page 17). The resulting immuno proteasomes are known to 
efficiently process peptide precursors for antigen presentation to cytotoxic T- 
lymphocytes and, in this way, play an essential role in immunoglobulin CD8 
positive T-cell mediated immunity (Rock et al. 2002). Compared to the 
constitutive proteasome, the immune proteasome shows structural alterations and 
an increased chymotrypsin-like and trypsin-like activity as well as a decreased 
caspase-like activity. This leads to a more effective generation of peptides with 
either hydrophobic or basic and less acidic C-termini (Aki et al. 1994; Dahlmann 
et al. 2000). Such differences between constitutive and immune proteasome are 
suggested to be connected to distinct efficiencies in the particular processing of 
antigens (Kloetzel 2001). Besides these conventional immuno proteasomes, there 
are also mixed proteasomes present in cells containing both constitutive and 
immuno proteasome proteolytic active ?-subunits (Griffin et al. 1998; Dahlmann 
et al. 2000). 
Another proteasome type is called thymo proteasome which is exclusively 
expressed in cortical thymic epithelial cells. It seems to be involved in the 
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development and presumably positive selection of CD8+ T-cells in the thymus. It 
assembles in the same way as the immuno proteasome with the exception of the 
?5i (Lmp7) subunit which is replaced by the highly homologous ?5t subunit 
(Tomaru et al. 2009). 
1.4 Influence of interferon-? on ubiquitination 
1.4.1 Influence of interferon-??on the cell  
Interferon-? is a proinflammatory cytokine which, in case of immunological or 
inflammatory processes, is secreted mainly by lymphocytes expressing the surface 
immunoglobulins CD4 or CD8 and natural killer cells, whereas other cell types 
like macrophages, in addition, are able to secrete this cytokine. It has central 
antiviral and immuno regulatory functions. It binds to heterodimeric interferon-? 
receptors on the cell surface and activates the “JAK-STAT” pathway, that induces 
the transcription of about 400 genes, belonging to antiviral, microbicidal, 
antiproliferative and pro-apoptotic proteins, to proteins for the production of NO 
intermediates and to reactive oxygen species (ROS) (Schroder et al. 2004). Most 
of them play a role in the MHC class I antigen presentation pathway.  
Furthermore, interferon-? enhances translation by activation of the mTOR 
(mammalian target of rapamycin) pathway (Kaur et al. 2008). Dysfunctions in the 
interferon-? release are connected to a set of diseases. For example, it may 
contribute to autoimmune diseases such as lupus erythematosus, multiple sclerosis 
or type 1 diabetes (de Marquesini et al. 2010; Lee et al. 2010; Lin et al. 2010). 
1.4.2 Influence of interferon-? on ubiquitin proteasome system 
The influence of interferon-??on the proteasome leads to an increase in immuno 
proteasomes formation and, in parallel, to a reduction of the amount of 26S 
proteasome through destabilization of 19S-20S interaction. The latter is probably 
attributed to dephosphorylation of ?-subunits (Rivett et al. 2001). This dynamic 
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change of the proteasome pool leads to a decrease of the proteasome activity in 
the early immune response as the result of the presence of interferon-?. It is then 
followed by a delayed increase due to the assembly of an increasing number of 
immuno proteasome (Seifert et al. 2010).  
Interferon-? is also influencing the process of ubiquitination. It enhances the 
transcription of about 20 E3 ligases and of the E2 enzyme UBE2L6 which is 
important for antigen cross-presentation by dendritic cells (Ebstein et al. 2009). 
Apart from that, it also leads to an enhancement of Ub-conjugate formation which 
is accompanied by an intermediate accumulation of high molecular weight Ub- 
conjugate species over the IFN? stimulation time (cf. Figure 7). 
Most of these accumulating Ub-conjugates contain K48-linkages and are 
proteasomal targets, while the number of K63-linkages does not change 
significantly. The transient accumulation (maximum 4-12 h IFN? induction) is 
caused by the enhanced ubiquitination which is accompanied by the decrease of 
26S proteasome during the initial phase due to a delayed immuno proteasome 
formation.  
After being formed, the immuno proteasome starts to degrade the accumulating 
Ub-conjugates with a twofold increased turnover, as compared to the standard 
proteasome activity, until the normal level of Ub-conjugates has been retained 
(24-48 h interferon-?). Most of the accumulating Ub-conjugates are oxidized, 
caused by reactive oxygen species (ROS) due to the induced oxidative stress. The 
majority of them consists of newly synthesized but defective ribosomal products 
(DRiPs) (Seifert et al. 2010) (cf. Figure 7). 
It is well known that heat shock and ROS, in particular, stimulate the degradation 
of newly synthesized proteins (Medicherla et al. 2008). These nascent oxidized 
proteins form Ub-rich inclusions called ALIS (also: aggresome or aggresome-like 
induced structures). They are transiently built up during the IFN? induction time. 
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Figure 7 Influence of interferon-? on the ubiquitin proteasome system: (A) IFN? induces an 
enhancement of translation and a subsequent increase of the formation of defective ribosomal 
products (DRiPs). Additional interferon-? induces the formation of reactive oxygen species (ROS) 
mainly causing a subsequent oxidation of nascent newly synthesized species. This leads to a 
significant increase of the concentration of non-functional, damaged proteins which have to be 
degraded via the ubiquitin proteasome system (UPS). (B) The non-functional proteins are 
ubiquitinated to target them for degradation via the proteasome. (C) The ubiquitin conjugates 
accumulate. (D) Immuno proteasome formation induced by interferon-? can compensate the 
decreased standard proteasome activity after a time delay, leading to the degradation of the 
accumulating Ub-conjugates. The resulting peptides serve as precursors for the by IFN? enhanced 
MHC class I antigen presentation to cytotoxic T-lymphocytes, an important signal to indicate the 
infection of the cell.  
The immuno proteasomes effectively degrade nascent oxidant-damaged proteins 
under inflammatory conditions and, in this way, prevent the proliferation of 
oxidative damage and promote cell viability. The appearance of ALIS is closely 
connected to the pathology of diseases like EAE (experimental autoimmune 
encephalomyelitis) (Seifert et al. 2010). The fact, that DRiPs are the main source 
for antigen processing and the induction of the MHC class I antigen presentation 
pathway, emphasizes the importance of the ubiquitin proteasome system in the 
early immune response associated to interferon-? induction (cf. Figure 7). 
In spite of the identification of accumulating Ub-conjugates as nascent oxidant-
damaged proteins and DRiPs, there are still questions about their nature.  
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1.5 Aims of this research study 
The interferon-? influenced ubiquitination and the transient accumulation of 
ubiquitin-conjugates represent key processes within the immune response of 
organisms. Therefore, the elucidation of the inherent reaction sequences, the 
participating enzymes, their reaction mechanisms and the details of control and 
coupling to the metabolism has become a central field of active research in 
biochemistry, medicine and pharmacy.  
An understanding of the processes in the cell under inflammatory conditions 
should give important and, presumably, decisive hints for the treatment of cancer, 
autoimmune diseases or chronic inflammation. Although considerable progress 
has been made in the past (Seifert et al. 2010), many questions regarding a large 
part of the molecular details, couplings and reactive pathways are still unresolved. 
To date, informations on the identity, composition and relative concentration of 
the Ub-conjugates which are formed and accumulated transiently during the 
response of cells to interferon-? are not revealed in detail. In this context, the main 
task of this work was to develop an analytical approach to identify and 
characterize the pattern of typical interferon-? induced ubiquitin conjugates in 
selected experiments.  
This work started with the following key questions characterizing the main 
aspects to be investigated by the intended experiments: 
1.  What is the composition of the ubiquitin-chain linkages in the 
accumulating conjugates? Are there only K48 linkages present in the 
accumulated ubiquitin-conjugates?  
2.  Is it possible to identify specific newly synthesized ubiquitinated 
proteins that accumulate in response to interferon-? analytically? 
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3.  Is there a special preference in ubiquitination for newly synthesized 
proteins or protein groups or is the ubiquitination process an over-all, less 
specific process? 
To answer to these questions, the experimental approach had to be developed with 
emphasis on the following steps:  
- optimization and selection of a potent isolation method of the Ub-conjugates,  
- characterization and establishment of an appropriate cell culture model,  
- selection, testing and optimization of the analytical method.  
The detailed approach and experimental planning had to focus on the analytes of 
importance. The decisive criterion for the selection of any particular technique for 
cell cultivation, Ub-conjugate separation and detection is the critical step of the 
analytical data processing and analysis. 
 
 
CHAPTER 2   
 
 
 
2 Materials and Methods 
2.1 Equipments and materials 
Chemicals and solutions 
All current chemicals used were purchased from Carl Roth GmbH, Merck KGaA, 
AppliChem GmbH and VWR International, if not otherwise denoted. Their purity 
was in general ? 99 % unless declared otherwise. For the mass spectrometric 
preparations and nano Liquid Chromatographic (LC) separation of peptides, 
methanol, acetonitril and water in LC grade were used from Roth. If not declared 
otherwise, all used solutions were aqueous.  
 
Enzymes 
Enzyme Supplier 
Lysozyme AppliChem GmbH 
DNaseI Sigma Aldrich GmbH 
BamHI New England Biolabs  
XhoI New England Biolabs 
Trypsin/P Promega GmbH 
Lysyl endopeptidase (LysC) Wako Chemicals GmbH 
T4 DNA ligase New England Biolabs 
High Fidelity DNA polymerase Roche 
Taq polymerase Invitrogen 
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Plasmids, primers and cDNA 
Plasmid/ primers/cDNA Source/ Supplier 
pTOPO Invitrogen  
pEGFP-N3 Invitrogen 
pcDNA3.1 Invitrogen 
myc-His-Sequestosome-1/ pcDNA3.1 F. Ebstein & A. Lehmann 
10xHis-Ub-EGFP/pEGFP-N3 M. Seeger 
Human cDNA J. Steffen 
Forward primer: XhoI-HA-Ub: 
CCCTCGAGATGGAGTACCCATACGATGTTCCAGATT
ACGCTGAGATGCAGATCTTCGTGAAAACCCTT 
BioTez AG 
Reverse primer: BamHI-Ub:  
GAGGGATCCACCACCTCTCAGACGCAGGACCAG 
BioTez AG 
 
Instruments 
Instrument Supplier 
UV VIS photometer Ultraspec 2100 pro Amersham Biosciences 
Table top centrifuge Eppendorf 
Thermocycler Uno Thermoblock Biometra 
SW40 swing out rotor Beckman Coulter 
Rotor JA-25.50 Beckman Coulter 
Rotor JA-14 Beckman Coulter 
DMR Mikroscope Leica  
Nano-LC  Eksigent 
LTQ-Orbitrap Thermo Fisher Scientific 
FACSCalibur Becton Dickinson 
SynergyTM HT Microplate Reader Amicon 
Incubator Heraeus 
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Kits 
Kit Supplier 
BCA Protein Assay Kit Thermo Fisher Scientific  
QIAprep Spin Miniprep Kit Qiagen 
QIAGEN Plasmid Maxi Kit Qiagen 
QIAquick Gel Extraction Kit Qiagen 
TOPO® TA Cloning® Kit Invitrogen 
Expand High Fidelity PLUS PCR System Roche  
Quick Ligation™ Kit New England Biolabs 
Ubiquitinated Protein Enrichment Kit Merck KGaA 
ECL Plus™ Western Blotting Detection System GE Healthcare 
Page silverTM Silver staining Kit Fermentas 
 
Cell culture materials and chemicals  
Materials and chemicals Supplier 
SILAC DMEM PAA Laboratories GmbH 
Basal Iscove medium Biochrom AG 
OptiMEM® Gibco 
Lipofectamin™ 2000 Invitrogen 
L-glutamine PAA Laboratories GmbH 
Fetal bovine serum Biochrom AG 
Dialyzed fetal bovine serum PAA Laboratories GmbH 
Penicilline/ Streptamycine PAA Laboratories GmbH 
Trypsin/ EDTA PAA Laboratories GmbH 
Geneticine (G418) Calbiochem 
Puromycine PAA Laboratories GmbH 
Dimethylsulfoxid (DMSO) Sigma Aldrich 
Cell culture dishes Greiner 
Cryo conservation vials Corning 
Human interferon-? (IFN?)  Roche 
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Inhibitors 
 
Inhibitor Supplier 
MG132 VWR International 
Complete® Inhibitor Mix Roche 
N-Ethylmaleimide (NEM) Sigma-Aldrich 
Phenylmethylsulfonfluoride (PMSF) Sigma-Aldrich 
Chloroacetamide (CAA) Merck KGaA 
 
Antibodies 
Denotation Antigen Organism Dilution 
(Western Blot) 
Source 
Dako Ubiquitin Rabbit 1:2500 Dako 
FK2 Ubiquitin Mouse 1:5000 Enzo Biomol  
? GAPDH Glyceraldehyde 3-
phosphate dehydrogenase 
(GAPDH) 
Rabbit 1:5000 Santa Cruz  
? HA Haemagglutinine epitope 
(YPYDVPDYA) 
Mouse 1:1000 Sigma Aldrich  
?GFP Green fluorescent protein 
(GFP)  
Mouse 1:5000 Covance 
? 5xHis Pentahistidine Mouse 1: 2000 Santa Cruz 
? Wars Tryptophanyl-tRNA 
synthetase 
Rabbit 1:1000 Santa Cruz  
? Trim21 Tripartite motif 21 Rabbit 1:1000 Santa Cruz 
? p62 Sequestosome 1 Rabbit 1:500 Enzo Biomol  
? c-myc Myc epitope 
(EQKLISEEDL) 
Mouse 1:1000 Enzo Biomol 
? Rpt5 Proteasome regulatory 
subunit human Rpt5 
Mouse 1:1000 Enzo Biomol 
? Rabbit- HRP Rabbit IgG Goat 1: 5000 Dianova 
? Mouse- HRP Mouse IgG Goat 1:5000 Dianova  
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Commercial affinity matrices 
Matrix Supplier 
ProteinA-sepharose (FastFlow) GE Healthcare 
ProteinG-sepharose (FastFlow) GE Healthcare 
GSH-sepharose (FastFlow) GE Healthcare 
S5a(UIM2)-agarose Enzo Biomol 
hHR23b(UBA2)-agarose Enzo Biomol 
Monoclonal antibody against haemagglutinine 
epitope coupled to agarose 
Sigma Aldrich 
Rad23-Agarose Merck  
 
Consumables 
Consumable Supplier 
PVDF membrane Millipore 
Whatman paper (3MM) Schleicher und Schuell 
X-Ray films  Kodak 
Tubes/ Tips/ Plastic Pipettes Greiner/Eppendorf 
Bio-Spin Columns Biorad 
RotiBlock® Roth 
 
Electrophoresis markers and ampholines 
 
Electrophoresis markers and ampholines Supplier 
1KB Plus DNA Ladder Invitrogen 
Page RulerTM Prestained Protein Ladder Fermentas 
Ampholine pI 2-11 Serva 
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Software  
Software  Version Supplier 
ImageJ  1.42q National Institutes of Health  
Microsoft Office  2007 Microsoft  
MaxQuant 1.0.13.13 Max Planck Institute  
Xcalibur 2.0.7 Thermo Fisher Scientific  
Melanie Viewer 7.05 Institute of Bioinformatics  
Corel Draw 13.0.0739 (2005) Corel Corporation  
EndNote 8.0.1 Thomson Reuters  
Cell Quest  Becton Dickinson 
 
Databases 
Database Web address for the period of access 11/2007-9/2010 
UniProt http://www.expasy.ch 
SCUD http://scud.kaist.ac.kr/ 
UbiProt http://ubiprot.org.ru/ 
ENSEMBLE http://www.ensembl.org/ 
Expasy http://www.expasy.ch 
Pubmed http://www.ncbi.nlm.nih.gov/ 
ISI web of Knowledge http://apps.isiknowledge.com 
MedPilot http://www.medpilot.de/ 
 
2.2 Molecular biological methods 
2.2.1 Polymerase chain reaction (PCR) 
For the polymerase chain reaction, 25 pmol of each forward and reverse primer 
were combined with ? ?L human cDNA (see equipments and materials 2.1), 
0.5 ?L High Fidelity Polymerase, 5 ?L 10x reaction buffer, 0.4 mM dNTP’s 
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(1 ?L), 40.5 ?L PCRpure H2O und 0.5 ?L DMSO. The reaction mixture was 
incubated inside a thermocycler running the procedure described in Table 1.  
After the end of this procedure, 2 ?L Taq polymerase were added and the reaction 
mixture was incubated for further 10 min at 72 °C. This last step is required for 
the synthesis of the polyA-end groups at the DNA-fragments to assure the 
successful ligation into a TOPO® vector. The control of the PCR was performed 
using agarose gel electrophoresis. 
Table 1 Program for the Thermocycler as used for the PCR reaction 
Step Temperature/Time Repeats 
Initial Denaturation 95 °C/ 2min 1 
Denaturation 95 °C/ 30sec 
30 Cycles Annealing 60 °C/ 30sec 
Polymerization 72 °C/ 30sec 
Final Polymerization 72 °C/ 10min 1 
2.2.2 Agarose based gel electrophoresis 
TEA buffer 4 mM tris(hydroxymethyl)-aminomethan, 1.2 mM sodium acetate, 4 mM ethylene 
diamine tetraacetic acid (EDTA) adjusted with acetic acid to pH 8.3 
10x DNA loading buffer 50 % (v/v) glycerole, 0.25 % (w/v) bromphenol blue, 0.25% (w/v) 
xylencyanol in TAE buffer  
The agarose gel was prepared by solving 2% (w/v) agarose in boiling TEA buffer, 
adding 50 ?g/mL ethidiumbromide and waiting until it was polymerized. Voids 
for loading of DNA solutions were generated within the gel by a comb that was 
placed in the gel during polymerization. After polymerization, 10 ?L PCR product 
mixed with 2 ?L 10x DNA loading buffer as well as DNA marker were filled into 
separate voids. The electrophoretic separation was performed at a voltage of 60 V 
for 1 h. Evaluation of the electrophoresis result was made by determination of the 
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DNA size via the DNA marker with help of UV lamp followed by its comparison 
to the expected, theoretical size.  
2.2.3 Ligation of the PCR products into a TOPO® vector 
Using a TOPO® TA Cloning® Kit 1 ?L PCR product, 1 ?L salt solution, 1 ?L 
vector and 3 ?L MilliQ water were mixed, shortly centrifuged and then incubated 
at room temperature for 5 min.  
2.2.4 Competent E.coli cells 
LB-medium 10 g bacto-trypton, 5 g yeast extract, 10 g NaCl, 200 ?L NaOH added MilliQ H2O to 
1 L (autoclaved) 
LB-agarplates 1 % (w/v) agarose dissolved in boiling LB-medium supplemented with antibiotics 
were polymerized on sterile plates, 
?a medium 0.5 % (w/v) yeast extract, 2 % (w/v) bacto-trypton, 40 mM MgSO4 solved in MilliQ 
H2O and adjusted with KOH to pH 7.6 (autoclaved) 
Buffer TfbI 30 mM potassium acetate, 100 mM RbCl, 10 mM CaCl2, 50 mM MnCl2, 15 % (v/v) 
glycerol dissolved in MilliQ H2O, adjusted to pH 5.8 with acetic acid and stored sterile at 4 °C  
TfbII buffer 10 mM MOPS, 75 mM CaCl2, 10 mM RbCl, 15 % (v/v) glycerol dissolved in MilliQ 
H2O, adjusted to pH 7and stored sterile at 4 °C 
E.coli cells of either the strain DH5? or BL21 were seeded on an LB-agarplate 
and incubated at 37°C over night (o/n). One colony was picked and grown in 
5 mL ?a-medium o/n. On the following day, the culture was expanded on 100 mL 
?a-medium. At an optical density (OD600) of 0.5, the o/n culture was incubated for 
5 min on ice to cool down. The following working steps were performed at 4 °C 
under sterile conditions. The cells were centrifuged (5 min, 6000 rpm), then 
resuspended in TfbI-buffer and incubated for 15 min. After final centrifugation, 
the cells were resuspended in 4 mL ice cold TfbII buffer and subsequently 
incubated 15 min on ice, before 100 ?L aliquots were finally freezed at -80 °C. 
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2.2.5 Transformation  
Antibiotics stock solutions (1000x) 10 mg kanamycine per mL sterile MilliQ H2O; 100 mg 
ampicilline per ml (50 % (v/v) ethanol)  
IPTG stock solution 1 M isopropyl-?-D-thiogalactopyranoside (IPTG) in sterile MilliQ H2O  
X-Gal stock solution 20 mg 5-brom-4-chlor-3-indoxyl-?-D-galactopyranosid in 1 mL 
dimethylformamide 
Glycerol stock solution 80 % (v/v) glycerol in water 
2 ?L of the cloned vector were added to one tube with competent E.coli for DNA 
amplification of either the strain 10F‘ from TOPO® TA Cloning® or DH5? or for 
gene expression to the strain BL21. The transformation was initiated applying a 
heat shock for 30 sec at 42 °C. The heat shock was followed by incubation on ice 
for 5 min. Then, the transformed bacteria were incubated at 37 °C for one hour 
with 250 ?L LB-medium for their progeny. For the selection of positive E.coli 
clones, 50 ?L of the transformed bacteria were plated on LB-agarplates 
supplemented with antibiotics. In case of using the TA Cloning Kit 40 ?L IPTG 
und 40 ?L X-Gal were added, which allow the selection of clones containing the 
PCR product. The clones containing the vector without the PCR product 
expressed a blue dye with regard to an intact lacPromoter controlled gene, those 
with PCR product carried a destroyed promotor and occured as white colonies. 
For the long term storage, 0.5 mL transformed bacterial culture in LB-medium 
were transferred into a sterile 1.5 mL tube. After addition of 0.5 mL autoclaved 
glycerol stock solution, the bacterial stocks were stored at -80 °C until usage. 
2.2.6 Plasmid DNA isolation and sequencing 
For the amplification of the DNA, a positive clone was picked and injected into 
LB-medium. The bacterial culture was shaken at 37°C o/n. Plasmid DNA was 
isolated with the help of either a QIAprep Spin Miniprep Kit or a QIAGEN 
Plasmid Maxi Kit depending on the quantity of the bacterial culture. After 
photometric determination of the DNA concentration, an aliquot was sequenced 
by Agowa GmbH.  
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2.2.7 Digestion via restriction enzymes 
E.coli clones containing the correct target DNA sequence were amplified once 
more. A reaction mixture for the digestion with the restriction enzymes BamHI 
and XhoI of the cloning product was prepared in parallel to one with an empty 
pEGFP-N3 vector. The composition of the reaction mixtures was 5 ?g vector, 
2.5 ?L of each restriction enzyme (see equipments and materials 2.1), 
4 ?L10xNEB buffer 3 and MilliQ to a final volume of 40 ?L. For digesting, the 
solutions were incubated for 2 h at 37 °C. The fragments from plasmid digestion 
were separated via agarose gel electrophoresis. The bands with the correct DNA 
size (249 bp HA-Ub and 4.5 kbp pEGFP-N3) were cut off from the gel under UV 
light and the DNA was isolated using a QIAquick Gel Extraction Kit. 
2.2.8 Ligation into pEGFP-N3 vector 
The ligation was performed using a Quick Ligation™ Kit and incubating the 
reaction mixture 1.5 h at room temperature. The composition of the reaction 
mixture was 13 ?L MilliQ, 2 ?L 10x buffer ligase T4, 1 ?L ligase T4 and, 
resulting from the restriction enzymatic digestion 2 ?L of pEGFP-N3 vector, 2 ?L 
HA-Ub DNA. Competent E.coli DH5? cells were transformed with 4 ?L ligation 
product. The plasmid was amplified, isolated and digested again by restriction 
enzymes and analyzed via agarose gel electrophoresis as well as being sequenced. 
The correct ligation constructs were amplified. 
2.3 Human cell culture methods 
2.3.1 Cell lines, buffers and media 
Cell lines 
Without any exception the human epithelial cell line HeLa from cervix adeno 
carcinoma was used. This cell line from the American Tissue and Cell Culture 
Company served as basis for the establishment of stable transfectants (Table 2).  
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Table 2 Plasmids used for transfection into human HeLa cells 
Stable cell line Protein construct/ host vector Selection criteria 
HA-Ub-HeLa HA-Ub/ pEGFP-N3 0.5 mg/mL G418 
His-Ub-HeLa 10xHis-Ub/ pEGFP-N3 (from M. Seeger) 0.5 mg/mL G418 
Transient transfected 
HeLa 
Myc-His-Sequestosome-1/ pcDNA3.1 
 (from F. Ebstein & A. Lehmann) 
2 ?g/mL 
Puromycine 
Phosphate buffered saline (PBS) 
Phosphate buffered saline was produced by dissolving 8 g NaCl, 0.2 g KCl, 1.6 g 
Na2HPO4 x 10 H2O, 0.2 g KH2PO4 in 1 L H2O. The pH was then adjusted with 
HCl to 7.2. 
SILAC(stable isotopic labeling with amino acids in cell culture) medium 
SILAC DMEM was supplemented with 2 mM L-glutamine und 10 % (v/v) 
dialyzed fetal bovine serum (dFBS), 3 mM of L-lysine as well as 1.5 mM 
L-arginine (Table 3) of the respective isotopes (light/ medium heavy/ heavy) by 
dilution of a 3000x stock solution in PBS. Finally, the respective antibiotics were 
added as listed in Table 2 for the transfectant selection. 
Table 3: Source and denotation of L-arginine and L-lysine isotopes used in cell culture for SILAC 
experiments 
Isotope Source Mass shift; denotation of labeled cells 
L-lysine*2HCl  Sigma Aldrich + 0 Da; light (L) 
L-arginine*HCl Sigma Aldrich + 0 Da; light (L) 
L-lysine*2HCl 4,4,5,5-D4 
(96-99% D) 
EURISO-TOP + 4 Da; medium heavy (M) 
L-arginine*HCl U-13C6 
(98% 13C) 
EURISO-TOP + 6 Da; medium heavy (M) 
L-lysine*2HCl U-13C6 U-
15N2 (98% 13C : 98% 15N)  
EURISO-TOP + 8 Da; heavy (H) 
L-arginine*HCl U-13C6 U-
15N4 (98% 13C : 98% 15N) 
EURISO-TOP + 10 Da; heavy (H) 
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Iscove medium for general culturing 
For all non SILAC experiments, Basal Iscove medium was supplemented with 
1 % (v/v) penicillin/ streptomycin solution, 2 mM L-glutamine and 10 % (v/v) 
fetal bovine serum (FBS), as well as the respective antibiotics (Table 2 on page 
35) as selection pressure for the stabile transfectants. 
Liquid nitrogen storage medium 
Basal Iscove medium was supplemented with 20 % (v/v) FBS and 10 % (v/v) 
DMSO. 
2.3.2 Subcultivation 
The adherent cells were cultured in cell dishes (d= 10/ 15 cm) with Iscove 
medium at 37 °C; 5.5 % CO2 and 95 % humidity. For sub cultivation 75 - 90 % 
confluent cells were washed with PBS buffer and detached with Trypsin/ EDTA. 
The cell suspension were diluted with Iscove medium (1:3 (v/v)) and centrifuged 
for 5 min at 1.000xg and 4 °C. The pellet was resuspended in Iscove medium and 
seeded (1:6-1:10, growing area to growing area). As an alternative for the storage 
of the cells, they were resuspended in freezing medium and transferred into cryo 
conservation vials where they were cooled down o/n to -80 °C. At the following 
day, they were conveyed into liquid nitrogen for long-term storage. 
2.3.3 Transfection and generation of stable transfectants 
Transfection 
One day before transfection, cells were divided. The cell number was determined 
with help of a Neubauer cell counting chamber and 3x 106 cells were seeded on a 
6-well-plate per well. For the transfection, 500 ?L OptiMEM medium were mixed 
with 25 ?L Lipofectamin™ 2000 and ?? ?g of the respective plasmid (see Table 2 
on page 35). After incubation of the transfection mixture for 15 min at room 
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temperature, the supernatant medium of the cells was replaced by it. With 
additional 1.5 mL fresh Iscove medium, the cells were incubated for 24 h (37 °C, 
5 % CO2). Then, the transfection medium was replaced with culturing medium. 
Either the cells were used directly for stimulation experiments or they were used 
for the establishment of stable transfectants.  
Generation of stable transfectants 
For the generation of a stable transfected cell line, the cells were selected with the 
antibiotics regarding to the resistance gene included into the transfected vectors 
(antibiotic & concentration compare Table 2 page 35). The cells were initially 
cultivated for one passage under this selection pressure, before they were sub-
cultured on a 96-well-plate with one or two cells per well. After growing to a 
confluence of 80 - 90 %, the cells were implemented into a 24-well-plates well. 
An aliquot of these cells was checked for transfection efficiency using a 
fluorescence associated cell sorting (FACS) instrument. Positive clones were 
further cultivated under selection conditions and their expression of the 
transfected vector was checked at regular intervals via the fluorescence of the 
green fluorescent protein (EGFP).  
2.3.4 “Short” stable isotope labeling with amino acids in cell culture 
The experimental approach for the “short” stable isotope labeling with amino 
acids in cell culture (SILAC) was adapted from the laboratory of M. Selbach. 
Eight hour SILAC experiments 
For the eight hours „pulsed“ SILAC experiments, cells were cultivated for 24 h 
with SILAC medium containing natural isotopes of L-lysine/L-arginine to 
accustom the cells to the new medium. Prior to the stimulation, the cells were 
washed three times with PBS buffer (in order to remove natural isotopes of amino 
acids completely). Then, the SILAC medium with “medium heavy” isotopes 
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(L-lysine + 4 Da and L-agrinine + 6 Da) was added to the one half of the cell dish 
serving as reference. The SILAC medium containing “heavy” isotopes (L-lysine 
+ 8 Da and L-agrinine + 10 Da) and 100 U/mL human interferon-??was added to 
the remaining half. Both samples were incubated with 10 ?M MG132 for 30 min 
before cell harvesting for the stabilization of Ub-conjugates by proteasomal 
inhibition. 
One-hour SILAC experiments 
For the one hour „pulsed“ SILAC experiments, half of the cell dishes were 
cultivated for 6.5 h with Iscove medium containing 100 U/mL human interferon-?. 
In parallel, the other half was cultivated as reference in Iscove medium without 
interferon-?. Before carrying out a stable isotopic labeling, the cells were washed 
three times with PBS buffer (to completely remove natural isotopes of amino 
acids), followed by a 30 min starvation in a SILAC medium free of lysine and 
arginine. Then, “medium heavy” isotopes (L-lysine + 4 Da and L-agrinine + 6 Da) 
were added to the interferon-? untreated cells, and “heavy” isotopes (L-lysine 
+ 8 Da and L-agrinine + 10 Da) as well as 100 U/mL human interferon-??were 
added to the rest. After 30 min, 10 ?M MG132 (stabilization of Ub-conjugates by 
proteasomal inhibition) were added to both samples, followed by incubation for 
further 30 min, before the cells were harvested.  
For direct comparison of Ub-enrichment with co-precipitants, interferon-? 
stimulated cells were labeled either with “medium heavy” or “heavy” Lys/Arg in 
parallel. The rest of the experimental setup was the same as described above (one-
hour SILAC experiments). Instead of combining the lysates after harvesting and 
subsequent purifying the Ub-conjugates, the “medium heavy” labeled cell lysates 
were subjected to agarose-precipitation (co-precipitants) while the “heavy” 
labeled Ub-conjugates were isolated with Rad23-matrix (the technique will be 
described below, cf. 2.4.2). Finally the eluates were combined.  
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2.3.5 Interferon-??induction of HeLa cells and cell harvesting 
Interferon-??induction 
The supernatant Iscove medium of the ca. 80 % confluent cells coming from 
chapter 2.3.4) was replaced by fresh medium containing either 100 U/mL human 
interferon-? or as reference sample no interferon-?. Both samples were 
incubated with 10 ?M MG132 for 30 min before the cells were harvested to 
stabilize the Ub-conjugates by proteasomal inhibition. 
Cell harvesting 
Lysis buffer (modified Ripa buffer) 50 mM tris(hydroxymethyl)-aminomethan pH 7.6, 10 % (v/v) 
glycerol, 150 mM NaCl, 1 % (v/v) NP-40, 0.025 % (w/v) sodium deoxycholate, 1 mM 
ethylendiaminetetraacetate (EDTA), before use freshly added: 10 ?M MG132, 1 mM 
phenylmethylsulfonfluoride (PMSF), 10 mM N-ethylmaleimide (NEM), 40 ?L Complete® stock 
solution; ?? ?? chloroacetamide (CAA) 
Inhibitor stock solutions 1 M NEM and 100 mM PMSF each in dimethylsulfoxide, 1 tablet 
Complete® in 50 mL MilliQ water, 10 mM MG132 in absolute ethanol; 55 mM CAA in sterile 
MilliQ water 
After 8 h of interferon-? induction and 20 min incubation with additional 10 ?M 
MG132, the cells were washed with PBS buffer, before they were detached with 
trypsin/ EDTA. The pellet was washed with PBS prior to lysis in ice cold lysis 
buffer. The suspension was vortexed and incubated for 20 min on ice, before the 
proteins were separated from DNA, cell compartments and membrane fragments 
via centrifugation (14,000xg; 4 °C; 30 min). The supernatant was stored at -80 °C 
until usage. 
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2.3.6 Determination of protein concentration 
The determination of the protein concentration was performed photometrically 
using either a BCA Kit or measuring the absorption at a wavelength of ?= 280 nm 
(A280= 1 equates to 1 mg/mL). 
2.4 Isolation of ubiquitin conjugates 
2.4.1 Preparation of isolation matrices 
Isolation of GST-tagged recombinant proteins 
Lysis buffer 50 mM tris(hydroxymethyl)-aminomethan pH 7.6 (with HCl), 100 mM NaCl, 2 mM 
KCl, 10 mM MgCl2, 0.5 mM dithiothreitol (DTT), 0.01% (v/v) NP-40 with freshly added 
Complete® (1 tablet), 0.4 mg/mL Lysozyme and 0.2 mg/mL DNaseI 
Washing buffer 50 mM tris(hydroxymethyl)-aminomethan pH 7.6 (with HCL) 
E.coli BL21 was transformed with GST tagged ubiquilin-1 (?UbL domain) in a 
pGEX-KG vector (M. Seeger, M374). 1 L bacterial culture with an OD600 of 0.6 
was induced with 0.4 mM IPTG. The culture was grown for 3 h at 37 °C, before 
the recombinant proteins were isolated. For this step, first, the bacteria were lysed 
with ice cold lysis buffer and incubated for 30 min on ice. To increase the lysis 
efficiency, the suspension was treated 4x 30 sec with ultrasound (on ice). DNA, 
cell compartments and membrane fragments were terminated via centrifugation 
(14,000xg, 30 min, 4 °C). The supernatant was incubated with 10 mL 
GSH-sepharose o/n at 4 °C (rolling). After washing with 3x 15 mL washing 
buffer, the beads were used directly for affinity purification of Ub-conjugates or 
stored at 4 °C in washing buffer spiked with 0.05 % (w/v) sodium azide until 
usage. 
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Cross linking of antibodies 
The protocol was adapted from the laboratory of M. Selbach 
Binding buffer PBS  
 Washing buffer 0.2 M sodium tetraborate buffer pH 9  
Cross-linking buffer washing buffer with 25 mM dimethylpimelimidate  
Blocking buffer 0.2 M ethanolamine pH 8  
2 mg/mL antibodies were solved in PBS, and combined with PBS equilibrated 
ProteinA/G-sepharose. For the binding of ProteinA/G to the antibodies, the 
suspension was incubated o/n at 4°C under inversion. To control the binding 
efficiency, an aliquot of the antibody solution were taken before and after the 
binding and compared via SDS-PAGE followed by coomassie staining. Prior to 
the cross-linking, the beads were equilibrated twice with washing buffer to 
remove free amines. Afterwards, the 10-fold volume (solution to beads) of 
cross-linking buffer was added and the beads were incubated under inverting for 
45 min at room temperature. Then, the beads were washed again with washing 
buffer, before the free amines were blocked by incubation with blocking buffer for 
2 h at room temperature. Finally the beads were washed twice with PBS and either 
directly used for immuno precipitation or stored under PBS containing 
0.05 % (w/v) natriumazide at 4 °C until their usage. 
2.4.2 Immuno precipitation and affinity purification  
Immuno precipitation 
Matrices anti-HA-agarose, anti-Ub(Dako) cross linked to ProteinA/G-sepharose 
Elution buffer 1: 3x100 ?L 0.1 M glycine-HCl pH 2.5 
Affinity purification 
Matrices Rad23-agarose & agarose- control beads, S5a(UIM2)-agarose & 
hHR23b(UBA2)-agarose, ubiquilin-1-GST-GSH-sepharose 
Elution buffer 2: 3x100 ?L 6 M urea/2 M thiourea 
Counter ion exchanging solution 2.5 M sodiumacetate adjusted to pH 5 with acetic acid 
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The cell lysates resulting from the interferon-? stimulation experiments (chapter 
2.3.5) were combined with affinity matrix (50 ?L matrix per 2-5x 107 cells from 
two cell dishes d=15 cm). After incubation for 4 h at 4 °C, the supernatant and the 
Ub-conjugates bound to the matrix were separated by filtration via a Biorad 
column. The beads were washed with the 20fold volume of lysis buffer (see 
2.3.5), before the Ub-conjugates were eluted from the matrix with elution buffer 1 
in case of immuno precipitation and with elution buffer 2 instead in case of 
affinity purification. The proteins in the elution fraction were precipitated with 
ethanol at -80°C o/n after addition of 70 ?L sodium acetate pH 5 and 1.63 mL of 
absolute ethanol. The precipitated proteins were pelletized (14,000xg, 4 °C, 1 h) 
and the supernatant was discarded. Due to the following analysis, the proteins 
were solved in respective buffers for either gel electrophoresis or mass 
spectrometry. For proving the enrichment of the Ub-conjugates aliquots of the 
lysates, the supernatant after matrix binding, the washing fraction and the elution 
fractions were controlled via western blot. 
2.5 Bioanalytical methods 
2.5.1 Preparation of the ubiquitin conjugates for mass spectrometry 
2.5.1.1 “In-solution” digestion 
Reduction and alkylation  
ABC buffer  50 mM ammonium bicarbonate (ABC) solved in LC grade water 
Precipitate lysis buffer  6 M urea/ 2 M thiourea (pH 8)  
Dithiothreitol (DTT) stock solution 100 mM in 50 mM ABC buffer 
Chloroacetamide stock solution 55 mM in 50 mM ABC buffer 
The protein pellets resulting from purification of Ub-conjugates (cf. 2.4.2) were 
dissolved in 20 ?L 6 M urea/ 2 M thiourea and reduced via incubation with 2 ?L 
DTT stock solution for 30 min at RT. The as-reduced proteins were incubated 
with 2 ?L chloroacetamide for additional 20 min in darkness at room temperature 
mainly to achieve the alkylation of cysteins. 
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Digest of the proteins to peptides for mass spectrometric analysis 
The protocol was adapted from the laboratory of M. Selbach. 
Enzyme stock solutions 0.5 ?g/?L LysC and Trypsin/P each solved in 50 mM ABC buffer 
Digest stop solution 10% (v/v) trifluoro acetic acid (TFA) in LC grade H2O 
The proteins were first pre-digested with 0.5 ?g LysC for 3 h at room temperature 
(RT). After this pre-digest, the concentrated salt solution was diluted by addition 
of 4x v ABC buffer, in order to ensure the digest with 0.5 ?g Trypsin/P, o/n at RT. 
After the incubation, the digestion was stopped by acidic denaturation of the 
proteases by decreasing the pH below 2.5 via addition of trifluoroacetic acid. 
2.5.1.2 “In–gel” digestion 
Destaining solution 200 mmol ammonium bicarbonate solved in a 1:1 (v/v) solution of deionized 
water and acetonitrile (ACN) 
The bands/ spots from a coomassie stained gel were cut off and transferred into a 
reaction tube. First of all the gels were destained by incubation in 500 ?L 
destaining solution for 30 min at 37 °C. After destaining the gel, pieces were 
shrank in 50 ?L ACN for 10 min at room temperature, followed by equilibration 
in ABC buffer. The proteins were first pre-digested with 0.5 ?g LysC for 3 h 
37 °C, before 0.5 ?g Trypsin/P was added. The tryptic digest was performed by 
incubating the solution over night at 37 °C. After the incubation time, the 
digestion was stopped via denaturation of the proteases by decreasing the pH 
below 2.5 via addition of TFA. 
2.5.1.3 Desalt of peptides via reversed phase liquid chromatography 
Buffer A   3 % (v/v) acetonitrile, 0.5 % (v/v) trifluoro acetic acid  
Buffer B  80 % (v/v) acetonitrile, 0.5 % (v/v) trifluoro acetic acid 
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Stage tips were prepared by using C18-empore filter matrix and activating it with 
methanol. After equilibration of the matrix, with 125 ?L buffer A the peptide 
solutions were bound to the matrix and washed once more with 80 ?L buffer A. 
Prior to mass spectrometric analysis, the peptides were eluted with 60 ?L buffer B 
into an auto sampler plate. The volume was reduced to 2-3 ?L by evaporation. 
Finally, about 5 ?L buffer A were added. 
2.5.2 Mass spectrometric analysis 
The mass spectrometric analysis was performed by F. Hosp (MDC, Berlin) using 
nano-liquid chromatography (nanoLC) in-line coupled via an electrospray 
ionization source to a LTQ-Orbitrap mass spectrometer.  
Nano-liquid chromatographic peptide separation 
The peptides were eluted and separated using on-line C18 reverse-phase 
nanoscale liquid chromatography. The column was an in-house manufactured 
10 cm fritless silica micro column with an inner diameter of 75 ?m, which was 
packed with ReproSil-Pur C18-AQ 3 ?m resin. A linear gradient from 10 % (v/v) 
to 60 % (v/v) acetonitrile in 0.5 % (v/v) acetic acid with a flow rate of 200 nL/ min 
was used. The gradient was applied for 155 min in case of the samples resulting 
from the eight hours stable isotope labeling experiments and 60 min for the 
samples from the one hour labeling experiments. 
Mass spectrometric measurements 
Separated peptides were ionized via electro spray ionization source. The peptide 
detection and fragmentation was performed choosing an m/z range of 300 to 1700, 
a resolution of 60,000 and a target value of 1x 106 for the precursor ion spectra. A 
fragmentation (MS/MS) of the 5 most intense ions selected was made with a 
target value of 5.000. The activation type for the fragmentation was collision 
induced dissociation (CID) with normalized collision energy of 35 %. 
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Analysis of the mass spectrometric data 
The mass spectrometric data were analyzed with the MaxQuant software package. 
Generated peak lists were searched on a MASCOT search engine against a 
manually curated version of the IPI human database. Parameters for protein 
identification and quantification were set as follows: required false discovery rate 
(FDR) of 1 % at the peptide and protein level, a minimum required peptide length 
to six amino acids and a minimum SILAC pair count of three. The median of the 
detected SILAC pairs serve as value for the relative quantification. 
2.6 Biochemical methods  
2.6.1 Sodiumdodecylsulfoxide-polyacrylamide gel electrophoresis  
Adapted from Laemmli (Laemmli 1970). 
10x sample buffer  5 mL glycerol, 1 g sodium dodecylsulfate (SDS), 5 mL 1 M 
tris(hydroxymethyl)-aminomethan adjusted to pH 6.8 with HCl, 0.025 % (w/v) bromphenol blue, 
200 mM DTT  
10x running buffer 144.1 g glycine; 30.3 g tris(hydroxymethyl)-aminomethan; 10 g sodium 
dodecylsulfate  (SDS) for use diluted 1:10 (v/v) with MilliQ H2O dilution. 
5x running gel solution (15%/ 12.5%/ 10%/ 8% acryl amide gel): 7.5 mL 1.5 M 
tris(hydroxymethyl)-aminomethan adjusted to pH 8.8 with HCl; 15/ 12.5/ 10/ 8 mL acrylamide 
(30%); 7.5/ 10/ 12.5/ 14.5 mL MilliQ H2O; 150 ?L 20% (w/v) SDS, added shortly before use: 
200 ?L 10 % (w/v) ammonium peroxodisulfate (APS); 18 ?L tetramethylethylendiamine 
(TEMED) 
5x stacking gel solution (5%): 1.25 mL 1 M tris(hydroxymethyl)-aminomethan adjusted to pH 6.8 
with HCl; 2.5 mL acrylamide (30%); 11.6 .mL MilliQ H2O; 75 ?L 20% (w/v) SDS; freshly added: 
100 ?L 10% (w/v) APS; 7.5 ?L TEMED 
For five gels (Hoefer system; 9 x 7 cm, Spacer 0.75 mm), 30 mL running gel 
solution was prepared. Right after initiating the polymerization with the radical 
starter TEMED and APS, the gels were incubated at room temperature with an 
isopropanol overlay for a minimum time of 1 h. Then, the isopropanol from the 
polymerized gels was replaced by the stacking gel solution. For later sample 
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loading, combs were put into the stacking gel during polymerization. By this 
procedure, voids were formed for the subsequent sample loading. The stacking gel 
was polymerized by incubation for a minimum time of 1 h at room temperature. 
The samples were loaded into the voids, after the proteins were denaturated in 
sample buffer at 95 °C for 5 min. One sample bag was filled with a protein size 
marker for later determination of the molecular weights of the proteins. The gel 
electrophoretic separation was performed at 120 V. 
2.6.2 Two dimensional gel electrophoresis 
First dimension - non equilibrium pH gel electrophoresis 
2D sample buffer 9 M urea, 1 % (v/v) NP-40, 500 ?L ampholines pI 2-11, 0.5 mL ?-mercapto-
ethanol, 0.3 % (w/v) SDS, MilliQ H2O to10 mL, sterile filtrated, stored in aliquots at -20 °C.  
Overlay buffer 9 M urea, 250 ?L ampholines pI 2-11 MilliQ H2O to10 mL, sterile filtrated, stored 
in aliquots at -20 °C  
First dimension gel 9 M urea, 0.66 mL acryl amide (28.38 g acryl amide, 1.62 g bis-acrylamide 
add MilliQ to100 mL), 2% (v/v) NP-40, 1 mL MilliQ H2O, 250 ?L ampholines pI 2-11, shortly 
before pouring gels added 13 ?L 10% (v/v) APS and 9 ?L TEMED. The gels were polymerized 
under overlay buffer for a minimum of 1h at room temperature. 
Anode buffer      0.01 M H3PO4  
 Cathode buffer  0.02 M NaOH 
The first dimension gel solution was spiked with the radical starters APS and 
TEMED, shortly before it was filled into glass capillaries (15 cm, d= 5 mm), 
where it was polymerized for a minimum time of 1 h at room temperature under 
overlay buffer. Then the ethanol precipitated proteins were solved in 2D sample 
buffer at room temperature for a minimum of 3 h. The overlay buffer was replaced 
with the solved proteins. The electrophoresis was performed at 400 V for 4 h. 
Second dimension SDS-PAGE 
For the composition of the gels as well as running buffer see 2.6.1on page 45.  
Equilibration buffer 10 % (v/v) glycerol, 70 mM DTT, 2.3 % (w/v) SDS, 62 mM 
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tris(hydroxymethyl)-aminomethan pH 6.8 (adjusted with HCl), MilliQ H2O to 50 mL. 
Fuser agarose 10 % (v/v) glycerol, 2.3% (w/v) SDS, 62 mM tris(hydroxymethyl)-aminomethan 
pH 6.8 (adjusted with HCl), 1 % (w/v) agarose added MilliQ to 22.5 mL, agarose was dissolved 
through heating shortly before use, finally 0.025 % (w/v) bromphenol blue and 70 mM DTT were 
added to the hot solution 
The gels from the first dimension electrophoresis were equilibrated with 
equilibration buffer 3x 15 min at room temperature. Afterwards, they were placed 
on the stacking gel and fixed with fuser agarose. The electrophoresis was 
performed at 80 V overnight. The separation length was 4 cm with 5% SDS-
polyacrylamide gel for stacking and 15 cm with 12.5% SDS- polyacrylamide gel 
for separation. For gel composition, see 2.6.1 on page 45. 
2.6.3 Staining of polyacrylamide gels 
Coomassie staining 
Staining solution 0.1 % (w/v) coomassie R250, 30 % (v/v) methanol, 10 % (v/v) acetic acid  
Destaining solution 30 % (v/v) methanol, 10 % (v/v) acetic acid in MilliQ H2O 
The gels with the size separated proteins from electrophoresis were incubated with 
staining solution for 30 min. The staining solution was then replaced by 
destaining solution. The destaining of the background was complete after 
3x 15 min incubation with destaining solution.  
Silver staining 
The silver staining of the polyacrylamide gels with proteins separated by gel 
electrophoresis was performed by using a Page silverTM Kit with its respective 
declared protocol. 
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2.6.4 Semidry Western blotting and immuno detection 
Semidry Western blotting 
Semidry blot buffer 5.82 g tris(hydroxymethyl)-aminomethan, 2.93 g glycine, 20 % (v/v) methanol, 
filled up with MilliQ H2O to 1 L  
Amido black staining solution 50 % (v/v) MilliQ H2O, 40 % (v/v) methanol, 10 % (v/v) acetic acid, 
0.1 % (w/v) amido black| PBST: 0.4 % (v/v) tween was solved in PBS  
Three slices of Whatman paper were saturated with semidry blot buffer and 
placed on the anode of the blot chamber. On this layer, a methanol activated 
polyvinylidenfluoride (PVDF) membrane was placed followed by the SDS-gel 
with the separated proteins (cf. 2.6.1) and three further slices buffer saturated 
Whatman papers. The semidry blot chamber was closed. The proteins were 
blotted at 400 mA for two hours on the PVDF membrane, alternatively for 
15 min, if the gels were used for coomassie-staining afterwards. The success of 
the blotting was controlled via protein staining with amido black solution. The 
background was destained by washing with water.  
Immuno staining of Western blotted proteins 
After blotting, free binding sides of the membrane were blocked with RotiBlock® 
(30 min, RT). The membranes were then incubated over night at 4 °C with the 
first antibody against the antigen of interest (for the used antibodies and their 
dilution, see equipments and materials 2.1). The following day, the antibody 
solution was removed and the membrane was washed 3×5 min with PBST 
followed by incubation with the second antibody, targeting an antigen from the 
first antibody. After one hour of incubation at room temperature, the membrane 
was again washed 3x 5 min with PBST. After these steps, the membranes were 
incubated for 5 min in ECL Plus™ detection system solution which utilizes a 
chemiluminescence technique for the detection of proteins. The emitted light was 
detected by autoradiography. For the documentation, the films were scanned and 
processed using CorelDraw software. Relative signal differences between two 
samples were densitometrically determined with help of ImageJ software. 
CHAPTER 3   
 
 
3 Results 
This chapter compiles the results of this study regarding the identification and 
characterization of the interferon-? induced Ub-conjugates. The central 
experimental approach relied on the close combination of sample pretreatment, 
chromatographic separation and mass spectrometric identification. The general 
analytical objective was divided into several sub-goals which also determine the 
structure of this chapter as described below. 
Prior to the actual analytical experiments, three preparatory investigations had to 
be carried out in order to optimize the sample handling steps. The first concerned 
the selection and optimization of the most effective and best isolation strategy 
with respect to the key analytes (cf. 3.1 p. 50). In a second, an appropriate cell 
culture model had to be established and characterized (cf. 3.2 p. 53). The first two 
steps delivered the prerequisites for the immuno-chemical characterization of the 
Ub-conjugates (cf. 3.3 p. 57). The last step consisted of testing, selection and 
optimization of the mass spectrometric approach. This included, in particular, an 
optimization of the digestion conditions (cf. 3.4 p. 59) and a quantification 
strategy (cf. 3.4.3 & 3.4.4 p. 63 ff.).  
After all aspects of sampling, isolation and quantification were defined, the key 
questions of this work could be resolved. Therefore the devised final analytical 
procedures were applied to the identification of the interferon-? induced 
Ub-targets (cf. 3.5.1 p. 70) and to the identification of probable further Ub-targets 
(cf. 3.5.2 p. 75). In this way, the composition of the different Ub-linkages in the 
chains and the specificity of Ub-conjugates had to be determined, and the 
suitability of the analytical method for their identification had to be proven as 
well. In addition, the preference in ubiquitination for special newly synthesized 
proteins or protein groups had to be explored (cf. 3.5.3 p. 78). Finally, an 
immuno-chemical analysis has been carried out as an independent second method 
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to endorse the existence of the mass spectrometrical determined Ub-targets (see 
3.6 on p.86).   
3.1 Isolation of ubiquitin conjugates 
The basis for the successful analysis of ubiquitin(Ub)-conjugates was the selection 
of an isolation procedure with an optimal efficiency and reproducibility. It 
represented a key processing step for the subsequent characterization and 
identification of the Ub-conjugates. Inherent contaminations are ubiquitous for 
any protein purification from cells. They result from non-covalent adherence of 
proteins due to unspecific binding to the isolation matrix (e.g. agarose) to the Ub-
binding matrix or to the Ub-conjugates. The relative amount of these 
contaminating proteins influences the identification rate and their presence can 
lead to false positive identifications that have to be considered in the evaluation of 
the results.  
In principle, all isolation methods for Ub-conjugates are based on three general 
strategies, i.e. they use the affinity of Ub for either (1) ubiquitin binding domains 
(Maor et al. 2007; Ventadour et al. 2007) or (2) antibodies against Ub (Matsumoto 
et al. 2005; Vasilescu et al. 2005). Alternatively, the isolation can be based on (3) 
N-terminal tagged Ub connected to the subsequent tag affinity matrix (Kirkpatrick 
et al. 2005; Tagwerker et al. 2006; Jeon et al. 2007). The first question to be 
answered concerning these three methods was: Which of the isolation strategies is 
the most effective and best suited for the intended results?  
3.1.1 Evaluation of different isolation methods 
The three different purification strategies were evaluated for the isolation of 
interferon-? induced Ub-conjugates from HeLa cells. In case of the tag-based 
purification technique transfected HeLa cells were used??The Ub-conjugates were 
stabilized by proteasome inhibitors applied to the cells prior to their harvest. An 
inhibitor mix containing especially proteasomal and deubiquitinating enzyme 
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inhibitors were additionally present in the lysis buffer. The lysates were then 
immediately incubated with the respective affinity matrix or, as a negative control, 
with a non-affinity matrix consisting of agarose beads. Consequently, the Ub-
conjugates were eluted from the isolation matrices. Aliquots of the elution 
fractions were immuno-blotted and then probed with an antibody against Ub 
(Figure 8).  
Although each of the applied matrices was able to enrich Ub-conjugates, there 
were considerable differences concerning the efficiency. The most effective 
purification methods were based on the use of yeast Rad23 and the HA-tag 
(Figure 8 (A) and (C) left panel). The use of hHR23b(UBA2), hRpn10(UIM2) and 
His-tag (cf. Figure 8 (A) & (C)), however, led to a poor enrichment, and the 
minimum efficiency of purification was met in the case of ubiquilin 1(UBA) and 
antibodies against Ub from Dako Company (cf. Figure 8 (A) & (B)). Other 
attempts showed also poor enrichment, among them a self made antibody against 
K48-linked tetraUb. They are therefore omitted here.  
Additionally, an evaluation was carried out regarding the unspecific affinity 
matrix binding/ co-precipitation of endogeneous proteins to the haemagglutinine 
epitope (HA) of the influenza virus and sequences equal to 5xHis or longer 
(Figure 9). For this task, a comparative test was performed with both transfected 
and non-transfected HeLa cells each of which were probed with an antibody 
against a sequence containing five histidines (A) or, in the case of the HA-tag, 
against HA epitope (B). In contrast to antibodies against HA, antibodies against 
5xHis showed high cross reactivity with endogenous proteins containing histidine 
rich sequences.  
3.1.2 Decision on the best enrichment method for ubiquitin conjugates  
As described above, high purification efficiencies were only found with the 
purification procedure based on the ubiquitin binding protein Rad23 and on the 
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antibody against the haemagglutine epitope (HA) in connection with HA-tagged 
Ub overexpressing HeLa cells (Figure 8 p. 52). Both methods were applied for 
their particular advantages. In the case of Rad23 based Ub-conjugate purification, 
the advantage is a preferred enrichment of Ub-conjugates targeting proteasomal 
degradation based on its high affinity for K48-linked tetraUb-chains (Raasi et al. 
2003). The advantage of HA-tag based enrichment was that an average spectrum 
of all accumulated Ub-chain topologies and thereby Ub-conjugates could be 
isolated and analyzed (Dammer et al. 2011). Another benefit of the HA-antibodies 
based purification was that they showed no cross reactivity to endogeneous 
proteins (Figure 9) in contrast to Rad23 that binds to non-ubiquitinated proteins 
through UBA-UbL domain interactions (Elsasser et al. 2002; Kim et al. 2004). 
  
 
 
Figure 8 Western blots of 12.5% SDS-PA gels incubated with a polyclonal antibody against 
Ub (Dako), illustrating the elution fractions resulting from the different Ub-conjugate 
isolation strategies; from left to right Ub-affinity enrichment with: (A) Ub binding domains 
(elution fractions (6 N urea/2 N thiourea)): panel 1 Rad23; 2 negative control (only agarose beads); 
3 hRpn10(UIM2); 4 hHR23b(UBA2); 5 hUbiquilin-1 (UBA), (B) Ub specific antibody (Dako) 
(elution with 0.1 M glycine pH 2.5); (C) N-terminal tagged Ub: panel 1 HA-tagged and panel 2 
untagged Ub-conjugates as negative control purified with monoclonal antibodies against HA 
(elution with 0.1 M glycine pH 2.5); His-tagged Ub-conjugates panel 3 eluted from Ni(NTA) 
matrix with 0.25 M imidazole. 
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Figure 9 Cross reactivity of the affinity matrix with endogeneous proteins: (A) Lysates from 
HeLa cells, 10xHis-Ub-EGFP, transfected (left panel) and untransfected HeLa cells (right panel), 
separated via 12.5 % SDS-PAGE, Western blotted and probed with antibodies against 
pentahistidine; (B) lysates from HA-Ub-EGFP transfected (left panel) and untransfected HeLa 
cells (right panel), separated via 8 % SDS-PAGE and Western blotted, staining based on 
antibodies against haemagglutinine epitope (HA). 
 
The disadvantage of a HA-tag based enrichment, in particular, the alterations of 
the cell metabolism resulting from transfection were deliberately accepted, as in 
this study two cell stages/ time points were compared. Nevertheless, for 
reproducibility, a well characterized stable cell culture had to be established as a 
model system with overexpressing HA-tagged Ub.   
3.2 Establishment of the cell culture model 
The use of N-terminal tagged ubiquitin in different host vectors is very common 
for the analysis of ubiquitin conjugates (Tagwerker et al. 2006; Jeon et al. 2007; 
Xu et al. 2008). The pEGFP-N3 vector with a pCMV (cytomegalo virus promoter) 
based overexpression system was chosen adapting a method developed by 
Kirckpartick et al. (Kirkpatrick et al. 2005). This method is based on the 
expression of a fusion protein consisting of N-terminal tagged Ub which is C-
terminally fused to a green fluorescence protein (EGFP).  
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Figure 10 Working principle of the transfected HA-Ub-EGFP fusion protein encoding 
pEGFP-N3 vector: After transfection (A), the selection of positive transfected cells from 
untransfected can be performed via the G418 antibiotic resistance carried by the pEGFP-N3 
vector. The HA-Ub-EGFP fusion protein that is overexpressed (B), controlled by a pCMV 
promotor, will be cleaved by Ub carboxy hydrolases (C) into EGFP (green fluorescent protein), 
(D) its fluorescence can be detected via FACS measurements (E), and by HA-tagged Ub (F), 
which can be integrated into Ub-chains via its activated free C-terminus. The Ub-conjugates that 
are infiltrated by HA-tagged Ub can be isolated using antibodies against HA which are coupled to 
beads (G). 
In vivo, the fusion protein is cleaved by cellular deubiquitinases and the tagged 
Ub is integrated into Ub chains; thus, the fluorescence of the EGFP can serve as a 
detectable expression control (see detailed mechanism in Figure 10). 
To establish the cell culture model system haemagglutinine (HA) tagged ubiquitin 
(Ub) was cloned into a pEGFP-N3 vector and transfected into human HeLa cells. 
The selection of a stable transfected HeLa cell line was based on the antibiotic 
resistance encoded on the pEGFP-N3 plasmid.  
The transfected HeLa cells had to be well characterized before they could be used 
as the model system. First, the transfection efficiency and the stability of the HA-
Ub-EGFP expression (cf. section 3.2.1) had to be determined. The intended 
cleavage of the fusion protein and thereby the successful activation of the HA-
tagged Ub for its integration into the Ub-chains had to be proven, too, as well as 
the most important aspect, the interferon-??inducibility of the?changes in Ub-
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conjugate accumulation in the transfected cells (cf. section 3.2.2, p.56). The 
following subsections present the corresponding results with regard to these 
aspects. 
3.2.1 Analysis of transfection efficiency and expression stability 
In order to evaluate the transfection efficiency and stability of the transfectants, 
the fluorescence and the number of GFP positive cells were determined using 
flow cytometry. The experiments revealed that about 80 % of the cells exhibited 
constant fluorescence during sub-cultivation which indicated their stable HA-Ub-
EGFP expression (Figure 11 (A)). The Ub-chain incorporation of HA-Ub was 
investigated by comparing western blotted immuno-precipitated HA-Ub-
conjugates probed with either HA or Ub-antibodies. As shown from Figure 12 
(A), both showed a broad high molecular weight “smear” arising from the Ub-
conjugates.  
 
 
Figure 11 Expression of the HA-Ub-EGFP fusion protein in the stably transfected cell line 
determined by flow cytometry and fluorescence microscopy: (A) Fluorescence intensity of 
1000 cells of the HA-Ub-EGFP transfected HeLa type (green curve) and untransfected HeLa type 
(black curve); y-axis: cell number, x-axis: fluorescence intensity of EGFP (FL1-H). (B): 
microscopic photos of the transfected cells taken with normanski optics (upper photo) and 
detected in terms of the emitted fluorescence light with a GFP filter (photo below). 
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Figure 12 Test results regarding HA-Ub expression, HA-Ub incorporation into Ub-chains as 
well as IFN? inducibility of Ub-conjugates in the HA-Ub-EGFP stably transfected HeLa 
cells. Western blots of 15 % SDS-PA gels: (A) proof of HA-Ub chain integration, enriched HA-
Ub-conjugates with antibodies against HA (left panel) show same high molecular weight “smear” 
as the antibodies against Ub (right panel); (B) the expressed fusion protein HA-Ub-EGFP is 
efficiently cleaved from HA-Ub (only free EGFP, 26 kDa, detected in the transfected cell lysates). 
Ub-conjugates accumulate in response to 8 h IFN??induction in the transfectants (cf. -/+ IFN??in 
2nd and 4th panel), but the difference is lower than detected for normal HeLa cells (compare -/+ 
IFN? in 1st and 3rd panel) when normalized ?GAPDH signal (densitometric quantification).  
 
These results demonstrate the successful establishment of a stably transfected cell 
line expressing HA-tagged ubiquitin that is efficiently incorporated into Ub-
chains.  
3.2.2 Interferon-? influence on the model system 
For the intended analysis of interferon-? induced Ub-conjugates, the influences of 
this cytokine on the stable transfectants had to be determined. The samples were 
prepared by treating each stably transfected and non-transfected HeLa cells for 
eight hours with and, in parallel, without interferon-?. An?induction time of eight 
hours was chosen for the following investigations, in agreement with the 
maximum of the conjugate accumulation as described by U. Seifert et al. (Seifert 
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et al. 2010). It was anticipated that, in this way maximum changes would be 
obtained and detected. The relative differences between the Ub concentrations of 
each of the four cell lysates were quantitatively compared via Western blotting of 
the lysates, by normalizing the densitometric ?Ub Western blot signal on the 
?GAPDH loading control signal (Figure 12 (B)).  
The experimental results in Figure 12 (B) illustrate that the ratio between 
interferon-? induced and uninduced Ub-conjugates amount to 2.6fold for the 
untransfected HeLa cells and only 1.5fold in the Ub overexpressing cells. This 
difference in the Ub-conjugate accumulation obviously resulted from a basically 
higher level of Ub expression and conjugation in the stable transfectants. 
Based on the observed difference in the ubiquitination of uninduced and induced 
stable transfected HeLa cells, it was reasonable to apply the stable transfectants 
for the intended experiments.  
Additional flow cytometric experiments (cf. supplementary data 5.3.1 p. 137f) 
unambiguously showed that the overexpression of the tagged Ub, as well as cell 
volume and granularity are not influenced by interferon-? and, as a second result, 
that the cell volume and granularity are also not influenced by transfection of the 
HA-Ub-EGFP plasmid.    
3.3 Analysis of ubiquitin-conjugates via 2D gel electrophoresis 
Due to its superior resolution for separation of complex mixtures compared to a 
one-dimensional gel electrophoresis, the two-dimensional gel electrophoresis was 
used for the characterization of the interferon-? induced changes in Ub-conjugates 
(cf. sections 3.1 and 3.2). Either interferon-??induced or uninduced HA-tagged 
ubiquitinated proteins were separated as first dimension via their isoelectric point 
(x-axis of Figure 13 p. 58) followed by a separation regarding molecular weight 
(y-axis of Figure 13) as second dimension.  
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Figure 13 Two dimensional gel electrophoresis of HA-tagged Ub-conjugates isolated from 
either uninduced (left) or 8 h interferon-? induced (100 U/mL IFN???right) HA-Ub-EGFP stably 
transfected HeLa cells: first dimension (horizontal): non-equilibrium pH gel electrophoresis (pI 2-
11; 4 h, 400 V); second dimension (vertical): SDS-PAGE (12.5 % polyacrylamide gel); (A) same 
gels silver stained after shortly Western blotted; (B) Western blot (PVDF membrane, 
400 mA,15 min) showing HA-positive signals. 
The gels were shortly blotted, then the gels were stained with silver (A) and the 
blot membrane was probed with antibodies against HA (B). Comparison of the 
silver-stained gels which are presented in Figure 13 shows that a higher amount of 
proteins could be enriched from the interferon-? induced cells (right side of (A)) 
as compared to uninduced cells (left side of (A)). Similar to the one dimensional 
electrophoresis (Figure 12), the results of the Western blot (Figure 13 (B)) 
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analysis showed a high molecular “smear”, but in addition, distinct spots could be 
observed, too. There are also differences in the distribution of the Ub-conjugates 
with respect to the uninduced Ub-conjugates (Figure 13 (B)). A decisive result is 
that the interferon-? induced Ub-conjugates are only partially separated in the first 
dimension. This indicates a characteristic feature of the Ub-conjugates and, 
additionally, shows that this technique is not well-suited for their separation. 
Adding up the intensity of all Western blot signals results in a nearly 1:1 ratio as it 
is expected due to the use of an antibody against HA-tag. The concentration of 
HA-tagged Ub should be equal due to the interferon-? uninducible overexpression 
of HA-tag.  
3.4 Optimization of mass spectrometric approach 
In general, there are two possible ways to analyze a complex protein mixture by 
mass spectrometry. The first is a gel electrophoretic separation, followed by “in 
gel” digestion and a liquid chromatographic separation of the peptides for the final 
mass spectrometric analysis (Marotti et al. 2002; Seyfried et al. 2008). The second 
strategy corresponds to an initial “in solution” digest of the conjugates, followed 
by a liquid chromatographic separation of the complex peptide mixture with a 
long gradient and, again, a final mass spectrometric analysis (Kirkpatrick et al. 
2005; Tagwerker et al. 2006; Jeon et al. 2007). Both methods were tested in this 
work in order to find the most suitable one for this study (cf. 3.4.2, p. 62).  
In both strategies, the proteins had to be digested to peptides to allow their 
identification. Therefore, it is obvious that the optimization of the mass 
spectrometric analysis of Ub-conjugates had to be started by optimizing their 
digestion with peptidases.  
3.4.1 Digestion of ubiquitin-conjugate with peptidases 
Trypsin is a protease which cleaves protein strands behind arginine and lysine 
positions. It is commonly used to pretreat Ub-conjugates prior to a subsequent 
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mass spectrometric analysis (Peng et al. 2001; Marotti et al. 2002; Peng et al. 
2003). This is due to its special property to omit the cleavage of the protein chain 
at an isopeptide bond adjacent to a lysine. An isopeptide bond resulting from 
ubiquitination leads to peptides with one tryptic miscleavage and the release of the 
two C-terminal glycines (that follow an arginine) from Ub at the ubiquitinated 
lysine (Figure 14 (A)). This diglycine motif clearly indicates an Ub-site and can 
be observed in the mass spectrum as a mass shift of 114.04 Da with respect to the 
unmodified and modified peptide (Marotti et al. 2002; Peng 2008).   
 
 
Figure 14 Trypsin (A) and LysC (B) cleavage sites in the amino acid sequence of 
tetraubiquitin (K48-linked) with their respective Ub-site indicator peptides (K48-linkage). 
Trypsin cleaves protein chains behind lysines and arginines ((A) K & R, blue letters), LysC behind 
lysines ((B) K, blue letters). Due to miscleavage at an ubiquitin attached to a substrate lysine (K, 
black letter), an Ub-site indicator peptide (red box) is produced. In case of Trypsin or a 
combination of Trypsin + LysC digest the Ub-site is marked by a diglycine (GG)-motif (A). 
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Besides this classical tryptic digest a successfully applied technique was the 
sequential digest of Ub-conjugates with LysC, an endopeptidase cleaving peptide 
bonds at the C-terminus of lysine and S-aminoethylcysteine residues, and trypsin 
(Tagwerker et al. 2006; Jeon et al. 2007). There seems to be no study up to now 
making a direct comparison of LysC, trypsin and sequential LysC-trypsin 
digestion protocols for the analysis of Ub-conjugates and especially Ub-site 
detection. In order to find the optimum digestion protocol, an answer had to be 
found to the question whether LysC improves or disturbs the detection of Ub-sites 
by influencing the tryptic indicator diglycine motif.  
To answer this, K48-linked tetraUb as a model substrate was digested in three 
different ways and then subjected to mass spectrometric analysis. The first variant 
consisted of a digestion with only LysC for three hours, the second was carried 
out with LysC-digestion for three hours followed by an overnight digest with 
trypsin, and the third sample was digested only with trypsin overnight which fits 
to the standard procedure. 
The semiquantitative analysis of the mass spectrometric results of these three 
digestion experiments are shown in Figure 15. The LysC pre-digest led to an 
increased signal intensity of detected peptides (A) and to a 5fold higher number of 
detected peptides with diglycine motifs as compared to the digestion with only 
trypsin (B). LysC also did not seem to cleave at lysine positions adjacent to an 
isopeptide bond. A diglycine motif cannot be detected in the three hours of the 
LysC digest, due to the fact that LysC does not cleave at positions after arginines 
resulting in a different K48-linkage indicator peptide (cf. Figure 14 (B)). 
The use of a pre-digestion with LysC followed by a tryptic digest represented the 
best method for the mass spectrometric preparation of Ub-conjugates. Therefore, 
this variant was selected as an appropriate method for all following mass 
spectrometric experiments. 
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Figure 15 Mass spectrometrically based comparison of the three different test digestions of 
tetraUb (K48-linked) with either the peptidase LysC or Trypsin/P or both for determining 
the optimal conditions for Ub-conjugate analysis: Three digests of K48-linked tetraUb (x-axis) 
have been performed with LysC (3 h, RT), with LysC (3 h, RT) followed by trypsin (o/n, RT), 
with trypsin only (o/n, RT). (A) ? - overall intensities ± S.D. normalized to the tetraUb sample 
which was digested only with trypsin; (B) ? - number of fragmented K48-linkage indicator 
peptides showing a diglycine motif  ± S.D.  normalized to the samples with only tryptic digestion 
(peptides containing only one tryptic miscleavage) 
3.4.2 Selection of the sample preparation procedure 
Finally, the most favorable sequence of preparation steps before mass 
spectrometric analysis had to be determined in order to guarantee the subsequent 
optimal analysis of Ub-conjugate. It had to be decided whether the Ub-conjugates 
should be separated first via gel electrophoreses followed by “in-gel” digest or 
whether they should be first digested to peptides “in-solution” and subsequently 
separated with high resolution for an optimal mass spectrometric analysis. 
The first variant, i.e. applying the mass spectrometric analysis to the Ub-
conjugates as separated by electrophoresis should have the advantage that, after 
short blotting of the Ub-conjugates, positive gel areas could be selected and 
directly subjected to digestion afterwards. A detection of low molecular weight 
proteins in high molecular weight areas of the gel accompanied by the presence of 
Ub potentially indicates their ubiquitination, even if no Ub-site can be observed 
(Seyfried et al. 2008). A corresponding test was performed with two-dimensional 
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electrophoresis deliberately accepting the restricted Ub-conjugate separation 
(described in section 3.3 p. 57). The subsequent mass spectrometric results, 
however, were not as successful as expected (data not shown). In fact, many 
contaminants were detected, that lower the coverage of conjugates. Furthermore, 
no Ub-site could be identified (except for K48 in Ub).  
Accordingly, the second variant of Ub-conjugate preparation for mass 
spectrometric detection, the “in-solution” digestion was also investigated. The 
smaller number of working steps of this approach helps to reduce contaminations. 
It is also characterized by a more efficient digestion as no gel-matrix slows down 
the molecular diffusion of the reactants and products of the digestion. 
Overall, the results of the “in-solution” digest showed less contaminants and a 
better protein identification rate as compared to the “in-gel” digest (data not 
shown). Therefore this approach was chosen for all further investigations.  
As a result of these pretesting experiments, most of the proteins were detected in 
both samples (induced/uninduced) with repect to both approaches, for “in-
solution” as well as for “in-gel” digest. Additionally, the individual sample 
preparation evokes a distinct surrounding for the particular Ub-substrates, usually 
termed as matrix effects in analytics. Thereby, the differing matrices of induced 
and uninduced Ub-conjugates digest might lead to a detection in only one of the 
two different samples during ionization and mass spectrometry, although a protein 
might be present in both samples. Accordingly, it was necessary to apply a 
quantification method in order to clarify the differences between the two stages 
(induced/ uninduced).  
3.4.3 “Short” stable isotope labeling with amino acids in cell culture  
Different mass spectrometry based quantification techniques for proteins are 
available (Bantscheff et al. 2007; Pieper et al. 2009; Unwin 2010). In the present 
work, stable isotope labeling with amino acids in cell culture (SILAC) was used. 
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Regarding to the early combination of two samples and, therefore, the possibility 
to treat the sample as a single one after cell lysis, SILAC offers high sample 
comparability and low sources of quantitative errors. The technique was adapted 
from Mann et al. (Ong et al. 2006).  
In comparison to the classic approach of a complete labeling of all cellular 
proteins, in which the cells had to grow in SILAC medium for a few passages, a 
shorter labeling period was chosen. This appeared to be of particular importance 
since prolonged labeling would lead to an increase of false positive Ub-conjugate 
identifications (through labeled co-precipitates). With regard to the aimed 
investigation of newly synthesized proteins, the optimal labeling time of the order 
of minutes would have been critical for the identification rate and the 
quantification of the labeled proteins. As a compromise, the cells were labeled for 
eight hours, which is the same time as the cytokine stimulation. This experimental 
design ensured that only those proteins were labeled which were synthesized 
during interferon-? treatment. Nevertheless, in awareness of the quantification 
restrictions a further experiment using a labeling period of one hour was 
performed, which guarantees that only the newly synthesized proteins are labeled.  
 
3.4.4 Final optimized experimental approach 
The following describes the experimental design (Figure 16) as finally applied for 
8 h SILAC (A) and 1 h SILAC (B) experiments. For the 8 h SILAC experiments, 
HA-Ub-EGFP stably transfected HeLa cells (A.1) or non-transfected HeLa cells 
(A.2) as negative control were cultivated for one day in Iscove medium. Then the 
cells were adopted for 24 hours to SILAC medium containing “light” lysine and 
arginine (natural isotopes only). The adopted cells were thoroughly washed with 
buffer to eliminate any remaining light isotope contaminants of lysine and 
arginine.  
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For labeling, one half of the cells was incubated with SILAC medium containing 
interferon-? and the so-called ”heavy” isotopes, with a molecular weight of lysine 
+ 8 Da and arginine + 10 Da (as compared to the molecules with natural isotopes). 
As reference, the second half of the cells was incubated with SILAC medium in 
parallel which contained no cytokines, but the so called “medium heavy” isotopes 
with the molecular weights of arginine + 6 Da and lysine + 4 Da. The lysine and 
arginine isotopes were incorporated into the proteins synthesized during an 
incubation of eight hours (Figure 16 (I)).  
The HA-tagged Ub-conjugates from the lysate mixture (A.1) as well as the co-
precipitants from the non-transfected lysates mixture as negative control and 
indicator for co-precipitation (A.2) were then precipitated with a HA-antibody 
matrix (Figure 16 (II)). After elution, the Ub-conjugates/ co-precipitants were 
digested and the peptides were separated via reversed phase nano-liquid 
chromatography using a long acetonitrile gradient.  
The detection was performed by using a LTQ-Orbitrap mass spectrometer. The 
data were analyzed with the MaxQuant software package. Generated peak lists 
were searched on a MASCOT search engine against a manually curated version of 
the IPI (international protein index) human database. A required false discovery 
rate (FDR) of 1 % at peptide and protein level, a minimum required peptide length 
of six amino acids and a minimum SILAC pair count of three were chosen. The 
median of the relative signal intensity of detected SILAC pairs served as the 
reference value for quantification (Figure 16 (III)). 
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For the 1 hour SILAC experiments, HeLa cells were cultured in Iscove medium 
without and in parallel with interferon-? for 6.5 hours (Figure 16 (B.1)). Then, the 
cells were thoroughly washed with buffer to eliminate remaining light isotope 
contaminants of lysine and arginine, followed by incubation (30 min) with SILAC 
medium which was free of lysine and arginine. After starvation, ”heavy” isotopes 
with a molecular weight of lysine + 8 Da and arginine + 10 Da (as compared to 
the molecules with natural isotopes) were added to the interferon-? treated cells, 
and “medium heavy” isotopes that had a molecular weight of arginine + 6 Da and 
lysine + 4 Da were added to the cells which were not treated by cytokine. The 
lysine and arginine isotopes were incorporated into the newly synthesized proteins 
during an incubation of one hour (Figure 16 (I)). The Ub-conjugates were isolated 
via a Rad23-agarose affinity chromatography (Figure 16 (II)).  
As a control experiment, interferon-? stimulated HeLa cells (Figure 16 (B.2)) 
were labeled in parallel with “medium heavy” and “heavy” isotopes of arginine 
and lysine for one hour (same sample treatment as (B.1)). The “medium heavy” 
labeled lysates were precipitated with agarose in order to check for unspecific 
precipitation, while the “heavy” labeled Ub-conjugates were isolated via Rad23-
agarose. Finally, the eluates were combined (Figure 16 (II)). 
The eluted Ub-conjugates/ co-precipitants were digested and analyzed in the same 
way as the ones from the 8 h labeling experiments (Figure 16 (III)) with exception 
of one analytical parameter, i.e. the minimum SILAC pair count was set to one 
instead of three. 
3.5 Results of mass spectrometric ubiquitin conjugate analysis 
It was shown in section 3.2.2 that an interferon-? induction between zero and eight 
hours led to a 2.6-fold increase in the Ub-conjugate accumulation of HeLa cells 
and only a 1.5-fold increase in the transfected Ub overexpressing cells, as used in 
this work. When applying the HA-Ub overexpressing cells as well as the non-
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Figure 17 Inducibility of Ub-conjugate accumulation in SILAC samples. – On the left: 
Lysates from 8 h “medium heavy” (M) labeled, uninduced and “heavy” (H) labeled IFN? 
induced (8 h) HA-Ub-EGFP stably transfected HeLa cells. On the right: Lysates from 1 h 
“medium heavy” Arg/Lys (M) labeled uninduced and 1 h “heavy” Arg/Lys (H) labeled IFN? 
induced (8 h) non-transfected HeLa cells. In both cases, the lysates were separated via SDS-
PAGE (12.5 % & 15 % PA gel), Western blotted und probed with antibodies against Ub & 
GAPDH. 
transfected HeLa cells to the SILAC technique, no increase in the Western blot 
signal could be observed (Figure 17). This has to be attributed to the SILAC 
medium which might cause oxidative stress due to the lack of growth factors 
(dialyzed fetal bovine serum) or due to the applied excess of basic amino acids 
(pH).   
Comparing the relative amount of the overall mass spectrometrical detected 
intensities of “medium heavy” (M) to “heavy” (H) peptides (Table 4), a relative 
amount of 1.2 (H/ M) could be observed for the 8 h SILAC experiment 
(column 2) representing a slight increase in enriched interferon-? induced to 
uninduced Ub-conjugates. After subtracting the background (column 3), this 
amount was decreased to a ratio near 1:1 which was also observed for the 1 h 
labeling results (Table 4 column 5) and which agrees with the Western blot results 
(Figure 17).  
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Table 4 Labeling efficiency of the 8 h and 1 h SILAC experiments. Relative intensity of all 
detected signal intensities of “heavy” labeled peptides (H) referred to total detected signal intensity 
of all “medium heavy” peptides (M). The ratio (H/M) represents 8 h and 1 h interferon-? induced / 
uninduced proteins that are present in enriched Ub-conjugates pool (column 2 & 5) and 
background precipitation (8 h SILAC negative control/ co-precipitants, column 3). Column 4 
represents the ratio of interferon-??induced enriched Ub-conjugates/ co-precipitants. 
8 h SILAC experiments 1 h SILAC experiments 
Relative signal intensity 
HA-Ub-EGFP transfected 
HeLa; antiHA-Agarose:
 8 h (H) /0 h (M) IFN? 
HeLa;  
antiHA-Agarose: 
 8 h (H) /0 h (M) IFN? 
HeLa; 8 h IFN?? 
Rad23-Agarose (H) 
/Agarose 
enrichment (M) 
HeLa;  
Rad23-Agarose: 
 8 h (H) /0 h (M) 
IFN? 
H/M 1.1 ± 0.2 1.2 1.3 ± 0.4 1.0 ± 0.3 
 
The one hour labeling experiment, comparing Rad23-based enriched Ub-
conjugates with agarose co-precipitants (Table 4 column 3), shows that by trend a 
higher amount of labeled proteins is found in the Ub-conjugates. This last aspect 
agrees with the knowledge that after interferon-? induction mainly newly 
synthesized proteins are ubiquitinated (Seifert et al. 2010). 
During the analysis of the enriched Ub-conjugates from 8 h labeling experiments 
via mass spectrometry, ca. 1500 proteins were identified per sample of which 650 
were quantified in three replicates. In the 1 h labeling experiments, only about 450 
proteins per sample were identified of which 260 were quantified. In all cases, 
quantitative differences between IFN? induced und uninduced Ub-conjugates 
could be observed in the datasets (that will be described below), according to their 
protein and Ub-chain composition, although the amount of Ub-conjugates seems 
to be equal (cf. Figure 17).  
The evaluation of the identified and quantified proteins resulting from mass 
spectrometry was carried out with regard to different aspects. First, the IFN? 
influence on Ub-chain linkages and substrate Ub-sites was investigated (cf. 3.5.1). 
Afterwards, ubiquitination candidates were selected that exhibited a reproducible 
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concentration increase in the IFN? induced sample as determined by 
quantification of the mass spectrometric results (cf. 3.5.2 p. 75). 
Finally, it was determined, whether the IFN? induced ubiquitination showed any 
substrate specificity (cf. 3.5.3 p. 78) and whether some substrates were 
contaminants from co-precipitation or real Ub-targets (cf. 3.5.4 p. 79). It has to be 
noted that there is an experimental limitation of the mass spectrometric analysis of 
complex Ub-conjugate mixtures which prevents an evaluation of the Ub-chain 
length or topology and, thereby, of the functions of ubiquitination for distinct 
substrates. 
3.5.1 Evaluation of ubiquitination sites 
An ubiquitination site is unambigously correlated to the presence of a diglycine 
motif (cf. Figure 14 (A) p. 60) which is represented by a 114.04 Da mass shift in 
the mass spectrum. After elimination of false positives eight validated and two 
potential peptides were selected containing this diglycine motif and showing 
seven different ubiquitination sites (Table 5 p. 72). Five of these seven Ub-sites 
belonged to Ub itself (cf. 3.5.1.1). The other two ubiquitination sites 
indicated Ub-substrates (cf. 3.5.1.2 p. 73). 
3.5.1.1 Ubiquitin chain linkage types  
The concentration of ubiquitin itself showed only an insignificant increase which 
was probably attributable to the low transcription enhancement (cf. Figure 18 
(A)). The following Ub-sites were detected in the 8 h labeling experiments K6, 
K11, (K27 low score), K48 & K63 and K6, K11, K48 & K63 in the 1 h labeling 
experiments (cf. MS2 spectra in supplementary data 5.3.2 p. 139).  
The focus of this subsection lies on the relative quantification results of the 
particular concentrations of IFN? induced and uninduced Ub-linkages (cf. Figure 
18 (B)-(D)).  
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Figure 18 Changes of ubiquitin gene transcription and Ub-linkage indicator peptides in
presence and absence to interferon-?: (A) Transcriptional changes of the four ubiquitin genes
represented by the median of binary logarithmical changes (Log2FC) between 8 h and 0 h
interferon-? induction. (B) & (C) The median values (n=3) of the absolute signal intensities of the
Ub fragments (modified by Ub (GG) (D)) detected by mass spectrometry are shown ± SD.
(B) results from 8 h labeling experiments, (C) from 1 h labeling experiments. ? peptides labeled
with “medium heavy” isotopes of Arg/ Lys (+ 6 Da/ + 4 Da) representing Ub fragments from
IFN? uninduced Ub-conjugated, ? peptides labeled with “heavy” isotopes of Arg/ Lys
(+ 10 Da/+ 8 Da) representing Ub fragments from interferon-? induced Ub-conjugates.   
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The detected peptides were analyzed by classifying them according to the 
intensity of the isotopic variants as “light”, “medium heavy” (M) and “heavy” 
(H). One detected Ub-site in the 8 h SILAC samples was the K27-linkage. It was 
only detected with a low Mascot score which marks it as potential present Ub-
linkage type in the samples. Furthermore, it was only detected as natural isotope 
which allows no conclusions about interferon-? induced quantitative changes. All 
other diglycine containing peptides (K6, K11, K48 & K63) were detected in all 
three isotopic variants in the 8 h labeling experiments. No change in the K63 and 
K6 linkages, a small decrease of K48, and an increase of K11-linkages were 
observed (Figure 18 (B)). It has to be mentioned that the analyzed K6 containing 
peptides are exclusively from endogeneous (untagged) Ub. Considering the results 
of the 1 h SILAC experiments, the linkage indicator peptides K6, K11, K48 and 
K63 were detected (Figure 18 (C)). Only the K48-linkage indicator peptide was 
quantified. In contrast to the 8 h labeling results, it showed in an increase by trend.  
Nevertheless, a key result for the quantified Ub-linkage indicator peptides (Figure 
18 (B) & (C)), except for K11 Ub-site indicator peptide, was that the standard 
deviation of the peptide intensity of the interferon-? induced peptides (“heavy” 
isotopes) was higher than that of the uninduced. This observation suggests a more 
rapid turnover of IFN? induced K6, K48 and K63 linked Ub-conjugates due to a 
higher remaining deubiquitinating enzyme/ proteasomal activity. This fact 
prevents an accurate determination of the cellular composition of the Ub-chains.  
3.5.1.2 Ubiquitination sites of substrates 
Apart from Ub and false positive Ub-sites, two additional proteins showed a 
diglycine motif detected only in the samples from 8 h SILAC experiments (Table 
5 p. 72). A single Ub-site indicator peptide from “chaperone-ABC1-like protein” 
shows a low Mascot score and this protein can thereby be seen as potential Ub-
substrate (cf. Figure 19 (A)).  
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Figure 19 MS2 spectra from 8 h SILAC experiments; potential Ub-site indicator peptide (low 
Mascot score) from chaperone-ABC1-like protein (A) and Ub-site indicator peptide of 4F2 
cell-surface antigen heavy chain protein (B). Signals from ion fragments are marked in the 
spectra (left hand side), their calculated masses with corresponding mass deviation (?? are shown 
in the table (upper, right hand side). Detection parameters and sample description as well as amino 
acid sequence with marked Ub-side are presented (lower right hand side); PEP= posterior error 
probability, Mascot score, PTM= post translational modification score. 
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Furthermore, both, indicator peptide and protein could not be quantified which 
indicates that it does not belong to the interferon-? induced accumulating Ub-
conjugates. The second detected Ub-site (cf. Figure 19 (B)) belongs to the “4F2 
cell-surface antigen heavy chain protein” and has already been described before 
(Meierhofer et al. 2008). Indeed, this protein was abundant in the sample, but its 
Ub-site indicator peptide was only detected in unlabeled form and its 
quantification at the protein level showed no significant changes (Log2FC (H/M) 
= 0.03, cf. Table 5 p. 72). These findings indicate that this protein also does not 
belong to the accumulating Ub-conjugates.  
Nevertheless, in spite of the low number of identified and quantified Ub-sites, this 
quantification was critical in light of the original aim, namely the investigation of 
the differences between induced and uninduced Ub-conjugates. Although the 
number of quantified and identified diglycine motifs could not be increased 
through experimental modifications, the remaining extensive datasets of the mass 
spectrometric experiments could be analyzed well in terms of potential Ub 
substrates as discussed in the following.  
3.5.2 Candidates for interferon-? influenced ubiquitination 
In targeting the identification of potential interferon-? induced ubiquitinated 
proteins, first of all, the binary logarithm of the proteins ratio “heavy” to ”medium 
heavy” isotopically labeled peptides was consulted. In this way, potential IFN? 
induced Ub substrates could be identified by searching for all proteins that have a 
log2FC (H/M) value above zero, because this means that their concentration in the 
isolated interferon-? induced Ub-conjugates is higher than that in the uninduced. 
Taking into account possible variations due to experimental preparation, the 
median of three biological replicates was calculated. A median above zero was 
regarded as increased by trend, a value of log2FC (H/M) above 0.25 (equal to a 
1.2fold increase) can be seen as increased and above 0.5 (equal to > 1.4fold 
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increase) as significantly increased. Based on this definition, the list of the 8 h 
SILAC mass spectrometric results for the Ub-conjugates was filtered again. 
The determination of the relative changes in the pool of Ub-conjugates in 
response to interferon-? leads to the result that 62 proteins were identified as Ub-
candidates from the results of 8 h labeling SILAC experiments (cf. supplementary 
data 5.3.3.1 p. 144). From these 62 proteins seven showed a reproducible 
significant increase higher than 1.4fold (log2FC (H/M) > 0.5) which was detected 
in all three biological replicates. Four of these proteins were also significantly 
increased in the background precipitation from non-transfected HeLa lysates with 
HA-antibodies. These four proteins were the signal transducer and activator of 
transcription “Stat1”, the tripatite motif “Trim21”, the cytoplasmatic 
tryptophanyl-tRNA synthetase “Wars” and finally the regulatory subunit of 
glutamate-cysteine ligase “Gclm”. The transcription of the genes of all four 
proteins were IFN? inducible and, therefore, it was an expected result, explainable 
by the proportional increase of these proteins in the pool of defective ribosomal 
products (DRiPs) as a consequence of the increased transcription and translation 
rates (latter was represented by the increase of the four proteins in the background 
precipitation). On the other hand, due to the simultaneous detection of these 
proteins in the background sample, one cannot exclude that these proteins are co-
precipitants and not ubiquitination targets.  
Three further proteins showed a reproducible cytokine stimulated increase by 
more than a factor of 1.4 in the pool of Ub-conjugates, but they were not detected 
in the negative control, which indicates that they are Ub-targets. These proteins 
were the immuno proteasome subunit “Lmp7” (also called ?5i), the proteasome 
activator “PA28?” and the poly[ADP-ribose] polymerase “Parp14”. The 
transcription of Lmp7, PA28? and Parp14 was IFN? inducible (cf. supplementary 
data Table 6 p. 144). It is highly probable that these proteins represent interferon-? 
induced DRiPs and Ub-conjugates, whereas due to the used HA-tag based 
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enrichment, it cannot be excluded that these conjugates are monoubiquitinated and 
thereby not targeting for proteasomal degradation.  
However, a number of other proteins also showed a more than 1.2fold increase in 
concentration and were therefore also identified as potential IFN??induced 
ubiquitination targets. The corresponding data of the in total 62 proteins are listed 
in the compiled supplementary data at the end of this work (cf. Table 6 p. 140).  
 
 
Figure 20 Comparison of interferon-? effects on transcription and ubiquitination. All proteins 
that show a Log2FC (8 h/ 0 h IFN?) > 0.26 were selected from affimetrix micro array (blue circles) 
and SILAC data (median of three biological replicates, 8 h SILAC: yellow circle, 1 h SILAC: 
green circle). The numbers represent the genes that show only an increase in the affimetrix data 
(transcribed genes) as well as the proteins that are only increased in purified Ub-conjugates 
(SILAC data). The overlapping region represents the number of proteins that show an increased 
translation and ubiquitination in response to IFN? ((A) denotes 8 h SILAC, (B) is 1 h SILAC). (C) 
represents the correlation of 8 h SILAC (yellow circle) and 1 h SILAC (green circle) experiments.  
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Regarding the quantification results from the 1 h SILAC experiments, it has to be 
emphasized that the results have to be considered with caution, due to the fact that 
they show high standard deviations and that their quantifications are sometimes 
based on one individual peptide species. Nevertheless, 51 proteins have been 
selected as Ub-candidates from the data showing an increase in the interferon-? 
Rad23 enriched ubiquitinated proteins of higher than 1.1fold by trend. The 
corresponding data are listed in the compiled supplementary data at the end of this 
work (cf. Table 7 p. 148). Due to the high affinity of Rad23 for proteasomal 
targets (Raasi et al. 2003) it is likely that these 51 proteins belong to the 
accumulating Ub-conjugates. 
A comparison of the 51 Ub-candidates selected from 1 h and the 62 Ub-
candidates/Ub-targets from 8 h SILAC results showed an overlap of 5 proteins (cf. 
Figure 20 (C) p. 77). But the comparability is restricted due to the distinct 
experimental setup. In particular, transfected HeLa cells and HA-tag based Ub-
conjugate enrichment were used for the 8 h labeling experiments in contrast to 
non-transfected HeLa cells and Rad23 based enrichment in case of the 1 h SILAC 
experiments. Furthermore, different nanoLC gradients (incline) have been used 
for the peptide separation before mass spectrometric analysis. 
3.5.3 Preferences of ubiquitination for newly synthesized proteins 
Previously, Seifert et al. (Seifert et al. 2010) showed that the interferon-? induced 
accumulating Ub-conjugates are predominantly newly synthesized proteins. 
Accordingly, it had to be checked, whether there was any preference for the 
ubiquitination of specific newly synthesized protein groups or if there is a general 
enhanced ubiquitination of all newly synthesized proteins. In order to test this 
hypothesis, affimetrix microarray data from N. Lange were consulted (listed in 
Table 8, p. 152) representing increased gene transcription (mRNA level) between 
IFN? induced and uninduced HeLa cells. 406 genes from this dataset showed a 
significantly increased transcription rate to levels higher than 1.3fold and 338 
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further an increase between 1.2 and 1.3fold in response to interferon-?. The 
enhanced transcribed genes were compared with the 62 proteins from 8 h labeling 
experiments that showed a significant increase (log2FC (H/M) > 0.25) with regard 
to the SILAC data. The overlap concerned 20 proteins (Figure 20?????, of which 
five were also detected to be increased in the negative sample ?cf.?Table 6 
p.??????. The overlap between interferon-? induced transcribed genes and the 51 
Ub-candidates from the 1 h SILAC experiments was only 4 (Figure 20 (B)). 
Accordingly, no general preference for enhanced transcribed genes due to 
interferon-??could be observed in the detected potential ubiquitination products.  
 
3.5.4 Proteasome ubiquitination 
Nearly all proteasomal and proteasomal activator subunits were detected and 
quantified in the 8 h and 1 h SILAC datasets. Considering the fact that one 
immunoproteasomal subunit and one IFN??inducible activator subunit were 
detected in all three samples (8 h SILAC) with significantly enhanced 
concentrations, it had to be answered, whether these proteasomal subunits were 
co-precipitants, Ub-targets or both. Potentially, this fact can be elucidated in the 
following section by comparing the distinct quantitative differences from the 8 h 
SILAC experiments and the affimetrix data of the regulatory particles, i.e. the 19S 
subunits, the ?-subunits, the ?-subunits, the PA200 activator, the PA28 and the 
immuno proteasome specific subunits. For this consideration the 1 h labeling 
results were not consulted due to their restricted reproducibility and 
quantification. 
 
3.5.4.1 19S regulatory particle 
The expected reaction in case of preferential co-precipitation of intact 19S 
regulatory particle is a homogeneous change in the ratio of the individual subunits 
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between induced und uninduced purified Ub-conjugates. A heterogeneous change 
would indicate either the predominant co-precipitation of incomplete 19S 
regulatory particle, a specific isolation of ubiquitinated subunits or both.  
The 19S regulatory particle subunits of the proteasome showed high variations in 
response to interferon-??concerning their transcription rates (see (A) and (B) in 
Figure 21, black bars). Considering the gene transcription, a slight increase by 
trend was observed with regard to eight “lid” (A) and “base” (B) subunits and a 
slight decreasing trend with regard to the eight subunits. In contrast, all subunits 
show a decrease in co-precipitation (white bars) in the presence of interferon-?, 
except for two ATPase subunits that show an increase. This apparent deviation 
from the transcription rate might indicate post-transcriptional protein regulation. 
All regulatory particle subunits ((A) & (B)) identified in the purified Ub-
conjugates (grey bars) showed a common decrease with weaker variations than 
that of the co-precipitants, except for Rpn13 which shows an increase. 
This data may indicate either the co-precipitation of intact 19S regulatory particles 
besides disassembled. Alternatively, according to the described ubiquitination 
targets of the 19S regulatory subunits Rpt2, Rpt1, Rpt4, Rpt5, Rpn1, Rpn2, Rpn7, 
Rpn8, Rpn10 and Rpn13 (Vasilescu et al. 2005; Xu et al. 2010), an ubiquitination 
of all 19S regulatory particles can be assumed. Although their ubiquitination rate 
seems to be influenced by interferon-?, the presented data (Figure 21) indicate that 
they do not belong to the Ub-conjugates accumulating in response to IFN?? One 
exception is Rpn13, which reveals an increased concentration in interferon-? 
induced Ub-conjugates. Nevertheless, the applied HA-tag based enrichment 
method does not allow any conclusions whether Rpn13 is polyubiquitinated or 
monoubiquitinated, in particular, whether its ubiquitination is targeting for 
proteasomal degradation or not. 
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Figure 21 Changes of the 19S regulatory particle subunits induced by interferon-?. Binary 
logarithm of the signal intensity changes of the following functional units between 8 h interferon-? 
induction and non-induced cells: (A) 19S “lid” subunits Rpn3 & 5-9 &11-12 as well as the 
facultative subunits Rpn10 and Rpn13 (Rpn: regulatory particle non-ATPase); (B) 19S “base” 
subunits Rpt1-6 (ATPases) and Rpn1-2 (non-ATPases). ? denotes changes in transcription 
determined by a micro array measurement (performed by N. Lange) ± S.D. (standard deviation), if 
more than one mRNA fragment was measured; ??denotes the median of three SILAC 
measurements of HA-tagged Ub-conjugates after purification from three biological replicates ± 
S.D.; ? denotes results of a SILAC measurement with a negative control or background 
precipitation (elution fraction from immuno precipitation with antibodies against HA from 
untransfected cells).  
 
3.5.4.2 Constitutive 20S proteasomal subunits 
The 20S core particle subunits have been detected in all samples with enriched 
Ub-conjugates. This poses the question whether they are co-precipitants, complete 
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20S core particles or only parts of them like ?-rings, or whether they correspond 
to Ub-targets. 
?-subunits 
Based on what is known about proteasome assembly (Groll et al. 1997; Murata et 
al. 2009), one should expect a homogeneous increase of the ?-subunits of 
transcription and translation with regard to the formation of immuno proteasomes 
(Kloetzel 2001; Seifert et al. 2010). Further, a uniformal increase of ubiquitination 
might be attributed to the correlation between DRiPs formation and the respective 
rate of its protein synthesis. The transcription rate (black bars, Figure 22 (A) on 
page 83) of all ?-subunits was uniformly increased after addition of interferon-? 
except for ?4, which was slightly decreased by trend.  
The detected interferon-? induced changes in the amount of co-precipitation of the 
distinct ?-subunits (white bars), however, were characterized by high disparities. 
This indicates a post-transcriptional regulation for ?-subunits.  
The levels of the ?-subunits in the enriched Ub-conjugates (grey bars) were 
considered, too. ?1,??2, ?6 and ?7 showed a clear increase of their concentrations 
in response to interferon-? indicating an increased ubiquitination rate. ?4 showed 
the same tendency, whereas ?3 exhibited a weak and ?5 a significant decrease. 
This suggests an escape of the ?5-subunit to ubiquitination in the presence of 
IFN?. A predominant co-precipitation of intact ?-rings (homogeneous increase in 
enriched Ub-conjugates) could not be observed, excluding a significant co-
precipitation of intact 20S or 26S proteasomes.  
The subunits ?1 and ?5 were confirmed as Ub-targets and the subunit ?4 as a 
probable target (Ventadour et al. 2007; Meierhofer et al. 2008; Xu et al. 2010). It 
is likely that all ?-subunits are Ub-targets, but with different ubiquitination 
sensitivities. 
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Figure 22 Changes of 20S core ?-subunits induced by interferon-?: Binary logarithm of the signal 
intensity changes of the following 20S constitutive proteasome subunits between 8 h interferon-? 
induced and non-induced cells: (A) ?-subunits ?1 to ?8 and ?????-subunits ?1 to ?7. ? denotes 
changes in transcription determined by a micro array measurement (performed by N.Lange) ± S.D. 
(standard deviation), if more than one mRNA fragment was measured; ??denotes the median of 
three SILAC measurements of HA-tagged Ub-conjugates after purification from three biological 
replicates ± S.D.; ? denotes results of a SILAC measurement with a negative control or 
background precipitation (elution fraction from immuno precipitation with antibodies against HA 
from untransfected cells).   
 
With respect to the presented results, one can assume that the subunits ?1,??2, ?6 
and ?7 (and perhaps ?4) belong to the accumulating Ub-conjugates. Nevertheless, 
the applied HA-tag based enrichment method does not allow any conclusions 
whether these ?-subunits are poly- or monoubiquitinated, in particular, whether its 
ubiquitination is targeting for proteasomal degradation or not.  
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?-subunits 
In the analysis of the changes of the constitutive proteasome ?-subunits in 
response to interferon-?, one should expect a decrease in the ?1, ?2 and ?5 
subunits as compared to the other ?-subunits with regard to their replacement by 
immuno subunits during the process of interferon-? induced immuno proteasome 
assembly (Kloetzel 2001; Seifert et al. 2010). This replacement might require a 
transcriptional or post-transcriptional down-regulation of ?1, ?2 and ?5 which 
would lead to a decrease in their presence on protein level. 
The transcription of ???????remained constant, ???showed a very weak increase, 
whereas the other ?-subunits (black bars, Figure 22 (B) on page 83) show slight 
but higher increase in presence of interferon-?. This observation supports the 
hypothesis of a transcriptional adaptation to immuno proteasome formation. In 
contrast, in the co-precipitants (white bars), representing the cellular protein level, 
the ?-subunits showed high variations in response to interferon-? indicating an 
additional post-transcriptional control mechanism. The expected decrease of ?1, 
?? and ?? regarding their protein level could indeed be observed in the 
background sample. Surprisingly, also ?? and ?? showed a decrease in their 
protein levels which was more than that found for ?1 and ??. 
Considering the ratio of interferon-? induced to uninduced purified Ub-conjugates 
(grey bars), there was an increase in the concentrations of ?3, ?4 and ?7, while 
those of ?2 and ?? remained constant. ?? and ?? showed a significant decrease. 
Overall, a predominant co-precipitation of intact ?-rings or 20S/26S proteasomes 
could not be confirmed. However, there were indications for an independent 
ubiquitination of distinct ?-subunits. With high probability, ?3, ?4 and ?7 are 
parts of the accumulating Ub-conjugates, in agreement with the already published 
polyUb-target ?3 and Ub-target ?4 (Ventadour et al. 2007; Xu et al. 2010). One 
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might suggest that ?3 is also an interferon-? induced polyUb-target belonging to 
the accumulating Ub-conjugates. Anyhow, as for the above described proteasomal 
subunits, the method used does not allow any statement whether this ?-subunits 
are polyubiquitinated or monoubiquitinated by means whether its ubiquitination 
targets for proteasomal degradation or not.  
3.5.4.3 Proteasomal activator and immuno proteasome subunits 
Finally, the changes in the presence of interferon-? were investigated with regard 
to the immuno proteasome specific subunits Lmp7 (?5i), Lmp2 (?1i) and Mecl-1 
(?2i) and the proteasomal activators PA28?, PA28?, PA28? and PA200 that were 
found in the enriched Ub-conjugates. These proteins showed an enhanced 
transcription in response to interferon-? (black bars, Figure 23).  
Among the co-precipitants, which represent the cellular protein level, none of 
these immuno subunits could be detected via mass spectrometry, although their 
expression is known to be upregulated (Kloetzel 2001). Examination of the 
differences in the interferon-? induced Ub-conjugates (grey bars) showed a 
significant increase in Lmp7 (?5i?, PA28? and PA28? concentrations, and a 
decrease for PA28? and PA200. Lmp2 (?1i??and Mecl-1 (?2i??could not be 
detected as isotopically labeled proteins by mass spectrometry. 
An ubiquitination of Lmp7 (?5i??and the PA28?, PA28? and PA28? as well as 
PA200 subunits has not yet been described in the literature, but can be assumed 
based on the presented data. In all five cases, the IFN? induced changes in 
transcription were proportional to the Ub-conjugates, indicating an ubiquitination 
of mainly DRiPs of these proteins. 
Lmp7 (?5i? and PA28? and PA28? are likely to be parts of the accumulating Ub-
conjugates, but the methodical restrictions of the HA-tag based enrichment do not 
allow any statements whether these proteins are polyubiquitinated or mono-
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ubiquitinated by means whether its ubiquitination is targeting for proteasomal 
degradation or not. 
3.6 Immuno chemical identification of ubiquitin targets 
The following immuno chemical identification of Ub-targets, as described in this 
section, started with a control experiment. It was carried out to check whether the 
data from SILAC described above and, in particular, the proteomic approach 
towards Ub-conjugate analysis could be confirmed via immuno chemical 
experiments (cf. 3.6.1).  
 
 
Figure 23 Influence of interferon-? on immuno proteasome subunits: Binary logarithm of the 
immuno 20S core subunits Lmp7 (?5i?, Lmp2 (?1i?, Mecl-1 (?2i??and of the proteasomal 
activators PA28?, PA28???PA28??and PA200 signal intensity changes of the following 
functional units between 8 h interferon-? induction and non-induced cells: ? denotes changes in 
transcription determined by one micro array measurement (performed by N. Lange) ± S.D. 
(standard deviation), if more than one mRNA fragment was measured; ??denotes the median of 
three SILAC measurements of HA-tagged Ub-conjugates after purification from three biological 
replicates ± S.D.; ? denotes results of a SILAC measurement with a negative control or 
background precipitation (elution fraction from immuno precipitation with antibodies against HA 
from untransfected cells).  
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Figure 24 Ubiquitination of p62/sequestosome-1: c-myc immuno precipitation has been 
performed from IFN? uninduced (left panel) and 8 h induced (right panel) c-myc transfected HeLa 
cells. The precipitates were size separated via 10 % SDS-PAGE and Western blotted. The Western 
blot has been probed with antibody against p62. The blot showed free c-myc-His-p62 (66kDa) and 
ubiquitinated c-myc-His-p62 represented by high molecular weight bands. The table (right hand 
side) shows the quantification results for p62 from Microarray data (transcription), SILAC data (1 
h: newly synthesized Ub-conjugates, 8 h: Ub-conjugates) and from the densitometric evaluation of 
the Western blot.  
 
Besides that, three selected potentially interferon-? induced ubiquitinated proteins 
were immuno-chemically confirmed. They were identified by the 8 h labeling 
SILAC experiments (cf. 3.5.2) and one from the 1 h labeling SILAC experiment. 
In addition, the number of attached Ub units was determined (cf. 3.6.2 and 3.6.3). 
3.6.1 Sequestosome-1 
To evaluate the results from SILAC, sequestosome-1 (also named p62), a known 
Ub-target (Xu et al. 2010), was chosen as a candidate for ubiquitination that did 
not belong to the interferon-??induced accumulating Ub-conjugates?(Figure 24: 8 h 
SILAC no change)???Sequestosome-1 binds specifically to polyUb chains that are 
K63-linked with its UBA domain (Seibenhener et al. 2004). Due to its UBA 
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domain it is also possible that the detected p62 in the SILAC data resulted from 
co-precipitation with K63-linked Ub chains.  
The transcription level in the presence of interferon-? was reduced by a factor of 
0.85 (cf. Figure 24, right table) than without, which is in good agreement with the 
SILAC data from the 1 h labeling experiment (factor 0.80, Figure 24). This 
indicates that in this case even the 1 h SILAC data based quantifications are 
maybe more precise than expected. Western blot analysis by comparing enriched 
HA-Ub-conjugates did not show any signal in the high molecular weight region. 
Therefore, cells have been transiently transfected with a vector carrying the DNA-
sequence of c-myc-His-tagged p62. 
Afterwards, both types of cells, those induced by eight hours interferon-? 
treatment as well as the uninduced cells were harvested and then subjected to a 
c-myc immuno precipitation. The eluates were blotted (see Figure 24) and high 
molecular signals indicated the presence of ubiquitinated p62. The signal with a 
p62 specific antibody showed comparable changes like transcription and 1 h 
SILAC (ratio interferon-? induced to uninduced ubiquitinated proteins: 0.74, 
Figure 24). This result confirmed the 1 h SILAC data and, in particular, the 
proteomic approach towards Ub-conjugate analysis. Furthermore, these data 
suggest a remarkable effect of quantified co-precipitated p62 (due to Ub-chain 
affinity) in case of 8 h SILAC experiments, as documented by the deviation from 
the other quantification values.  
3.6.2 Cytoplasmatic tryptophanyl t-RNA synthetase  
Tryptophanyl-tRNA synthetase (Wars) is an interferon-? inducible protein with 
aminoacyl activity. It exists in two forms due to alternative splicing, first as a full 
length protein (54 kDa) and, second, as a truncated form (48 kDa) (Tolstrup et al. 
1995). Besides this canonical activity, it is assumed that Wars has also a release 
factor activity evoking a termination of amino acid chain during translation 
(Fleckner et al. 1991; Bange et al. 1992).  
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Figure 25 Ubiquitination of Wars: Ub-conjugates from IFN? uninduced (left panel) and 8 h 
induced (right panel) HA-Ub-EGFP stable HeLa transfectants have been enriched. The conjugates 
have been size separated via 12.5 % SDS-PAGE and Western blotted. The Western blot has been 
probed with polyclonal antibody against Wars. The blot shows free Wars (54 kDa) and some 
distinct bands representing ubiquitinated Wars. The table (right hand) shows the quantification 
results for Wars from Microarray data (transcription), SILAC data (1 h: newly synthesized Ub-
conjugates, 8 h: Ub-conjugates) and from the densitometric evaluation of the Western blot. 
 
No ubiquitination of Wars itself has been observed or investigated until now. 
However, due to its enhanced expression (cf. Figure 25 right table), an increase in 
misfolded Wars or incompletely synthesized Wars is expected. The 8 h SILAC 
data showed a high increase of the Wars concentration in response to interferon-?. 
This occurred in both, enriched Ub-conjugates and co-precipitants (cf. Figure 25 
right table). These results gave a hint that Wars could be a contaminant. 
The 1 h labeling experiment indicates by tendency an increased ubiquitination in 
presence of interferon-?, and the comparison of enriched Ub-conjugates to co-
precipitants (right column) shows a specific enrichment of ubiquitinated Wars. 
To elucidate the ubiquitination of Wars enriched Ub-conjugates from IFN? 
uninduced and induced HA-Ub transfected HeLa cells were immuno-blotted and 
detected via a tryptophanyl-tRNA synthetase (Wars) specific antibody (Figure 
25). Besides a massive co-precipitation of free Wars, the precipitates show high 
molecular weight proteins that interact with the Wars specific antibody indicating 
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the existence of Ub-conjugated Wars. The number of attached ubiquitins is 
obviously mainly one, two and four. 
An increase in the signal intensity of induced compared to uninduced high 
molecular Wars species could be observed. Hence, one can conclude that Wars is 
polyubiquitinated and, in agreement with the SILAC data (cf. 3.5.2), its 
ubiquitination rate is enlarged in response to interferon-?. This confirms the 
suggestion that Wars belongs to the newly synthesized accumulating Ub-
conjugates induced by IFN?.  
 
3.6.3 Tripatite motif 21 
A further interferon-? influenced ubiquitination target is “tripatite motif 21” 
(Trim21) also known as Ro52. The E3-RING ligase Trim21 contains a B30.2 
domain that specifically binds immunoglobulin G (IgG) (Rhodes et al. 2007). This 
IgG binding domain also might bind to IgG region from the antibody against HA 
that was used for Ub-conjugate enrichment. Previous studies showed that Trim21 
undergoes auto-ubiquitination (Fukuda-Kamitani et al. 2002). Due to this fact the 
remaining question was, whether there was an enhancement of ubiquitination in 
the presence of interferon-? or not.  
The TRIM21 gene shows an interferon-? induced enhanced transcription (cf. 
Figure 26 table). Trim21 was also identified in the 8 h SILAC experiments as an 
Ub-candidate that showed in presence of interferon-? an increase in Ub-conjugate 
enrichment and also in co-precipitation. A high grade of co-precipitation of free 
Trim21 could be confirmed via Western blot (Figure 26). Nevertheless this 
Western blot also showed a clear interferon-? induced increase of Trim21 
ubiquitination. Attachments of one to eight ubiquitins could be observed, as 
proven by well separated distinct bands with mass differences of ca. 8 kDa 
(molecular weight of Ub).  
3  Results  91 
 
 
Figure 26 Ubiquitination of Trim21: Ub-conjugates from IFN? uninduced (left panel) and 8 h 
induced (right panel) HA-Ub-EGFP stable HeLa transfectants have been enriched. The conjugates 
were size separated via 12.5% SDS-PAGE and then Western blotted. The Western blot had been 
probed with polyclonal antibody against Trim21. The blot showed free Trim21 (52kDa) and mono 
to octa ubiquitinated Trim21 with a distance of 8.6 kDa (Ub) between the distinct bands The table 
(right hand side) shows the quantification results for Trim21 from Microarray data (transcription), 
SILAC data (1 h: newly synthesized Ub-conjugates, 8 h: Ub-conjugates) and from the 
densitometric evaluation of the Western blot.  
This observation affirmed the results from the quantitative mass spectrometry (cf. 
Figure 26 table) that Trim21 is one of the newly synthesized accumulating Ub-
conjugates in response to interferon-?. The fact that Trim21 has not been detected 
in the 1 h labeling experiment may result from the difference in the applied 
enrichment technique or from a methodical detection limit. 
3.6.4 Proteasome ATPase regulatory subunit Rpt5 
The proteasomal regulatory subunit Rpt5 has been identified as an Ub-candidate 
from the 1 h labeling experiments. It plays a decisive role in the 26S proteasome 
complex by serving as ATPase, proteasome activator, ubiquitin receptor as well as 
chaperone, but it was also identified in enriched ubiquitin conjugates from human 
MCF-7 cells under proteasomal inhibition (Lam et al. 2002; Verma et al. 2004; 
Vasilescu et al. 2005; Gillette et al. 2008).  
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Figure 27 Ubiquitination of Rpt5 Western Blot: Ub-conjugates from IFN? uninduced and 8 h 
induced non-transfected HeLa (left panel) and 10xHis-Ub-EGFP stable HeLa transfectants (right 
panel) have been enriched via Rad23-affinity and Ni(NTA)-affinity. The conjugates have been size 
separated via 12.5 % SDS-PAGE and Western blotted. The Western blot has been probed with 
monoclonal antibody against Rpt5. The blot shows free Rpt5 (49 kDa) and some distinct high 
molecular bands representing ubiquitinated Rpt5. The low molecular bands might represent Rpt5 
degradation products. The table (right hand) shows the quantification results for Rpt5 from 
microarray data (transcription), SILAC data (1 h: newly synthesized Ub-conjugates, 8 h: Ub-
conjugates) and from the densitometric evaluation of the Western blot. 
 
Therefore, it had to be elucidated, whether it belongs to the interferon-? induced 
ubiquitination targets or if it is a co-precipitant.   
A further aim was to determine, if its ubiquitination is targeting on proteasomal 
degradation or if it has regulatory functions in case of monoubiquitination. The 
gene transcription of Rpt5 (PSMC3) is not significantly influenced by interferon-? 
(cf. Figure 27, table). In the 8 h labeling experiments, it showed a decrease in Ub-
conjugate enrichment in presence of interferon-?. Its protein concentration does 
not seem to be influenced by interferon-? (co-precipitation), in agreement with the 
transcriptional changes.  
But the 1 h SILAC experiments showed a tendency for an increased enrichment of 
newly synthesized Rpt5 in isolated Ub-conjugates. Additionally, also an increase 
by trend in isolated Ub-conjugates in comparison to agarose co-precipitants was 
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observed. Although these 1 h SILAC data show high standard deviations (Figure 
27, table), the Western blot results (cf. Figure 27, picture) confirmed that Rpt5 
belongs to the newly synthesized and ubiquitinated proteins accumulating in 
response to interferon-?.  
A predominant co-precipitation could be excluded, although free Rpt5 was 
detected. Additional well separated bands at high molecular weights indicated a 
modification of Rpt5 with predominantly one to four ubiquitins. Small molecular 
weight bands in the Ub-conjugates enriched under native conditions (via Rad23) 
might indicate degradation products that are absent in the Ub-conjugates which 
were enriched under denaturating conditions (via His-tag). 
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CHAPTER 4   
 
 
4 Discussion 
The interferon-? regulated ubiquitination manifests itself by a transient 
accumulation of newly synthesized ubiquitinated proteins. It represents a key 
process within the immune response of organisms (Seifert et al. 2010). A progress 
in the understanding of the cellular processes under inflammatory conditions 
should give important and, presumably, decisive hints for the treatment of cancer, 
autoimmune diseases or chronic inflammation. Until now, a large part of the 
molecular details and reactive pathways still impose many questions concerning 
the identity, composition and relative concentration of the newly synthesized Ub-
conjugates that are transiently formed and accumulated during the cellular 
response to interferon-?.  
In this context, the findings described in this work represent the result of an 
improved analytical approach and its application to the identification and 
characterization of typical interferon-? induced newly synthesized ubiquitin 
conjugates. This chapter discusses and summarizes the most relevant aspects and 
consequences. In the first instance, the focus lies on the experiences with the 
improved analytical approach for the identification of specific newly synthesized 
ubiquitinated proteins in response to interferon-? (as described above sections 3.1 
to 3.4). Chapter 4 starts with a discussion of the improvements in the isolation of 
Ub-conjugates (section 4.1.1), the gel electrophoretic separation of the isolated 
Ub-conjugates (section 4.1.2), and the sample preparation for mass spectrometric 
analysis (section 4.3). Finally, the central mass spectrometric approach will be 
assessed (section 4.4).  
After the assessment of the selected analytical methods in 4.1 to 4.4, the 
discussion in sections 4.5 to 4.10 concentrates on the results of the applied 
techniques, in particular on the analysis of the Ub-conjugates accumulated in 
response to interferon-?. It concerns answers to the following three key questions:  
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1.  What is the composition of the ubiquitin-chain linkages in the 
accumulating conjugates?  
2.  Is it possible to identify specific newly synthesized ubiquitinated 
proteins analytically which accumulate in response to interferon-?? 
3.  Is there a preference in ubiquitination for special newly synthesized 
proteins or protein groups or is the ubiquitination process an over-all, less 
specific process? 
The answer to the first question, i.e. the characteristics and evidence of the Ub-
chain linkages in the interferon-? induced newly synthesized Ub-conjugates, is 
treated in section 4.5. As the answer to the second question, sections 4.6, 4.7 and 
4.8 discuss and summarize the identified specific newly synthesized ubiquitinated 
proteins as well as the candidates that accumulate in response to interferon-? 
together with the corresponding mass spectrometric data. The third and last 
question aiming at the preference in ubiquitination for special newly synthesized 
proteins or protein groups and at the relevance of the identified ubiquitin 
conjugates will be treated in section 4.9. The discussion will end with conclusions 
and related future perspectives in section 4.10.  
4.1 Methodic progress in the isolation of the Ub-conjugates 
4.1.1 Optimum isolation strategy for the targeted Ub-conjugates 
The initially devised, reproducible isolation of ubiquitin(Ub)-conjugates was a 
precondition for the subsequent successful characterization and identification of 
the Ub-conjugates. Many strategies and experiments concerning the isolation of 
Ub-conjugates have been described in the literature over the past years 
(Kirkpatrick et al. 2005; Vasilescu et al. 2005; Maor et al. 2007; Peng 2008).  
In this study, different strategies and affinity-matrices were evaluated and 
compared for the purification of Ub-conjugates (see experimental results 
described in chapter 3.1). Two methods have led to an enhanced enrichment of 
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interferon-? induced Ub-conjugates. The first method was an enrichment based on 
Ub associated domains (UBA) using Rad23, the second one was a purification 
procedure making special use of a haemagglutinine epitope (HA) as an N-terminal 
ubiquitin tag. Both techniques were applied in various experiments during this 
study, following and respecting their individual advantages and disadvantages. A 
major advantage of using Rad23 is the preferential enrichment of predominantly 
proteasomal targets (Raasi et al. 2003). But there is also a disadvantage, as it tends 
to a co-precipitation of not well defined proteins, for instance, UBL/UBA domain-
interacting proteins (Ryu et al. 2003). In contrast, the purification technique based 
on HA-tag shows no cross-reactivity towards endogeneous proteins and a well-
defined specificity for the haemagglutinine-tag (cf. section 3.1). Due to this and in 
combination with the consistent HA-Ub incorporation into all Ub-chain types, a 
cross-section of all Ub-chain topologies and Ub-substrates can be enriched 
(Dammer et al. 2011).  Nevertheless, the remaining disadvantage of using HA-tag 
based isolation strategy is the necessity of using a metabolically modified cell 
line. Finally, for the reproducible use of tag based enrichment, a well 
characterized, stably HA-tagged Ub overexpressing cell line was established as 
discussed in the following section. 
4.1.2 Cell culture model for the tagged ubiquitin based isolation 
The description of the results in chapter 3.2 already showed that the basic 
requirement of a potent cell culture model for the HA-tag based Ub-conjugate 
isolation could be fulfilled. The established cell model was proven to exhibit 
stable expression rates, to incorporate the tagged Ub into the chains, to have the 
same phenotype as non-transfected HeLa cells and, most importantly, to be 
sensitive to interferon-? with regard to the Ub-conjugate accumulation.  
However, on the other hand, the established cell culture model also showed a clear 
disadvantage, as the HA-tagged Ub overexpression resulted in a lower ratio of 
induced to uninduced conjugates as compared to the untransfected HeLa cells. 
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This is obviously a consequence of the distinctly higher level of Ub-expression 
and conjugation in the stable transfectants. Despite this, a difference in the 
composition and chain topology of the Ub-conjugates could be confirmed (section 
3.5). To conclude, a stably transfected cell line has been established that was well 
suited for the analysis of newly synthesized Ub-conjugates. 
4.2 Gel electrophoretic characteristics of ubiquitin conjugates  
By comparing interferon-? induced with uninduced isolated Ub-conjugates via 
two-dimensional gel electrophoresis (see results 3.3), an increased concentration 
of proteins (silver staining signal) and a different Ub-conjugate pattern (Western 
blot) were observed. Although distinct spots for some individual, predominant 
proteins could be clearly identified, two observations (from Western blot) 
indicated that the separation was not sufficient for the highly heterogeneous 
mixture of Ub-conjugates. The first evidence came from the presence of a high 
molecular weight “smear” of Ub-conjugates. The second observation was that, in 
particular, the interferon-? induced Ub-conjugates appeared to be not completely 
separable via non-equilibrium pH gel-electrophoresis (first dimension). The latter 
fact is a decisive characteristic of the interferon-? induced Ub-conjugates, but it 
also represents an exclusion criterion for the applicability of two dimensional gel-
electrophoresis for the separation of Ub-conjugates.  
4.3 Innovations in the preparation for mass spectrometry 
4.3.1 Ubiquitin-conjugate sample preparation for analysis 
In the past, Ub-conjugates have been identified by two different general 
experimental approaches based on mass spectrometry. Both were tested in this 
study, too. The first of these is called “in-gel” digest (Marotti et al. 2002; Peng et 
al. 2005; Seyfried et al. 2008). It consists of the “in-gel” digestion with trypsin 
applied to well-defined molecular weight fractions of the Ub-conjugates after gel 
electrophoretic size separation. The resulting peptides were analyzed via mass 
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spectrometry. The advantage of this approach is that even if no Ub-site indicator 
peptide is detectable, Ub-targets can be identified via their appearance in high 
molecular weight regions. This technique allows to reconstruct a virtual Western 
blot (Seyfried et al. 2008). However, its main disadvantage is the high 
contamination risk (e.g. ceratines) for the samples which, in combination with the 
steric hindrance of the high viscosity gel matrix during tryptic digestion, lowers 
the protein recoverage and identification rate in mass spectrometric analysis.  
The second general approach applied here to prepare Ub-conjugates for mass 
spectrometric analysis is called “in-solution” digest. The Ub-conjugates are 
directly digested with trypsin into peptides and separated with a long gradient in 
nano-LC prior to their measurement via mass spectrometry (Kirkpatrick et al. 
2005; Jeon et al. 2007). The advantage of this technique is a lower number of 
sample preparation steps, and thereby, less contamination sources, as well as the 
absence of steric hindrance by high viscosity during tryptic digest. The 
disadvantage is that the samples have a higher complexity, preventing the 
possibility to identify ubiquitination targets via Western blot reconstruction as 
well as discriminating the detection of low abundant proteins.  
 To conclude, by comparing various sample preparation techniques (cf. chapter 
3.4), it was found that the mass spectrometrical identification rate was 
inacceptable when applying “in-gel” digest in contrast to “in-solution” digest. 
Therefore, a particular “in-solution” digest technique was selected as the optimum 
experimental approach for the mass spectrometrical protein identification in this 
project. 
In the past, most investigations on the identification of Ub-conjugates relied on 
the use of trypsin alone due to its ability to produce specific mass 
spectrometrically detectable peptides serving as ubiquitination site indicator 
(Marotti et al. 2002; Peng 2008). Only a few studies have been published so far 
which report an application of other peptidases for the Ub-conjugate digest. One 
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of these studies compares the Ub-site detection connected to a digestion protocol 
using the peptidase GluC with the classical trypsin digestion (Warren et al. 2005). 
Two other publications report on a successful analysis of Ub-conjugates using a 
sequential digestion protocol with LysC and trypsin (Tagwerker et al. 2006; Jeon 
et al. 2007). No study is so far available that directly compares the digestion 
protocols for LysC, trypsin and sequential LysC-trypsin digest with respect to an 
optimization of the analysis of Ub-conjugates.  
In this context, a remarkable finding was that the pre-digest of K48-linked tetraUb 
as model substrate with LysC prior to the tryptic digest (Figure 15, p. 62) 
improves the specific detection of the characteristic GG-motif containing peptides 
that indicate Ub-sites. 
An additional key result of the pretesting experiments for mass spectrometric 
analysis during the process of optimization was that uninduced and interferon-? 
induced Ub-conjugates showed a high overlap in their protein identifications. This 
led to the necessity of comparing pairs of samples not only qualitatively but also 
quantitatively. Hence, the quantitative mass spectrometry was found to be 
indispensable for this project.  
4.3.2 Optimal quantitative mass spectrometric approach 
In analytical chemistry, different mass spectrometrical relative and absolute 
quantification techniques are available (Bantscheff et al. 2007; Pieper et al. 2009; 
Unwin 2010). At present, no potent absolute quantification technique is available 
for complex mixtures, but there are three possible strategies for a relative 
quantification. The first of these is based on the ratio of the detected signal 
intensity between two individual samples, it is semi-quantitative, due to the fact 
that the signal intensity also depends on the solution matrix. The second technique 
is based on a chemical labeling of peptides and proteins, and thereby highly 
dependent on the efficiency of labeling reaction. The third technique uses a stable 
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isotope labeling with corresponding amino acids in cell culture (SILAC). This 
approach offers the opportunity to combine labeled samples already on the level 
of the cell lysates, because the proteins from different treatments (f.e. -/+ IFN?) 
can easily be distinguished based on their different incorporated amino acid 
isotopes. The early combination of different samples and the treatment as a single 
sample in the following experimental steps (f.e. isolation of Ub-conjugates) led to 
a high comparability of the samples and a high accuracy of relative quantification 
(Ong et al. 2006; Bantscheff et al. 2007). Therefore, this method was chosen here 
as the primary technique. 
Some improvements of existing conventional protocols for SILAC (Ong et al. 
2006; Schwanhausser et al. 2009) had to be developed in this investigation (cf. 
3.4.3). Due the fact, that the interferon-? induced Ub-conjugates have been shown 
to consist of mostly newly synthesized proteins (Seifert et al. 2010), it was 
advantageous to choose a shorter labeling period in order to lower the background 
of labeled co-precipitants and, thereby, to minimize the rate of false positively 
detected Ub-conjugates. But with this shorter labeling time, it was unavoidable to 
accept a lower recoverage and quantification rate due to the increase of the ratio 
of labeled to unlabeled proteins in the sample. A time period in the range of 
minutes would be the optimum for the preferred labeling of only the newly 
synthesized proteins, but it would evoke massively decreased levels in protein 
identification as well as a decreased and imprecise quantification.  
Therefore, a time period of eight hours was initially chosen as a compromise, 
allowing a labeling of all synthesized proteins during interferon-? stimulation. In 
awareness of the above described restricted identification and quantification, 
additional experiments were performed using a labeling period of one hour, which 
corresponds to a preferred labeling of newly synthesized proteins. The results will 
be discussed below (section 4.4). 
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Another disadvantage of the SILAC technique was the fact that the labeling 
medium as described in the previous chapter 3.5, seems to induce oxidative stress. 
This probably results from the lack of growth factors (dialyzed fetal bovine 
serum) and/ or the effect of the used excess of basic amino acids Lys and Arg (pH 
effect) under the isotopic labeling conditions. The oxidative stress led to an 
increased ubiquitination in the uninduced cells, evoking a loss of the immuno-
chemically detectable difference between interferon-? induced and uninduced Ub-
conjugates.  
It is obvious that this is a critical observation, demonstrating that the 
investigations on cellular proteins via SILAC approach might be considerably 
influenced by the metabolic changes induced by this method itself. Hence, this has 
to be taken always into account when considering SILAC results. Nevertheless, as 
the results described in section 3.5 showed, the identification of Ub-conjugates 
and the corresponding detection of quantitative differences were successful. Their 
results are the topic in the following section.  
4.4 Evaluation of ubiquitin conjugate analysis 
Although several attempts have been carried out to optimize the isolation and 
sample preparation conditions, the rate of identified and, especially, of quantified 
ubiquitination sites (section 3.5.1) remained relatively low. The restricted 
quantification may be attributed to the above described methodical limitations of 
“pulsed” SILAC. 
A reason for the low identification rate of interferon-? induced Ub-conjugates 
might be again the cytokine induced oxidative stress (Seifert et al. 2010). Stress 
induced reactive oxygen species possibly lead to radical mediated cross-linking of 
proteins. This might be analogous to the in-vitro results of radical mediated 
photodynamic cross-linking with flavin mononucleotide as photosensitizer (Shen 
et al. 2000; Davies 2005). Cross-linking would cause a decreased solubility of the 
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conjugates, a less efficient tryptic digest (steric hindrance) and a decreased 
coverage rate in mass spectrometry due to unusual peptide modifications and 
constitutions. 
However, in the eight hours SILAC experiments five Ub-sites and further two 
potential Ub-sites were identified. Of these, four validated and one potential Ub-
site belonged to ubiquitin, while a fifth validated Ub-site as well as a second 
potential Ub-site were clearly related to two other proteins. In the one hour 
SILAC experiments, only the same four validated Ub-sites from ubiquitin have 
been identified as in the eight hours labeling experiment. The concentration 
changes of the Ub-linkage indicator peptides in response to interferon-? gave an 
insight into the specific chain composition and, thereby, also into the function of 
interferon-? induced Ub-conjugates (cf. 4.5). The Ub-site as well as an additional 
potential Ub-site belonging to two different (potential) Ub-substrates will be 
discussed below, too (cf. 4.6). 
4.5 Evidence of the interferon-? induced changes in Ub-chain linkages  
The Ub-linkage distribution is individual for distinct tissues and cell types 
(Bedford et al. 2011). There are no studies available about the Ub-linkage pattern 
of HeLa cells. However, investigations of the linkage composition of HEK293 
cells, by absolutely quantifying all eight linkages (inclusive N-terminal linear 
ubiquitination, representing 100 %), revealed that K48 (52 %) and K63 (38 %) are 
the most abundant linkages, followed by K29 (8 %) and the lower abundant K11 
(2 %) and K6 (0.5 %). But they also showed that different triggers of cellular 
stress (proteasomal inhibition, heat shock) result in individual Ub-linkage 
distributions (Dammer et al. 2011).  
An absolute quantification of the Ub-linkages was not performed in this study, but 
the analysis of Ub-conjugates in HeLa cells demonstrated an individual Ub-
linkage pattern of HeLa cells that changes in presence of interferon-? induced 
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cellular stress. The linkage types K6, K11, K48 and K63 are present in the 
presence as well as in the absence of interferon-?. Additionally, the K27-linkage 
indicator peptide was detected as potential Ub-site only in the eight hour SILAC 
experiments. However, its relative amount was not quantified which implies that 
it cannot be safely assigned as interferon-? influenced. A possible presence of 
K27-linkage is characteristic for HeLa cells compared to HEK293 cells, where 
this linkage type has not been detected (Dammer et al. 2011), the HEK293 cells in 
contrast contain characteristic K29-linkages that were not detected in HeLa cells.  
The K6 and K63 Ub-linkages were not quantified in the one hour labeling 
samples. This may be attributed to the mass spectrometrical detection limits or to 
the low affinity of the applied purification matrix Rad23 to K63-linked Ub-chains 
(Raasi et al. 2003). In the eight hour SILAC experiments the concentrations of 
these linkages showed only insignificant changes when comparing them in 
presence and absence of IFN?. These observations probably indicate that K6- and 
K63-linkages do not play a decisive role in the Ub-chains of interferon-? induced 
Ub-conjugates. The last aspect is in agreement with the previous investigations 
by Seifert et al. (Seifert et al. 2010) showing that K63-linkage is not important for 
the specific Ub-conjugate formation in response to interferon-?. Furthermore, it 
agrees with the literature describing that K6-linked and K63-linked chains are 
mainly related to DNA repair, signaling and endocytosis (Sobhian et al. 2007; 
Skaug et al. 2009). However, both linkage-types showed an enhanced instability 
in the presence of interferon-? (cf. section 3.5.1.1, standard deviation in Figure 18 
(B)). This may indicate an enhanced deubiquitination, perhaps in connection with 
a higher proteasomal turnover of the K6 and K63 linked ubiquitinated substrates, 
the latter probably prevents an accurate determination of their concentrational 
changes. The suggestion of a higher proteasomal turnover would agree with in 
vitro studies where K63 and K6 were suggested to be labels for targeting 
proteasome mediated proteolysis, too (Jacobson et al. 2009; Xu et al. 2009). In 
contrast, in vivo studies (Dammer et al. 2011) demonstrate that K63-linkaged Ub-
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chains are no predominant signal for proteasomal degradation, but play a key role 
in mediating Ub-conjugates to autophagosomes.  
With regard to the changes in concentration of K48-linkages, surprisingly, a weak 
decrease could be observed in the eight hours SILAC samples. This finding is in 
contrast to the results of the one hour labeling experiments where the opposite, i.e. 
an increase of K48-linkages was found. The latter agrees with previous studies 
which demonstrate the existence of mainly K48-linkages in the accumulating Ub-
conjugates (Seifert et al. 2010). Furthermore, K48 is the prevalent signal for 
proteasomal degradation (Thrower et al. 2000), confirming the data from the one 
hour SILAC experiments representing K48 linkages exclusively quantified in the 
newly synthesized proteins.  
The conflicting data from the eight hour labeling experiment could be explained 
by two effects: The first comes from the observed instability (cf. section 3.5.1.1, 
standard deviation in Figure 18 (B) & (C)) of K48-linked Ub which may be 
related to increased activities of deubiquitinases or/ and an increased proteasomal 
turnover recovering the real concentration of the K48-linkages. But this effect was 
also observed in the one hour labeling results. 
The second contributing effect for the unexpected change of the K48 Ub-linkage 
concentration in the eight hours SILAC experiments is the basically higher 
ubiquitin conjugation in the HA-Ub transfected cells (cf. section 3.2.2). This 
effect might be accompanied by the increased ubiquitination due to the oxidative 
stress under the SILAC conditions which leads to a high level of oxidatively 
damaged proteins. One may anticipate that they are labeled with K48-linked Ub-
chains for their proteasomal degradation. The methodically affected higher 
ubiquitination rate and, thereby, the increased amount of Ub-conjugates, even in 
the interferon-? untreated cells, may hide the normally observable increase from 
uninduced to induced Ub-conjugates. Due to the longer exposure to SILAC 
conditions in case of an eight hours labeling time period, the effect of oxidative 
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stress might be higher in these samples as compared to the SILAC conditions with 
a one hour exposure. 
A really interesting finding was that the concentration of K11-linkage type 
showed a relative increase in response to interferon-?? but only in the eight hour 
labeling results (cf. section 3.5.1.1 Figure 18 (B)). The missing quantification in 
the one hour experiment may be explained by worse detection limits or/ and a low 
affinity for this linkage type (Raasi et al. 2003). K11 linkages are known to play a 
role in the cell cycle control and ER associated degradation (Xu et al. 2009). On 
the one hand, the increase in K11 linkage formation could be attributed to the ER 
associated degradation (ERAD). The ERAD is the quality control system for 
newly synthesized proteins that are destined for the endomembrane system, for 
the plasma membrane or for secretion. Therefore, it is involved in marking 
defective ribosomal products (DRiPs) for their degradation via the Ub proteasome 
system (Xu et al. 2009). The DRiPs are assumed to be the link between antigen 
processing and translation. In case of infection, this guarantees access of the 
cellular immune system to viral proteins before they reach their final destination 
outside the cell (Reits et al. 2000; Yewdell 2005; Seifert et al. 2010). On the other 
hand, the increase of K11-linked chain formation may be due to its function in cell 
cycle control and, thereby, to its influence on proliferation by IFN???This probably 
explains that the detected K11 is the only Ub-linkage type that showed no changes 
in its stability (represented by the standard deviation of linkage indicator peptide) 
and may indicate an escape of K11-linked Ub-chains and their respective Ub-
conjugates from deubiquitination and/ or proteasomal degradation.  
The important finding of the instability of all linkage indicator peptides (K6, K27, 
K48 and K63) except for K11 (cf. section 3.5.1.1, higher standard deviations in 
Figure 18 (B) & (C)) in the presence of interferon-? may be caused by a higher 
enzymatic activity of deubiquitinating enzymes and/ or an increased proteasomal 
turnover. In this case, however, one has to assume a remaining enzymatic activity, 
although enzymatic inhibitors have been used excessively.  
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4.6 Identified ubiquitin conjugates 
Only one Ub-site and one additional potential Ub-site indicator peptide were 
identified in ubiquitin substrate analysis (cf. 3.5.1.2). Both were only detected in 
the eight-hour labeling experiments in the form of their natural isotopic variants. 
The potential Ub-site which has not been described before belonged to the 
mitochondrial “chaperone-ABC1-like” protein. There is little known about this 
protein, except that it was assumed to play a role in p53-mediated apoptosis 
through the mitochondrial pathway (Iiizumi et al. 2002). However, “chaperone-
ABC1-like” protein was also not quantified on the protein level. Hence, it is likely 
that it does not belong to the accumulating Ub-conjugates.  
The detected Ub-site (K147) of the protein “4F2 cell-surface antigen heavy chain” 
has already been identified and published before (Meierhofer et al. 2008). This 
protein, also termed antigen CD98, is involved in sodium-independent amino-acid 
transport (Pfeiffer et al. 1999). It has been quantified (protein level) indicating that 
its ubiquitination is not influenced by interferon-?, hence, it does not belong to the 
accumulating Ub-conjugates targeted by this study. But, as mentioned already 
before, the reason for not having detected any validated Ub-site in the one hour 
labeling experiment is very probable due to its specific detection limits. 
4.7 Identified interferon-? induced ubiquitination candidates 
Based on the quantification results of the HA-tag based enriched Ub-conjugates 
from eight hours SILAC exposure, 62 proteins were identified as candidates for 
IFN? induced ubiquitination (cf. listing in the supplementary data of Table 6). For 
seven of these 62 proteins, the concentrations were found to be predominant and 
reproducibly increased (cf. section 3.5.2). The corresponding genes of these seven 
proteins were IFN? inducible. This agrees with expectations in the literature 
(Seifert et al. 2010) which argue that the newly synthesized DRiPs are the main 
components of the accumulating Ub-conjugates, because an increased 
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transcription is assumed to lead to a proportionally increased amount of defective 
ribosomal products among the newly synthesized proteins.  
The immuno proteasome subunit (Lmp7or ?5i), the proteasome activator subunit 
(PA28?) and the poly-[ADP-ribose] polymerase (Parp14) were predominant and 
reproducibly increased in enriched Ub-conjugates, but not quantified in the 
negative immunoprecipitation control experiment (co-precipitants). Therefore, 
these three proteins were identified as Ub-targets. The role of the ubiquitination of 
Lmp7 (?5i) and Parp14 remains unclear due to the applied tag based purification 
which does not discriminate any Ub-chain with regard to length and linkage type. 
Additional immuno-chemical studies have to be performed in future to determine 
whether they are polyubiquitinated proteasomal targets or not. At present, they 
have to be considered as probably being part of the interferon-? induced 
accumulating Ub-conjugates. PA28? is suggested to be a polyubiquitination target 
due to the fact that it was detected with increased concentration in Ub-conjugates 
(1 h SILAC) purified via Rad23 which possesses a high affinity for proteasomal 
targets (Raasi et al. 2003). It is thereby assumed to be part of the accumulating 
Ub-conjugates, but an independent immuno-chemical confirmation of its Ub-
chain length has still to be performed in the future. 
The signal transducer and activator of transcription “Stat1”, the ubiquitin ligase 
tripartite motif “Trim21”, the cytoplasmatic tryptophanyl-tRNA synthetase 
“Wars” and the regulatory subunit of Glutamate-cysteine ligase “Gclm”, were also 
found to be reproducibly and predominantly increased in the HA-based enriched 
Ub-conjugates from interferon-? induced cells. As they were also detected as 
predominantly increased proteins in the negative control for immuno 
precipitation, they also might be co-precipitants rather than Ub-conjugates. Due to 
the HA-tag based enriched cross-section of all ubiquitinated proteins, the mass 
spectrometric data of the eight hours SILAC experiments alone allow no 
statement about the function of ubiquitination of these proteins. However, it could 
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be shown (via Western blot) that two of them, Trim21 and Wars, are part of the 
Ub-conjugates accumulating in response to interferon-???cf. section 3.6.2 & 3.6.3?. 
Trim21 was found to be modified by one to eight ubiquitins, while Wars seems to 
be modified predominantly by one, two and four ubiquitins. These two proteins 
are therefore clearly identified Ub-targets belonging to the series of newly 
synthesized interferon-? induced accumulating Ub-conjugates. Newly synthesized 
Wars was confirmed as proteasomal target by its detection in Rad23 based 
enriched Ub-conjugates (1 h SILAC), due to the predominant affinity of Rad23 to 
K48-linked tetraUb (Raasi et al. 2003). 
Overall, 51 candidates for interferon-? induced Ub-targets from the one hour 
SILAC experiments show a tendency towards a gradual increase in Rad23 
enriched Ub-conjugates in comparison to agarose co-precipitants and in 
comparison to interferon-? untreated Rad23 purified Ub-conjugates. These 
proteins are, with high probability, interferon-? induced proteasomal targets 
(specific Rad23 affinity). However, due to the methodically restricted accuracy of 
quantification, they have to be further investigated in the future like it was done 
for the proteasome regulatory subunit Rpt5 as one these 51 proteins. By immuno-
chemical investigations, it was shown that it belongs to the accumulating 
interferon-? induced Ub-conjugates and that Rpt5 was modified by mainly one to 
four ubiquitins (cf. 3.6.4). This result confirms the relevance of the one hour 
SILAC data, even when the reproducibility of the quantification results was low 
(as represented by the high variability in quantification).  
Via the SILAC experiments 108 Ub-candidates and Ub-targets were identified. 
However, the existence of further interferon-? induced Ub-targets that might be 
discriminated during mass spectrometrical analysis (detection limits), cannot be 
excluded. Only 5 proteins were identified in both, the one hour and eight hours 
labeling experiments (cf. 3.5.2). This low number can be explained by the 
differences in the detailed experimental conditions (cf. 3.4.4). In particular, for the 
eight hours labeling experiments, HA-tag based enriched Ub-conjugates from 
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HA-Ub-EGFP transfected HeLa cells were used, while for the one hour labeling 
experiments, Rad23 based purified Ub-conjugates from non-transfected HeLa 
cells were taken. These differing isolation techniques result, on the one hand, in 
the analysis of a cross-section of all Ub-targets (tag based enrichment, (Dammer 
et al. 2011)) and, on the other hand, of mainly proteasomal targets (Rad23 based 
enrichment, (Raasi et al. 2003)). The use of either transfected or non-transfected 
HeLa cells and thereby metabolically changed and native cells may additionally 
affect the Ub-protein identities. Furthermore, the effect of co-precipitant 
quantification is higher in case of eight hours SILAC experiments, whereas the 
mass spectrometrical detection limit (identification & quantification) is lower in 
the case of the one hour SILAC experiment. A further tentative explanation for 
the low overlap of the results of different labeling experiments may be attributed 
to the different length of the nanoLC gradients which were used for the peptide 
separation prior to MS analysis.  
4.8 Evaluation of the mass spectrometric data  
To judge the accuracy of SILAC based quantification, a particular protein called 
sequestosome-1 was selected which had been identified in enriched Ub-conjugates 
but did not belong to the interferon-? induced Ub-conjugates. Sequestosome-1 or 
p62 is known to be ubiquitinated (Xu et al. 2010), whereas it also contains an 
UBA domain with preferential affinity for K63-linked Ub-chains (Seibenhener et 
al. 2004). It could be shown (cf. section 3.6.1) that p62 is a polyubiquitination 
target and not only a co-precipitant. The Western blot based quantification of 
ubiquitinated p62 agreed with the one hour SILAC data as well as with the 
affimetrix data, demonstrating the applicability of the method with respect to the 
investigations of interferon-? induced Ub-conjugates. The data from the eight hour 
labeling experiments also showed that p62 does not belong to the accumulating 
Ub-conjugates, although the relative quantification data deviate from the others.  
4  Discussion  111 
 
 
Figure 28 Presence of proteasomal subunits caused by co-precipitation ubiquitination or 
both. (A) A predominant co-precipitation of proteasome. (B) A co-preciptiation can coexist next 
to ubiquitination in Ub-conjugate enrichment fraction. The differences from distinct ubiquitination 
efficiency of proteasomal subunits might then be lowered by the co-precipitation. (C) Massive 
differences of the changes in Ub-conjugate concentrations indicate a predominant and distinct 
ubiquitination of the proteasomal subunits. (light blue: 19S regulatory subunits, dark blue: 
Ubiquitin, red: HA-tag, green: antibody against HA, violet: Ub substrate, yellow: proteasomal ?-
subunits, green: proteasomal ?-subunits).  
 
A probable explanation is the longer labeling period which may imply a higher 
influence of quantified co-precipitated p62. To assess the contamination of the 
Ub-conjugates with co-precipitants, the focus was laid on the proteasomal 
subunits. They were quantified in the Ub-conjugates via SILAC and it was 
analyzed, whether they are co-precipitants (see (A) Figure 28) or ubiquitination 
targets (C) or both (B).  
A detailed comparison of the quantitative changes of the distinct proteasomal 
subunits in the purified Ub-conjugates (8 h SILAC, section 3.5.4) revealed, that a 
predominant co-precipitation of intact 26S or 20S proteasome as well as of intact 
?-rings or ?-rings could be excluded. The only co-precipitants that could not be 
excluded to have an influence on quantification are intact regulatory 19S particles 
besides disassembled ones. However, in agreement with the literature (Vasilescu 
et al. 2005; Ventadour et al. 2007; Xu et al. 2010), in which some proteasomal 
subunits were found to be ubiquitinated, the results presented here indicate an 
ubiquitination of discrete proteasomal subunits and proteasomal activators with 
distinct specific efficiencies.  
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The ubiquitination of nearly all subunits was found to be influenced by 
interferon-?, but only a few showed an increase indicating their probable 
affiliation to the targeted accumulating newly synthesized Ub-conjugates. These 
likely interferon-? induced ubiquitinated proteasomal subunits/ activators are 
Lmp7 (?5i), PA28?, PA28????3, ?4, ?7, Rpn13, ?1,??2, ?6, ?7 and ?4. 
Ventadour et al. (Ventadour et al. 2007) proved a polyubiquitination of ?3 and 
suggested also a polyUb of other 20S proteasomal subunits. Based on this study, 
one may conclude that the proteasomal subunits/ activators, identified as 
ubiquitinated, are likely to be polyubiquitinated and belong to the interferon-? 
induced accumulating Ub-conjugates.  
Although an analysis via tagged-Ub isolated cross-section of Ub-conjugates 
(Dammer et al. 2011) allows no conclusion about the Ub-chain topology, the 
identification of a few of these proteasomal subunits in Rad23 enriched Ub-
conjugates supports the hypothesis of their polyubiquitination. To conclude, based 
on the results in this work, one can assumed that both effects are present, a 
dominant co-precipitation of intact or partially intact 19S regulatory particles and 
a distinct ubiquitination of the different proteasomal subunits (see Figure 28 (B)). 
4.9 Relevance of interferon-? induced identified ubiquitin conjugates 
Representative proteins of different cellular pathways were among the 111 Ub-
candidates (incl. identified ubiquitinated proteasomal subunits, cf. section 3.5.4), 
three polyUb-targets and three mono- or polyUb-targets which were found as 
significantly increased (cf. 4.7) in the pool of interferon-? induced Ub-conjugates. 
Comparing the list of Ub-candidates and targets of each experiment (1 h & 8 h 
SILAC) with the list of genes that show increased transcription with interferon-?, 
no general preference in ubiquitination was found for these.  
Among the ubiquitination targets and candidates deduced from SILAC data, many 
are found whose transcription is interferon-? induced. Their ubiquitination rates 
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appear to be proportional to their transcription rates and probably also to their 
translation rates, as was for instance found for Wars. However, for other genes 
with increased transcription rate in the presence of IFN?, this effect was smaller 
(cf. section 5.3.3.3).  
A number of explanations are possible for the latter observation. There might be a 
smaller absolute cellular protein concentration that is below the mass 
spectrometrical detection limit. Alternatively, these proteins may have a higher 
resistance against oxidation, misfolding and/ or ubiquitination as a signal for 
degradation, or some genes may show increased transcription rates without 
concomitant increased translation (post-transcriptional regulation mechanisms). A 
tentative explanation for increased products of genes with interferon-? unaffected 
transcription within the pool of Ub-conjugates might be an ubiquitination which is 
not targeting for degradation, perhaps accompanied by an enhanced sensitivity of 
these proteins towards oxidation and/ or misfolding (finally resulting in an 
increased ubiquitination). Overall, these results support the hypothesis that a 
certain ubiquitination selectivity may also be caused by the probable existence of 
specific immune-ribosomes (Yewdell et al. 2006). In this context, it is assumed 
that immune-ribosomes interact with the ubiquitin proteasome system and, in 
particular, selectively translate proteins which are targeting for the processing of 
antigenic precursors or peptides. Nevertheless, other reasons cannot be excluded 
at this stage, such as an enhanced formation of DRiPs due to limitations or 
adaptions of specific tRNA or amino acid supply, or an increased chain 
termination during translation due to an increased release factor concentration.  
The latter aspects of tRNA metabolism adaption, as well as polypeptide chain 
termination, are supported by the enhanced expression of tryptophanyl tRNA 
synthetase (Wars) in response to IFN???An enhanced expression of Wars is also 
observed during maturation of antigen presenting cells (Krause et al. 1996; 
Matsunaga et al. 2002), which is suggested to be connected with the higher 
amount of tryptophane residues proteins of the immune system compared to other 
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human proteins (Xue et al. 1995). Resulting from alternative splicing, there are 
two forms of Wars present in human cells, a full length form (54 kDa) and a 
truncated form (48 kDa) (Tolstrup et al. 1995). Both forms possess aminoacyl 
activity and both bind to oxidized glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH), but only the activity of the truncated form is enhanced through this 
interaction. GAPDH is an enzyme involved in glycolysis known to be sensitive to 
oxidative stress (Eaton et al. 2002), whereby it seems to enhance the activity of 
Wars under oxidative stress. It may have an equivalent function in 
interferon-??induced stress. Besides the tRNA synthetase activity, Wars is 
suggested to exhibit a release factor activity, too. This release factor activity 
would support the premature translational termination (Fleckner et al. 1991; 
Bange et al. 1992). The predominant presence of tryptophanyl tRNA synthetase 
may increase the amount of incompletely synthesized non-functional proteins 
which is part of the observed newly synthesized accumulating Ub-conjugates.  
Up to now, nothing was known about an ubiquitination of Wars. This study 
reveals that Wars itself is a polyubiquitination target belonging to the 
accumulating interferon-? induced Ub-conjugates (cf. section 3.6.2). The observed 
increased ubiquitination may be regulatively connected to the decrease of DRiPs 
formation after the eight hours interferon-? induction or may be due to an 
increased rate of translation following from an increased concentration of nascent 
defective ribosomal forms. Alternatively, there may be a proportionality between 
enhanced expression and increased formation of defective Wars. 
Within this discussion, some concrete hypothesis can be made regarding the 
function of interferon-? enhanced ubiquitination in the early immune response. 
This is summarized in the following with regard to the two identified polyUb-
substrates, Trim21 and Rpt5, as well as to the three further identified polyUb or 
monoUb targets, Lmp7 (?5i), PA28? and Parp14. 
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Trim21 is an E3 ligase that polyubiquitinates transcription factors of the interferon 
regulatory factor (IRF) family in order to initiate their proteasomal degradation 
(Kong et al. 2007; Higgs et al. 2008; Higgs et al. 2010). The enhanced expression 
of Trim21 and the closely connected increasing IRF degradation may represent a 
mechanism to protect against the overexpression of type I interferons during an 
immune response. Trim21 also mediates the down-regulation of the nuclear factor 
?B (NF?B) signaling, which is involved in multiple biological processes such as 
inflammation or immune response (Niida et al. 2010). Trim21 also interacts with 
immunoglobulins in the context of their quality control via ERAD (Takahata et al. 
2008). Furthermore, Trim21 is involved in the pathology of the autoimmune 
disease “lupus erythematosus” also known as “Sjoegren syndrome”. Among 
others, patients with Sjoegren syndrome have auto-antibodies against Trim21 and 
an increased serum concentration of interferon-??(Willeke et al. 2009). All 
mentioned functions of Trim21 underline its key role in immune response. It is 
known that Trim21 itself undergoes auto-ubiquitination (Fukuda-Kamitani et al. 
2002). It could be demonstrated here that not only its transcription, but also its 
ubiquitination (cf. section 3.6.3) are enhanced by interferon-? induction. This 
indicates a proportionality between Trim21 transcription and the amount of 
defective Trim21 which is suggested to be ubiquitinated targeting for proteasomal 
degradation. The elucidation of a possible correlation between Trim21 
ubiquitination in the early immune response and Trim21 autoantigen presentation 
in autoimmune disease might be an interesting topic for future investigations.  
The interferon-? induced ubiquitination of the newly synthesized proteasome 
regulatory subunit Rpt5 supports the hypothesis that there exists no general 
correlation between transcription and translation, as there is no evidence that its 
mRNA level is influenced by interferon-?. Based on what is known about the 
interferon-??induced?accumulating Ub-conjugates which predominantly appeared 
to be oxidized proteins (Seifert et al. 2010), Rpt5 is probably extremely sensitive 
towards oxidation during its biosynthesis. This hypothesis is supported by studies 
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on the effects of ischemia induced oxidative stress in mice models and isolated 
hearts (Divald et al. 2010). These studies identified Rpt5 as highly sensitive 
towards carbonylation compared to other 19S proteasomal subunits. Rpt5 
carbonylation was found to be connected with a diminished proteasomal ATPase 
as well as proteolytic activity at constant levels of 20S proteasome. These effects 
are accompanied by an increased concentration of ubiquitinated proteins in the 
cytosol.  
These findings agree with the following three observations during interferon-? 
induced oxidative stress: a) a transient decrease in proteasomal activity 
(minimum: 4-12 h post induction), b) a lower 26S proteasome level (minimum: 8-
12 h post-induction) due to reduced 19S regulator- 20S proteasome association, 
while the total amounts of 20S complexes remain unchanged, and last but not 
least, c) a transient accumulation of Ub-conjugates (maximum: 4-12 h) (Seifert et 
al. 2010). Accordingly, it is likely that Rpt5 suffers from increased oxidation rates 
during its synthesis in the presence of interferon-?. One might suggest that the 
resulting non-functional, oxidized protein is then polyubiquitinated to target it for 
proteasomal degradation. The decreasing concentration of functional Rpt5 will 
diminish the association between 19S regulatory particle and 20S proteasome and, 
thereby, the proteolytic and ATPase activity of the 26S proteasome. Due to the 
decreased proteasomal activity, the polyubiquitinated oxidized Rpt5 will 
accumulate together with other Ub-conjugates (Seifert et al. 2010). 
The proteins PA28?, Lmp7 and Parp14 could be identified as interferon-? induced 
Ub-targets. However, the question was not completely solved, whether they are 
mono- or polyubiquitinated. It is likely that especially the proteasomal activator 
PA28? is polyubiquitinated due to its presence in Rad23 based enriched Ub-
conjugates (cf. 5.3.3.2). To elucidate the exact ubiquitin-chain topology of the 
three proteins immuno-chemical studies have to be performed in the future. 
Anticipating they are polyubiquitinated, their ubiquitination is probably connected 
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with the increase of the translation due to interferon-? (cf. 5.3.3.3) and thereby 
their increased concentration in DRiPs. The synthesis of PA28? is enhanced in the 
early immune response. PA28? forms heteroheptameric rings with PA28? 
subunits and serves as proteasomal activator. PA28 is involved in the formation of 
hybrid-proteasomes (PA28-20S-19S) that enhance the effectivity of Ub-conjugate 
degradation (Hendil et al. 1998). Lmp7 (?5i) is an immuno proteasome specific 
subunit, synthesized for the interferon-? induced assembly of immuno 
proteasomes, and is thereby connected to immune response (Kloetzel 2001). 
Parp14 exhibits ADP ribosyltransferase activity and enhances the transcription of 
Stat6. Its role in immune response might be connected to the involvement of its 
effector Stat6 into the interleukin-4 pathway (Aguiar et al. 2005; Kelly-Welch et 
al. 2005).  
4.10 Final conclusion and future perspectives 
To resume, a useful analytical approach has been developed in this work for the 
identification of Ub-conjugates that accumulate in response to interferon-?. It is 
based on a combination of adapted and modified Ub-conjugate isolation and 
sample pretreatment for mass spectrometrical analysis. Based on a comparative 
study, it was shown, for the first time that a predigestion of Ub-conjugates with 
LysC combined with the conventional tryptic digestion is more efficient than 
tryptic digestion alone with respect to the unambiguous identification of Ub-
conjugates. The approach can be considered as relevant and useful for future 
investigations concerning the molecular background of Ub-conjugate formation 
and its regulation.  
A further decisive improvement was the adaption, modification and successful 
application of pulsed stable isotopic labeling with amino acids in cell culture as a 
technique for the analysis of newly synthesized Ub-conjugates. It could be 
demonstrated that an identification of newly synthesized Ub-conjugates by means 
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of a comparative “pulsed” SILAC based analysis is possible by using labeling 
time periods as short as one hour. 
A subsequent important finding was the induction of a specific oxidative stress as 
side effect of the conditions of stable isotope labeling with amino acids in cell 
culture. This is obviously a central observation, demonstrating that investigations 
on cellular proteins via the popular SILAC approach may be strongly influenced 
by specific metabolic changes induced by this method itself which has to be 
considered in its future applications. Nevertheless, the obtained results principally 
confirm SILAC as an applicable technique for a comparative analytical 
investigation of different samples regarding their ubiquitin substrates and Ub-
chain-compositions.  
 
Figure 29 Amended picture of interferon-? induced Ubiquitination in the early immune 
response. Identified accmulating Ub-conjugates and Ub-candidates as well as their Ub-chain 
linkage composition (yellow box, right hand side) and correlation of protein ubiquitination and 
gene transcription (yellow box, left hand side) determined via SILAC based quantitative mass 
spectrometry and additional immuno-chemical approaches.  
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Another progress achieved in this work was the successful characterization of the 
interferon-? induced Ub-conjugates in terms of their specific Ub-linkage pattern 
and the identity of ubiquitinated substrates. The approach discussed here 
contributes to an improved understanding of the cellular processes in the early 
immune response. The most relevant results are briefly summarized in the 
following and are illustrated in Figure 29. 
In response to IFN?, negligible concentration changes, but an enhanced instability 
were observed regarding the Ub-linkages K6, K48 and K63, with the exception of 
K11 (eight hours SILAC experiments). This instability was also observed for the 
only quantified Ub-linkage K48 in the one hour labeling. The results suggest an 
enhanced deubiquitination and/ or, respectively, a higher proteasomal turnover of 
the proteins labeled by these linkages. The K48-linkage concentration in the one 
hour labeling experiment and, interestingly, also the K11-linkage concentration in 
the eight hours SILAC experiments increased in the presence of interferon-?. The 
increase in K48-linkage concentration is attributed to its function as a general 
signal for proteasomal degradation (Thrower et al. 2000), and therefore an 
expected result in agreement with the published data from Seifert et al. (Seifert et 
al. 2010). However, the observed increase in K11-linkage concentration was a 
new finding.  
With regard to the known functions of K11-linkages (Xu et al. 2009), this either 
indicates an enhancement of the ER associated degradation or, due to the constant 
stability of K11-linked Ub-chains, an involvement in cell signaling. The relevant 
details of the K11-linked Ub-chain formation and its relation to the ER associated 
degradation pathway will be interesting topics for further investigations of the 
cellular processes in the early immune response. 
Overall, the decisive progress of this work was that three polyUb-targets, three 
further  mono- or polyUb-targets and 111 potential targets could be identified that 
exhibit enhanced ubiquitination in the early immune response affected by the 
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presence of the cytokine interferon-? (see Figure 29). In this way, it could be 
shown that there is no general preference for the ubiquitination of proteins from 
interferon-? induced transcribed genes. 
An either mono- or polyubiquitination of proteasomal subunits was found in 
agreement with described Ub-sites of some of these subunits in the literature 
(Vasilescu et al. 2005; Ventadour et al. 2007; Xu et al. 2010). It is assumed that 
they are polyubiquitinated proteasomal targets based on the findings of Vasilescu 
et al. (Vasilescu et al. 2005). The elucidation of the ubiquitin-chain topology of 
proteasomal subunits and the function of ubiquitination will be an interesting 
aspect for future investigations. Investigations performed on the ubiquitination of 
newly synthesized subunit Rpt5 approved an increased modification by mostly 
one to four ubiquitins in presence of interferon-?. In this way, Rpt5 was identified 
as part of the accumulating Ub-conjugates. The reason for its ubiquitination which 
is independent of its transcription may be connected to its known high sensitivity 
towards carbonylation under oxidative stress (Divald et al. 2010). Furthermore, 
this effect appears to have a decisive influence on the proteasome activity which 
decreases transiently. In this way, it also influences the accumulation of Ub-
conjugates?(Seifert et al. 2010).  
The cytosolic tryptophanyl-tRNA synthetase (Wars) turned out to be an 
interesting and relevant Ub-target. The enhanced expression of Wars during 
maturation of antigen presenting cells as well as in the presence of 
interferon-??emphasize its role for the immune response (Krause et al. 1996; 
Matsunaga et al. 2002). Wars is an indicator for interferon-??induced?metabolic 
changes, which might support the hypothesis of translational adaption through 
immune-ribosome formation (Yewdell et al. 2006). In addition, its suggested 
release factor activity could explain the considerable increase in formation of 
defective ribosomal proteins as due to the enhancement of polypeptide chain 
termination during translation (Fleckner et al. 1991; Bange et al. 1992). The 
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increased ubiquitination of Wars seemed to be correlated to the decrease of DRiPs 
formation after the applied eight hours interferon-? induction. An alternative 
explanation of the increased ubiquitination of Wars could be an increased rate of 
translation connected to an increased concentration of nascent defective ribosomal 
forms. 
 Another clearly identified Ub-target is tripartite motif 21 (Trim21) which seems 
to play a key role in the early immune response. Efforts to gain more insight into 
its role may be worth as an interesting topic for future investigations. Trim21 is 
known to be involved in the pathology of the autoimmune disease lupus 
erythematosus, due to the formation of autoantibodies against this protein in 
connection with an increased interferon-? serum concentration (Fukuda-Kamitani 
et al. 2002; de Marquesini et al. 2010).  
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5.2 Abbreviations 
(v/v) ratio volume to volume 
(w/v) ratio weight to volume 
26S 26 Svedberg 
A280 absorption at an wavelength of 280 
ABC ammoniumbicarbonate 
ACN acetonitrile 
? 1-7 proteasomal a subunit 1 to 7 
APS ammonium peroxodisulfat  
Arg arginine 
?-ring 
heteroheptameric ring of the 20S proteasome core partice  
containing subunits a1 to a7 
ATP adenosine triphosphate 
BCA Bicinchonine acid (reagent for determining protein concentration) 
?i-subunit Immuno proteasome specific beta subunit 
bp base pairs 
?-ring 
heteroheptameric ring of the 20S proteasome core partice  
containing subunits ? 1 to ? 7 
CAA chloroacetamide 
cDNA complementary DNA 
cf. confer 
CID collision induced dissociation 
c-myc c-myc epitope EQKLISEEDL 
d diameter 
DNA desoxyribo nucleic acid 
Da Dalton, unit equal to g/mol 
dFBS dialyzed fetal bovine serum 
DMF dimethylformamide 
DMSO dimethylsulfoxide 
DRiPs defective ribosomal products 
DTT dithiothreitol 
DUB deubiquitinating enzyme 
E1 ubiquitin activating enzyme 
E2 ubiquitin conjugating enzyme 
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E3 ubiquitin ligating enzyme/ ligase 
E4 factor for ubiquitin chain assembly 
EDTA ethylene diamine tetraacetic acid 
ER endoplasmatic reticulum 
ERAD endoplasmatic reticulum associated degradation 
FACS  fluorescence associated cell sorting 
FBS fetal bovine serum 
FDR false discovery rate 
FL1-H FACS parameter representing the fluorescence of GFP 
FSC 
FACS parameter representing the cell size/ volume  
(FSC stands for forward scatter of the cell) 
G glycine 
g gravity 
GFP/EGFP green fluorescent protein 
Gly glycine 
GSH 
Glutathione (a pseudotripeptide with the sequence glutamine acid,  
cysteine and glycine) 
GST glutathione S-transferase (binds glutathione (GSH)) 
h hour(s) 
H “heavy” isotopes, arginine + 10 Da and lysine + 8 Da 
HA haemagglutinine epitope from influenca virus YPYDVPDYA 
HECT domain homologous to E6-AP carboxy terminus domain 
His histidine 
hPlic-1 human Plic-1 also called Ubiquilin-1 
HRP horse radish peroxidas 
IFN? human interferon-? 
IgG immuno globuline G 
IP immuno precipitation 
IPTG isopropyl-?-D-thiogalactopyranoside 
ISG15 interferon stimulated gene 15 
JAMM  
motif protease Jab1/MPN/Mov34 metalloenzyme protease 
K lysine 
K48 lysine atamino acid position 48 
K48-linkage isopeptide bond to an ubiquitin at lysine amino acid position 48 
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kbp kilo base pairs 
L “light” isotopes, natural isotopes of arginine and lysine 
?? wave length 
LB-medium Luria Bertani medium 
LC liquid chromatography 
Log2FC binary logarithm 
Lys lysine 
M  “medium heavy” isotopes, arginine + 6 Da and lysine + 4 Da / L-methionine 
m/z mass to charge 
M1 methionine at amino acid position 1 
MDC max delbrück center Berlin 
MHC I major histocompatibility complex class I 
min minute(s) 
MJD protease MACHado-Joseph disease protease 
MOPS 3-(N-morpholino)propanesulfonic acid 
MS mass spectrometry /mass spectrum 
NEB New England Biolabs 
NEDD8 
Neural precursor cell expressed developementally down-regulated 8  
(a Ubiquitin-like modifier) 
NEM N-ethylmaleimide 
NEpHGE non equilibrium pH gel electrophoresis 
NTA nitrolotriacetic acid 
NTP nucleotide triphosphate 
o/n  over night 
OD600 optical density at w wavelength of 600 nm 
OTUB protease ovarian tumor ubiquitin protease 
p. page 
PA/ PAG polyacryl amide/ polyacryl amide gel 
PAGE polyacryl amide gel electrophoresis 
PBS/ PBST phosphate buffered saline/ phosphate buffered saline with 0.4% tween-20 
pCMV cyto megalo virus promotor 
PCR  polymerase chain reaction 
PEST sequence proline (P), glutamine (E), serine (S) and threaonine (T) rich sequence 
PMSF phenylmethylsulfonfluoride 
polyA-end poly adenosine end 
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PTM post translational modification / modifier  
PVDF polyvinylidenfluoride 
R arginine 
RING domain really interesting new gene domain 
ROS reactive oxygen species 
RP  reversed phase 
Rpn10 regulatory particle non-ATPase subunit 10 
Rpt5 regulatory particle ATPase subunit 5 
RT room temperature 
S.D. standard deviation 
SCF complex skp cullin f-box complex 
SDS sodiumdodecylsulfate 
sec second(s) 
SILAC stable isotope labeling with amino acids in cell culture 
SSC 
FACS parameter representing the cell granularity  
(stands for side scatter of the cell) 
SUMO small ubiquitin-like modifier 
TEMED tetramethylethylendiamine 
TFA trifluoro acetic acid 
Tris tris(hydroxymethyl)-aminomethan 
U (IFN?) 
Unit= the amount of IFN? that is required to produce equivalent antiviral  
activity to that expressed by 1 unit of the NIH IFN? reference standard  
(1 unit equals ? 0.05 ng/mL) 
Ub ubiquitin/ubiquitinated 
Ub side amino acid that is attached to the C-terminus of an Ub 
UBA domain ubiquitin associated domain 
UbL domain ubiquitin-like domain 
UCH ubiquitin carboxy hydrolase 
UIM domain ubiquitin interacting motif domain 
UPS ubiquitin proteasome system / ubiquitin specific protease 
UV ultra violett 
X-Gal 5-brom-4-chlor-3-indoxyl-?-D-galactopyranosid 
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5.3 Supplementary data 
5.3.1 Expression level of tagged ubiquitin and phenotype of cells 
The effect of interferon-? on expression level and phenotype of the cells was 
tested. For this effort one half of each cell line, stably transfected and non-
transfected HeLa cells, was induced for 8h with interferon-?, the other half was 
left uninduced. 1000 cells/ aliquot of trypsinated cells were measured by flow 
cytometry, to determine the following parameters: fluorescence (FL1-H), the cell 
volume (FSC) and granularity (SSC). Then histograms of fluorescence, 
granularity and cell size have been plotted against the cell number (Figure 30). 
No significant changes of the fluorescence intensity (FL1-H) and, accordingly, 
also of the expression level of tagged Ub could be observed in the presence of 
interferon-? (expected result: pCMV promotor not influenced by hIFN??. 
Additionally, no significant changes were found concerning granularity (SSC) 
(number and size of compartements) and cell size (FSC) caused by interferon-??or 
transfection. 
Overall, the results show that the overexpression of the tagged Ub, as well as cell 
size and granularity were not interferon-? influenced and, as second result, that the 
cell size and granularity were also not influenced by transfection of the HA-Ub-
EGFP plasmid. 
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Figure 30 Influence of transfection and hIFN? on fluorescence, cell size and granularity of 
HeLa cells. Row 2: Influence of 8 h IFN? (100 U/mL) on untransfected HeLa cells (black graph) 
in comparison to uninduced HeLa cells (grey area). Row 3: Influence of 8 h IFN? (100 U/mL) on 
HA-Ub-EGFP stably transfected HeLa cells (black graph) by comparison to uninduced stably 
transfected cells (grey area). Row 4: Influence of stable transfection with HA-Ub-EGFP on HeLa 
cells, non-transfected (grey area) as well as stably transfected (black graph) cells. 
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5.3.2 MS2 fragmentations of Ub-linkage indicator peptides 
 
Figure 31-1 MS2 spectra of Ub-linkage indicator peptides from 8h SILAC experiments (A) 
K48 Ub-site indicator peptide (B) K63 Ub-site indicator peptide. Signals of fragment ions are 
marked in the spectrum, their calculated mass with corresponding mass deviation (?? are shown in 
the table (lower right hand side). Detection parameters and sample description as well as amino 
acid sequence with marked Ub-sides are presented, too (lower right hand side); PEP= posterior 
error probability, Mascot score, PTM= post translational modification score. 
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Figure 31-2 MS2 spectra of Ub-linkage indicator peptides from 8 h SILAC experiments (C) 
K6 Ub-site indicator peptide (D) K11 Ub-site indicator peptide. Signals of fragment ions are 
marked in the spectrum, their calculated mass with corresponding mass deviation (?? are shown in 
the table (lower right hand side). Detection parameters and sample description as well as amino 
acid sequence with marked Ub-sides are presented, too (lower right hand side); PEP= posterior 
error probability, Mascot score, PTM= post translational modification score. 
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Figure 31-3 MS2 spectrum of a potential Ub-linkage indicator peptide from 8 h SILAC 
experiments (E) potential K27 Ub-site indicator peptide. Signals of fragment ions are marked 
in the spectrum, their calculated mass with corresponding mass deviation (?? are shown in the 
table (lower right hand side). Detection parameters and sample description as well as amino acid 
sequence with marked Ub-sides are presented, too (lower right hand side); PEP= posterior error 
probability, Mascot score, PTM= post translational modification score. 
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Figure 32-1 MS2 spectra of Ub-linkage indicator peptides from 1 h SILAC experiments (A) 
K6 Ub-site indicator peptide (B) K11 Ub-site indicator peptide. Signals of fragment ions are 
marked in the spectrum, their calculated mass with corresponding mass deviation (?? are shown in 
the table (lower right hand side). Detection parameters and sample description as well as amino 
acid sequence with marked Ub-sides are presented, too (lower right hand side); PEP= posterior 
error probability, Mascot score, PTM= post translational modification score. 
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Figure 32-2 MS2 spectrum of Ub-linkage indicator peptides from 1 h SILAC experiments (C) 
K48 Ub-site indicator peptide (D) K63 Ub-site indicator peptide. Signals of fragment ions are 
marked in the spectrum, their calculated mass with corresponding mass deviation (?? are shown in 
the table (lower right hand side). Detection parameters and sample description as well as amino 
acid sequence with marked Ub-sides are presented, too (lower right hand side); PEP= posterior 
error probability, Mascot score, PTM= post translational modification score. 
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5.3.3.3 Affimetrix microarray data for the ratio 8 to 0 hours interferon-? 
Table 8 Interferon-? induced transcribed genes. Data based on Affimetrix microarray analysis 
of an experiment performed by N. Lange. Genes showing a transcriptional increase of >0.25 with 
respect to their Median [log2FC (8 h / 0 h IFN?)] ± standard deviation (S.D.) are listed. 
Gene?Title? Gene?Symbol?
Median?
[log2FC(8?h/0?h?IFN?)]?
±?S.D.?
indoleamine?pyrrole?2,3?dioxygenase? INDO? 6.43?
interleukin?18?binding?protein? IL18BP? 4.87?
ubiquitin?conjugating?enzyme?E2L?6? UBE2L6? 4.86?
guanylate?binding?protein?2? GBP2? 4.43? 1.6?
chloride?intracellular?channel?2? CLIC2? 4.08?
guanylate?binding?protein?1? GBP1? 3.85? 0.22?
sterile?alpha?motif?domain?containing?9?like? SAMD9L? 3.72? 0.75?
guanylate?binding?protein?3? GBP3? 3.62?
interferon?regulatory?factor?1? IRF1? 3.46?
poly?(ADP?ribose)?polymerase?family?member?9? PARP9? 3.39? 0.93?
chemokine?ligand?11? CXCL11? 3.36?
proteasome?subunit?LMP2? PSMB9? 3.35?
basic?leucine?zipper?transcription?factor,?ATF?like?2? BATF2? 3.35?
intercellular?adhesion?molecule?1?(CD54)? ICAM1? 3.32? 1.35?
retinoic?acid?receptor?responder?3? RARRES3? 3.28?
Guanylate?binding?protein?5? GBP5? 3.27? 0.54?
interferon?induced?protein?with?tetratricopeptide?repeats?3? IFIT3? 3.07?
apolipoprotein?L,?6? APOL6? 2.99? 1.06?
transporter?1,?ATP?binding?cassette?? TAP1? 2.88? 0?
secreted?and?transmembrane?1? SECTM1? 2.84?
deltex?3?like?? DTX3L? 2.82?
interferon?induced?with?helicase?C?domain?1? IFIH1? 2.81?
tryptophanyl?tRNA?synthetase? WARS? 2.79? 0.08?
interferon?stimulated?transcription?factor?3,???48kDa? ISGF3G? 2.75?
XIAP?associated?factor?1? BIRC4BP? 2.74? 0.28?
tripartite?motif?containing?22? TRIM22? 2.69?
toll?like?receptor?3? TLR3? 2.66?
signal?transducer?and?activator?of?transcription?1? STAT1? 2.57? 0.47?
interferon?induced?protein?with?tetratricopeptide?repeats?2? IFIT2? 2.47?
apolipoprotein?L,?3? APOL3? 2.45?
STEAP?family?member?4? STEAP4? 2.4?
interferon?induced?protein?with?tetratricopeptide?repeats?1?? IFIT1? 2.37?
absent?in?melanoma?2? AIM2? 2.34?
interferon?induced?protein?44? IFI44? 2.32?
apolipoprotein?L,?2? APOL2? 2.27?
RAD50?homolog?? RAD50? 2.23?
tripartite?motif?containing?21?? TRIM21?? 2.2?
transmembrane?protein?140? TMEM140? 2.17?
chemokine?(C?X?C?motif)?ligand?10? CXCL10? 2.14?
DEAD?(Asp?Glu?Ala?Asp)?box?polypeptide?58? DDX58? 2.07? 0.38?
poly?(ADP?ribose)?polymerase?family,?member?14? PARP14? 2.05? 1.26?
hypothetical?protein?FLJ20035? FLJ20035? 2.05?
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interleukin?7? IL7? 2.03?
major?histocompatibility?complex,?class?I,?E? HLA?E? 2.02? 0.53?
caspase?1? CASP1? 2.02? 0.68?
interferon?induced?protein?35? IFI35? 1.94?
cathepsin?S? CTSS? 1.94? 0.22?
hypothetical?protein?LOC154761? LOC154761? 1.9?
R?spondin?3?homolog? RSPO3? 1.85?
SP110?nuclear?body?protein? SP110? 1.83? 0.36?
N?myc?(and?STAT)?interactor? NMI? 1.81?
NLR?family,?CARD?domain?containing?5? NLRC5? 1.77?
hyaluronan?and?proteoglycan?link?protein?3? HAPLN3? 1.74?
acyl?CoA?synthetase?long?chain?family?member?5? ACSL5? 1.74? 0.16?
ISG15?ubiquitin?like?modifier? ISG15? 1.69?
coiled?coil?domain?containing?68? CCDC68? 1.69?
interleukin?15?receptor,?alpha? IL15RA? 1.68?
IL2?inducible?T?cell?kinase? ITK? 1.67?
apolipoprotein?L,?4? APOL4? 1.64?
hypothetical?protein?LOC643977? FLJ32255? 1.62? 0.17?
v?maf?musculoaponeurotic?fibrosarcoma?oncogene?homolog?F?? MAFF? 1.59?
complement?component?1,?r?subcomponent? C1R? 1.57?
cathepsin?O? CTSO? 1.57?
interferon,?gamma?inducible?protein?16? IFI16? 1.57? 0.07?
transmembrane?protease,?serine?3? TMPRSS3? 1.54? 0.67?
interferon?induced?protein?44?like? IFI44L? 1.5?
complement?component?1,?s?subcomponent? C1S? 1.49?
proteasome?subunit?MECL?1? PSMB10? 1.49?
interleukin?15? IL15? 1.47? 0.13?
interferon?induced?protein?with?tetratricopeptide?repeats?5? IFIT5? 1.46? 0.08?
proteasome?subunit?Lmp7? PSMB8? 1.45?
phospholipid?scramblase?1? PLSCR1? 1.43? 0.26?
zinc?finger?CCCH?type,?antiviral?1? ZC3HAV1? 1.43? 0.14?
guanylate?binding?protein?4? GBP4? 1.42? 1.04?
B?cell?CLL/lymphoma?6?(zinc?finger?protein?51)?? BCL6? 1.41?
hypothetical?protein?BC004921? LOC93349? 1.38?
colony?stimulating?factor?1?? CSF1? 1.37?
interferon?regulatory?factor?2? IRF2? 1.36?
Fas?(TNF?receptor?superfamily,?member?6)? FAS? 1.35? 0.07?
tumor?necrosis?factor?receptor?superfamily,?member?14?? TNFRSF14? 1.35?
CD74?molecule,?major?histocompatibility?complex,?class?II?invariant?chain? CD74? 1.34?
Beta?2?microglobulin? B2M? 1.32?
tripartite?motif?containing?69? TRIM69? 1.31? 1.46?
poly?(ADP?ribose)?polymerase?family,?member?12? PARP12? 1.31?
caspase?7,?apoptosis?related?cysteine?peptidase? CASP7? 1.28?
butyrophilin,?subfamily?3,?member?A3? BTN3A3? 1.28? 0.09?
major?histocompatibility?complex,?class?II,?DM?alpha? HLA?DMA? 1.27?
suppressor?of?cytokine?signaling?1? SOCS1? 1.27? 1.44?
IBR?domain?containing?2? IBRDC2? 1.27?
2'?5'?oligoadenylate?synthetase?like? OASL? 1.26? 0.24?
nicotinamide?N?methyltransferase? NNMT? 1.23? 0.26?
selenoprotein?X,?1? SEPX1? 1.23?
transporter?2,?ATP?binding?cassette,?sub?family?B?? TAP2? 1.21? 0.53?
family?with?sequence?similarity?111,?member?A? FAM111A? 1.2?
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interferon,?alpha?inducible?protein?27? IFI27? 1.19?
complement?component?4A?? C4A?? 1.19? 0.28?
IBR?domain?containing?3? IBRDC3? 1.16? 0.01?
2',5'?oligoadenylate?synthetase?1,?40/46kDa? OAS1? 1.15? 0.41?
Chromosome?20?open?reading?frame?118? C20orf118? 1.14? 0.14?
response?gene?to?complement?32? RGC32? 1.14?
oxidized?low?density?lipoprotein?receptor?1? OLR1? 1.14?
phorbol?12?myristate?13?acetate?induced?protein?1? PMAIP1? 1.1? 0.06?
hypothetical?protein?FLJ31033? FLJ31033? 1.09? 0.24?
betacellulin? BTC? 1.09?
SAM?domain?and?HD?domain?1? SAMHD1? 1.08? 0.1?
tumor?necrosis?factor?superfamily,?member?10?? TNFSF10? 1.08? 0.65?
signal?transducer?and?activator?of?transcription?2? STAT2? 1.07? 0.84?
absent?in?melanoma?1? AIM1? 1.07?
negative?regulator?of?ubiquitin?like?proteins?1? NUB1? 1.06? 0.23?
receptor?interacting?serine?threonine?kinase?2? RIPK2? 1.06? 0.01?
promyelocytic?leukemia? PML? 1.05? 0.41?
interleukin?32?? IL32? 1.05?
butyrophilin,?subfamily?3,?member?A1? BTN3A1? 1.05? 0.43?
Proline?rich?Gla?(G?carboxyglutamic?acid)?4?? PRRG4? 1.04? 0.25?
hypothetical?protein?FLJ11286? FLJ11286? 1.03? 0.12?
interleukin?6?(interferon,?beta?2)? IL6? 1.03?
interferon?stimulated?exonuclease?gene?20kDa? ISG20? 1.01? 0?
sulfide?quinone?reductase?like? SQRDL? 1.01?
myxovirus?resistance?2?? MX2? 1.01?
alpha?kinase?1? ALPK1? 1?
transmembrane?protein?158? TMEM158? 1?
Ubiquitin?specific?peptidase?30? USP30? 1?
transmembrane?protein?149? TMEM149? 0.99?
major?histocompatibility?complex,?class?II,?DP?beta?1? HLA?DPB1? 0.99?
major?histocompatibility?complex,?class?II,?DM?beta?? HLA?DMB? 0.98?
leucine?aminopeptidase?3? LAP3? 0.97?
ubiquitin?specific?peptidase?18?? USP18?? 0.96?
serpin?peptidase?inhibitor,?clade?G?member?1,?? SERPING1? 0.96?
butyrophilin,?subfamily?3,?member?A2? BTN3A2? 0.96? 0.05?
lupus?brain?antigen?1? LBA1? 0.96?
C?type?lectin?domain?family?2,?member?? CLEC2B?? 0.96? 0.21?
damage?regulated?autophagy?modulator? DRAM? 0.95?
lactamase,?beta? LACTB? 0.95? 0.21?
peroxisomal?proliferator?activated?receptor?A?interacting?complex?285? PRIC285? 0.95? 0.51?
cytochrome?P450,?family?11,?subfamily?A,?polypeptide?1?? CYP11A1? 0.95?
2'?5'?oligoadenylate?synthetase?3,?100kDa? OAS3? 0.94?
HEG?homolog?1? HEG1? 0.94? 0.1?
myeloid?differentiation?primary?response?gene?(88)? MYD88? 0.93?
solute?carrier?family?25,?member?28?? SLC25A28? 0.93? 0.12?
cullin?associated?and?neddylation?dissociated?2?? CAND2? 0.92?
follistatin? FST? 0.92? 0.16?
protein?phosphatase?2C? PPM2C? 0.91? 0.25?
polycomb?group?ring?finger?5? PCGF5? 0.89? 0.68?
hypothetical?gene?supported?by?BC040060? LOC387895? 0.88?
sorting?nexin?10? SNX10? 0.87?
SP100?nuclear?antigen? SP100? 0.86? 0.11?
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type?1?tumor?necrosis?factor?receptor?shedding?aminopeptidase?regulator? ARTS?1? 0.85? 0.11?
hepatocyte?nuclear?factor?4,?gamma? HNF4G? 0.84?
zinc?finger,?NFX1?type?containing?1? ZNFX1? 0.83?
cylindromatosis?? CYLD? 0.82? 0.29?
optineurin? OPTN? 0.82? 0.01?
chromosome?X?open?reading?frame?38? CXorf38? 0.81?
tripartite?motif?containing?38? TRIM38? 0.81? 0.11?
aspartyl?aminopeptidase? DNPEP? 0.81? 0.07?
sterile?alpha?motif?domain?containing?9? SAMD9? 0.79? 0.13?
calcium?binding?and?coiled?coil?domain?2? CALCOCO2? 0.79?
tudor?domain?containing?7? TDRD7? 0.78?
microtubule?interacting?and?transport,?domain?containing?1? MITD1? 0.78?
carbonyl?reductase?3? CBR3? 0.77?
MOB1,?Mps?One?Binder?kinase?activator?like?2C?? MOBKL2C? 0.77?
nuclear?receptor?coactivator?7? NCOA7? 0.77?
GRAM?domain?containing?3? GRAMD3? 0.76?
pre?B?cell?colony?enhancing?factor?1? PBEF1? 0.76? 0.08?
hect?domain?and?RLD?6? HERC6? 0.76?
NK3?transcription?factor?related,?locus?1?? NKX3?1? 0.75?
Hypothetical?gene?supported?by?AK001829? LOC440498? 0.75?
PHD?finger?protein?11? PHF11? 0.73? 0.41?
5'?3'?exoribonuclease?1? XRN1? 0.73? 0.03?
GABA(A)?receptor?associated?protein?like?1? GABARAPL1? 0.73? 0.09?
limb?bud?and?heart?development?homolog?? LBH? 0.72?
opioid?growth?factor?receptor? OGFR? 0.72? 0.23?
Ras?homolog?gene?family,?member?T1? RHOT1? 0.71?
serine?palmitoyltransferase?long?chain?base?subunit3? SPTLC3? 0.71?
endothelial?cell?growth?factor?1?? ECGF1? 0.7? 0.34?
ATPase,?Class?V,?type?10D? ATP10D? 0.7?
interleukin?18?(interferon?gamma?inducing?factor)? IL18? 0.7?
HLA?B?associated?transcript?5? BAT5? 0.69?
v?ral?simian?leukemia?viral?oncogene?homolog?A?? RALA? 0.68? 0.23?
tripartite?motif?containing?56? TRIM56? 0.68?
LIM?homeobox?9? LHX9? 0.67?
hypothetical?protein?MGC5618? MGC5618? 0.67?
claudin?23? CLDN23? 0.67?
schlafen?family?member?5? SLFN5? 0.67? 0.18?
zinc?finger?protein,?multitype?2? ZFPM2? 0.66?
2'?5'?oligoadenylate?synthetase?2,?69/71kDa? OAS2? 0.66?
chromosome?5?open?reading?frame?15? C5orf15? 0.66?
proline?serine?threonine?phosphatase?interacting?protein?2? PSTPIP2? 0.65?
phospholipid?scramblase?4? PLSCR4? 0.65?
MHC?class?I?polypeptide?related?sequence?B? MICB? 0.65?
adenosine?deaminase,?RNA?specific? ADAR? 0.65?
cysteinyl?leukotriene?receptor?1? CYSLTR1? 0.65? 0.06?
D4,?zinc?and?double?PHD?fingers,?family?3? DPF3? 0.65?
tripartite?motif?containing?34?? TRIM34?? 0.64?
egf?like?module?containing,?mucin?like,?hormone?receptor?like?1? EMR1? 0.64? 0.06?
angiopoietin?1? ANGPT1? 0.63? 0.05?
hypothetical?protein?FLJ35390? FLJ35390? 0.63?
synaptopodin?2? SYNPO2? 0.63?
Zinc?finger?and?BTB?domain?containing?16? ZBTB16? 0.63?
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spermidine/spermine?N1?acetyltransferase?1? SAT1? 0.62? 0.04?
dual?specificity?phosphatase?5? DUSP5? 0.62?
chromosome?8?open?reading?frame?4? C8orf4? 0.62?
major?vault?protein? MVP? 0.62?
FOS?like?antigen?1? FOSL1? 0.61?
CUB?domain?containing?protein?1? CDCP1? 0.61?
solute?carrier?family?12?member?7? SLC12A7? 0.61?
calcium?channel?P/Q?type,?alpha?1A?subunit? CACNA1A? 0.6?
caspase?4? CASP4? 0.6?
signal?peptide,?CUB?domain,?EGF?like?3? SCUBE3? 0.6?
gliomedin? GLDN? 0.6? 0.36?
ets?variant?gene?6? ETV6? 0.59? 0.05?
mucin?1,?cell?surface?associated? MUC1? 0.59? 0.04?
nuclear?protein?1? NUPR1? 0.59?
zinc?finger?protein?36?? ZFP36? 0.58?
signal?transducer?and?activator?of?transcription?3?? STAT3? 0.58? 0.03?
major?histocompatibility?complex?class?II,?DP?alpha?1? HLA?DPA1? 0.58? 0.11?
scavenger?receptor?class?F,?member?1? SCARF1? 0.58?
Methylmalonic?aciduria?cblA?type? MMAA? 0.58?
chromodomain?helicase?DNA?binding?protein?9?? CHD9?? 0.58?
tripartite?motif?containing?15? TRIM15? 0.57?
neuropilin?1? NRP1? 0.57?
serine/threonine/tyrosine?kinase?1? STYK1? 0.57? 0.15?
NudC?domain?containing?1? NUDCD1? 0.57?
protein?tyrosine?phosphatase?type?IVA,?member?3? PTP4A3? 0.57?
tumor?necrosis?factor?superfamily,?member?13b? TNFSF13B? 0.57?
UDP?glucuronosyltransferase?1?family?polypeptide?A4? UGT1A4? 0.57?
hypothetical?protein?MGC16075? MGC16075? 0.57?
ADP?ribosylation?factor?like?6?interacting?protein?2? ARL6IP2? 0.56?
schlafen?family?member?12? SLFN12? 0.56?
kringle?containing?transmembrane?protein?1? KREMEN1? 0.56?
F?box?protein?6? FBXO6? 0.56?
Biogenesis?of?lysosome?related?organelles?complex?1?subunit?3? BLOC1S3? 0.56?
proteasome?activator?PA28?beta? PSME2? 0.56?
CCAAT/enhancer?binding?protein?delta? CEBPD? 0.55?
proline?rich?Gla?(G?carboxyglutamic?acid)?1? PRRG1? 0.55?
similar?to?annexin?II?receptor? AXIIR? 0.54?
LON?peptidase?N?terminal?domain?and?ring?finger?1? LONRF1? 0.54?
interleukin?1?receptor,?type?I? IL1R1? 0.54?
SIN3?homolog?B,?transcription?regulator?? SIN3B? 0.54? 0.11?
CASP8?and?FADD?like?apoptosis?regulator? CFLAR? 0.54? 0.05?
solute?carrier?family?12,?member?8? SLC12A8? 0.54?
toll?like?receptor?4? TLR4? 0.54? 0?
BCL2?antagonist/killer?1? BAK1? 0.54?
cholinergic?receptor,?nicotinic,?beta?1?? CHRNB1? 0.54?
leukocyte?derived?arginine?aminopeptidase? LRAP? 0.54? 0.06?
malic?enzyme?3,?NADP(+)?dependent,?mitochondrial?? ME3?? 0.54?
major?histocompatibility?complex,?class?II,?DQ?beta?1?? HLA?DQB1?? 0.54?
pleckstrin?homology?like?domain?family?A?member?1? PHLDA1? 0.53? 0.09?
aryl?hydrocarbon?receptor?nuclear?translocator?like?2? ARNTL2? 0.53? 0.27?
5'?nucleotidase,?cytosolic?III? NT5C3? 0.53?
plasminogen?activator,?urokinase?receptor?? PLAUR? 0.53? 0.07?
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EPH?receptor?B2? EPHB2? 0.53? 0.1?
Jun?dimerization?protein?p21SNFT? SNFT? 0.52?
carbonic?anhydrase?XIII? CA13? 0.52? 0.26?
Kruppel?like?factor?4?? KLF4? 0.52? 0.08?
karyopherin?alpha?5?(importin?alpha?6)? KPNA5? 0.51?
activating?transcription?factor?3? ATF3? 0.51? 0.11?
hypothetical?protein?FLJ36031? FLJ36031? 0.51?
glutamate?cysteine?ligase,?modifier?subunit? GCLM? 0.51? 0.1?
muscle?RAS?oncogene?homolog? MRAS? 0.51?
synapsin?II? SYN2? 0.51?
serine?palmitoyltransferase?long?chain?base?subunit2? SPTLC2? 0.51?
RanBP?type?and?C3HC4?type?zinc?finger?containing?1? RBCK1? 0.51? 0.18?
nucleotide?binding?protein?1?? NUBP1? 0.51?
transmembrane?protein?87A? TMEM87A? 0.51?
frizzled?homolog?5?? FZD5? 0.5?
metallothionein?1G? MT1G? 0.5?
WD?repeat?domain?25? WDR25? 0.5?
interferon?(alpha,?beta?and?omega)?receptor?2? IFNAR2? 0.5?
5,10?methylenetetrahydrofolate?reductase?? MTHFR? 0.5? 0.22?
spermatogenesis?associated?16? SPATA16? 0.5?
TRAF?type?zinc?finger?domain?containing?1? TRAFD1? 0.5? 0.08?
RNA?binding?motif,?single?stranded?interacting?protein?1? RBMS1? 0.5?
CD40?molecule,?TNF?receptor?superfamily?member?5? CD40? 0.49?
zinc?finger?protein?479? ZNF479? 0.49?
ATP?binding?cassette,?sub?family?D?member?3? ABCD3? 0.49?
Src?homology?2?domain?containing?family?member?4? SHC4? 0.49? 0.17?
Ribosomal?protein?L27a? RPL27A? 0.49?
major?histocompatibility?complex?class?II?DR?beta?1?? HLA?DRB1?? 0.49?
RAB27B,?member?RAS?oncogene?family?? RAB27B?? 0.49? 0.15?
DENN/MADD?domain?containing?4A? DENND4A? 0.49?
interferon,?alpha?inducible?protein?6? IFI6? 0.48?
tripartite?motif?containing?25? TRIM25? 0.48? 0.12?
eukaryotic?translation?initiation?factor?2???kinase?2? EIF2AK2? 0.48?
CD47?molecule? CD47? 0.48? 0.27?
DEAD?(Asp?Glu?Ala?Asp)?box?polypeptide?23? DDX23? 0.48? 0.05?
mal,?T?cell?differentiation?protein?like? MALL? 0.48?
RAB20,?member?RAS?oncogene?family? RAB20? 0.47?
proteasome?activator?PA28?alpha? PSME1? 0.47?
solute?carrier?family?25?member?22? SLC25A22? 0.47?
dopamine?receptor?D2? DRD2? 0.47?
GLI?Kruppel?family?member?GLI3?? GLI3? 0.47?
KIAA1618? KIAA1618? 0.47?
hypothetical?protein?LOC286254? LOC286254? 0.47?
Solute?carrier?family?4?member?1? SLC4A1AP? 0.47?
protocadherin?beta?15? PCDHB15? 0.47?
suppressor?of?cytokine?signaling?3? SOCS3? 0.47? 0.03?
ring?finger?protein?31? RNF31? 0.47?
coiled?coil?domain?containing?33? CCDC33? 0.47?
nucleotide?binding?oligomerization?domain?containing?1? NOD1? 0.46?
brain?protein?I3? BRI3? 0.46?
ADP?ribosylation?factor?GTPase?activating?protein?3? ARFGAP3? 0.46?
matrix?metallopeptidase?14?? MMP14? 0.46?
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BTB?(POZ)?domain?containing?14A? BTBD14A? 0.46?
RAS?p21?protein?activator?? RASA1? 0.46?
Solute?carrier?family?4?member?5? SLC4A5? 0.46?
jun?dimerization?protein?2? JDP2? 0.46?
UDP?galactose?4?epimerase? GALE? 0.46?
tensin?1?? TNS1? 0.46?
Hypothetical?protein?LOC727918? LOC727918? 0.46?
TAP?binding?protein?(tapasin)? TAPBP? 0.46?
calmodulin?like?3? CALML3? 0.45?
superoxide?dismutase?2,?mitochondrial? SOD2? 0.45? 0.04?
RAB27A,?member?RAS?oncogene?family? RAB27A? 0.45? 0.11?
metallothionein?2A? MT2A? 0.45?
chromosome?2?open?reading?frame?18? C2orf18? 0.45?
lethal?giant?larvae?homolog?1?? LLGL1? 0.45?
cytoglobin? CYGB? 0.45?
zinc?finger?protein?533? ZNF533? 0.45?
SH3?domain?protein?D19? SH3D19? 0.45?
IKK?interacting?protein? IKIP? 0.45? 0.16?
NMD3?homolog?? NMD3? 0.45?
ras?homolog?gene?family,?member?J? RHOJ? 0.45?
splA/ryanodine?receptor?domain?and?SOCS?box?containing?1? SPSB1? 0.45?
chromosome?3?open?reading?frame?23? C3orf23? 0.45? 0.05?
Janus?kinase?2?? JAK2? 0.44? 0.16?
glutaredoxin?? GLRX? 0.44? 0?
heterogeneous?nuclear?ribonucleoprotein?A3? HNRPA3? 0.44?
lines?homolog?1?? LINS1? 0.44? 0.08?
3?hydroxyisobutyrate?dehydrogenase? HIBADH? 0.44?
hexokinase?1? HK1? 0.44?
FLJ35767?protein? FLJ35767? 0.44?
Mov10,?Moloney?leukemia?virus?10? MOV10? 0.44?
PQ?loop?repeat?containing?2? PQLC2? 0.44?
Family?with?sequence?similarity?122C? FAM122C? 0.44? 0.12?
KIAA0146? KIAA0146? 0.43?
chromosome?1?open?reading?frame?38? C1orf38? 0.43?
Bone?marrow?stromal?cell?antigen?2? BST2? 0.43? 0.09?
guanine?nucleotide?binding?protein???polypeptide?4? GNB4? 0.43?
tumor?necrosis?factor,?alpha?induced?protein?1?? TNFAIP1? 0.43? 0.05?
Nedd4?binding?protein?1? N4BP1? 0.42?
strawberry?notch?homolog?2? SBNO2? 0.42? 0.03?
kelch?like?9?? KLHL9? 0.42?
Interleukin?10?receptor,?beta? IL10RB? 0.42?
fibronectin?type?III?and?SPRY?domain?containing?1?like? FSD1L? 0.42?
insulin?like?3?? INSL3? 0.42?
Hypothetical?LOC541471? LOC541471? 0.42?
Kruppel?like?factor?6? KLF6? 0.42? 0.08?
Succinate?dehydrogenase?complex,?subunit?A?? SDHA?? 0.42?
metallothionein?1M? MT1M? 0.42?
major?histocompatibility?complex,?class?I?related? MR1? 0.42?
XAGE?4?protein?? RP11?167P23.2?? 0.42?
ribosomal?protein?L38? RPL38? 0.42? 0.16?
solute?carrier?family?16,?member?6?? SLC16A6? 0.42?
nibrin? NBN? 0.42? 0.13?
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similar?to?laminin?receptor?1?(ribosomal?protein?SA)? LOC127406? 0.42?
Deltex?3?homolog?? DTX3? 0.41?
zinc?finger?protein?200? ZNF200? 0.41? 0.07?
chromosome?10?open?reading?frame?103? C10orf103? 0.41?
DKFZP434B0335?protein? DKFZP434B0335? 0.41?
zinc?finger,?CCHC?domain?containing?10? ZCCHC10? 0.41?
Ras?related?GTP?binding?C? RRAGC? 0.41? 0.03?
Ubiquitin?protein?ligase?E3C? UBE3C? 0.41?
PR?domain?containing?1,?with?ZNF?domain? PRDM1? 0.41?
metallothionein?1H? MT1H? 0.41?
neurofibromin?1?? NF1? 0.41?
Quinolinate?phosphoribosyltransferase?? QPRT? 0.41?
rhomboid?domain?containing?1? RHBDD1? 0.41?
CD53?molecule? CD53? 0.41?
chromosome?8?open?reading?frame?60? C8orf60? 0.41?
plasticity?related?gene?3? RP11?35N6.1? 0.41?
RIO?kinase?3?? RIOK3? 0.4?
interferon?induced?transmembrane?protein?1?? IFITM1? 0.4? 0.2?
PR?domain?containing?2,?with?ZNF?domain? PRDM2? 0.4?
serpin?peptidase?inhibitor,?clade?B,?member?11? SERPINB11? 0.4?
nonhomologous?end?joining?factor?1? NHEJ1? 0.4?
WD?repeat?and?FYVE?domain?containing?3? WDFY3? 0.4?
N?acetylated?alpha?linked?acidic?dipeptidase?like?1? NAALADL1? 0.4?
Tripartite?motif?containing?16?like? TRIM16L? 0.4?
histidine?triad?nucleotide?binding?protein?3? HINT3? 0.4?
thioredoxin?like?4B? TXNL4B? 0.39?
similar?to?Complement?C3?precursor? LOC653879? 0.39?
similar?to?Interferon?induced?transmembrane?protein?3?? LOC391020? 0.39?
syntrophin,?beta?2? SNTB2? 0.39? 0.02?
chromosome?12?open?reading?frame?4? C12orf4? 0.39?
proteasome?subunit,?alpha?2? PSMA2? 0.39?
coenzyme?Q10?homolog?? COQ10B? 0.39?
zinc?finger?protein?313? ZNF313? 0.39? 0.03?
metallothionein?1X? MT1X? 0.39?
coiled?coil?domain?containing?32? CCDC32? 0.39?
centaurin,?alpha?1? CENTA1? 0.39?
microtubule?associated?protein?2? MAP2? 0.39?
ubiquitin?specific?peptidase?15? USP15? 0.39?
calcium?channel,?voltage?dependent,???subunit?6? CACNG6? 0.39?
SCO?cytochrome?oxidase?deficient?homolog?1?? SCO1? 0.38?
zinc?finger?protein?655? ZNF655? 0.38?
deleted?in?lymphocytic?leukemia,?2?? DLEU2?? 0.38?
hypothetical?protein?FLJ36032? FLJ36032? 0.38?
Hermansky?Pudlak?syndrome?3? HPS3? 0.38? 0.07?
arylsulfatase?family,?member?J? ARSJ? 0.38?
Catechol?O?methyltransferase? COMT? 0.38?
zinc?finger?protein?267? ZNF267? 0.38?
LysM,?putative?peptidoglycan?binding,?domain?containing?2? LYSMD2? 0.38?
adult?retina?protein? LOC153222? 0.38?
Mdm4?? MDM4? 0.38?
Rho?family?GTPase?3? RND3? 0.38?
cholinergic?receptor,?nicotinic,?gamma? CHRNG? 0.38?
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methylenetetrahydrofolate?dehydrogenase?2? MTHFD2? 0.37?
dual?specificity?tyrosine?(Y)?phosphorylation?regulated?kinase?4? DYRK4? 0.37?
nuclear?factor?(erythroid?derived?2)?like?3? NFE2L3? 0.37?
toll?interleukin?1?receptor?(TIR)?domain?containing?adaptor?protein? TIRAP? 0.37?
solute?carrier?family?10?member?1? SLC10A1? 0.37?
zygote?arrest?1?? ZAR1?? 0.37?
Nasal?embryonic?LHRH?factor? NELF? 0.37?
FLJ36874?protein? FLJ36874? 0.37? 0.14?
PI?3?kinase?related?kinase?SMG?1?? SMG1?? 0.37?
calcium/calmodulin?dependent?protein?kinase?II??? CAMK2D? 0.37?
multiple?inositol?polyphosphate?histidine?phosphatase,?1? MINPP1? 0.37?
N?ethylmaleimide?sensitive?factor?attachment?protein,??? NAPA? 0.37? 0.06?
Proteasome?subunit?alpha?7? PSMA3? 0.37? 0.06?
serpin?peptidase?inhibitor,?clade?B?member?4? SERPINB4? 0.37?
tripartite?motif?containing?14? TRIM14? 0.37? 0.02?
solute?carrier?family?30?,?member?7? SLC30A7? 0.37? 0.04?
Sine?oculis?homeobox?homolog?1?? SIX1? 0.37?
interleukin?22?receptor,?alpha?1? IL22RA1? 0.37?
Phosphodiesterase?4D?interacting?protein?? PDE4DIP? 0.37?
transmembrane?protein?173? TMEM173? 0.37?
ATPase?V0?subunit?d2? ATP6V0D2? 0.37?
glucosaminyl?(N?acetyl)?transferase?3? GCNT3? 0.37?
Hypothetical?protein?LOC200169? LOC200169? 0.37?
sphingosine?kinase?1? SPHK1? 0.36?
breast?cancer?anti?estrogen?resistance?3? BCAR3? 0.36?
protein?kinase?D2? PRKD2? 0.36?
tripartite?motif?containing?26? TRIM26? 0.36?
ureidopropionase,?beta? UPB1? 0.36?
LIM?domain?and?actin?binding?1? LIMA1? 0.36? 0.06?
HLA?G?histocompatibility?antigen,?class?I,?G? HLA?G? 0.36? 0.12?
peptidylprolyl?isomerase?A?(cyclophilin?A)?? PPIA?? 0.36?
hypothetical?protein?FLJ43663? FLJ43663? 0.36?
DnaJ?(Hsp40)?homolog,?subfamily?C,?member?12? DNAJC12? 0.36? 0.05?
solute?carrier?family?2?member?3? SLC2A3? 0.36? 0.04?
solute?carrier?family?7?member?8? SLC7A8? 0.36?
hypothetical?protein?LOC153684? LOC153684? 0.36?
family?with?sequence?similarity?82,?member?C? FAM82C? 0.36?
family?with?sequence?similarity?120A? FAM120A? 0.36?
Spondin?2,?extracellular?matrix?protein? SPON2? 0.36?
tubulin?folding?cofactor?E?like? TBCEL? 0.36?
RNA?binding?protein? FLJ20273? 0.36? 0.12?
hypothetical?protein?MGC4677? MGC4677? 0.36?
DENN/MADD?domain?containing?1A? DENND1A? 0.35?
tetraspanin?17? TSPAN17? 0.35?
KIAA0746?protein? KIAA0746? 0.35?
chromosome?16?open?reading?frame?7? C16orf7? 0.35?
glutathione?S?transferase?kappa?1? GSTK1? 0.35?
guanylate?kinase?1?? GUK1? 0.35?
YEATS?domain?containing?2? YEATS2? 0.35?
hypothetical?protein?LOC730961? LOC730961? 0.35?
prokineticin?receptor?2? PROKR2? 0.35?
ectodermal?neural?cortex?? ENC1? 0.35?
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deleted?in?lymphocytic?leukemia?2?like? DLEU2L? 0.35?
CDC42?small?effector?2? CDC42SE2? 0.35?
chromosome?9?open?reading?frame?103? C9orf103? 0.35?
CTD?small?phosphatase?2? CTDSP2? 0.35? 0.02?
interleukin?4?receptor? IL4R? 0.35? 0.02?
calreticulin? CALR? 0.35?
Calcium/calmodulin?dependent?protein?kinase?II??? CAMK2B? 0.35?
Pleckstrin?homology?domain?containing,?family?A?member?8? PLEKHA8? 0.35?
hypothetical?protein?LOC147299? LOC147299? 0.35?
ethanolamine?kinase?1?? ETNK1? 0.35?
transglutaminase?2? TGM2? 0.35?
biliverdin?reductase?A?? BLVRA? 0.35? 0.01?
G?protein?coupled?receptor?158? GPR158? 0.35?
F?box?protein?11? FBXO11? 0.35?
serine/threonine?kinase?17a?? STK17A? 0.35?
KIAA0040? KIAA0040? 0.34? 0.05?
TIA1?cytotoxic?granule?associated?RNA?binding?protein? TIA1? 0.34?
Esophageal?cancer?associated?protein? MGC16824? 0.34?
Nuclear?factor?of?activated?T?cells?5,?tonicity?responsive? NFAT5? 0.34?
zinc?finger?protein?302? ZNF302? 0.34? 0.02?
metallothionein?1H?like?protein? LOC645745? 0.34?
caspase?2,?apoptosis?related?cysteine?peptidase?? CASP2? 0.34?
similar?to?60S?ribosomal?protein?L35? LOC643653? 0.34?
RAR?related?orphan?receptor?B? RORB? 0.34?
N?deacetylase/N?sulfotransferase?2? NDST2? 0.34?
pannexin?1? PANX1? 0.34?
BTB?(POZ)?domain?containing?9? BTBD9? 0.34?
mediator?of?RNA?polymerase?II?transcription,?subunit?25?? MED25?? 0.34?
DENN/MADD?domain?containing?3? DENND3? 0.34?
DIM1?dimethyladenosine?transferase?1?like?? DIMT1L? 0.34? 0.01?
Phosphorylase?kinase,?beta? PHKB? 0.34?
chromosome?7?open?reading?frame?29? C7orf29? 0.34?
sal?like?2?? SALL2? 0.34?
spermatogenesis?associated?4? SPATA4? 0.34?
myosin,?light?chain?4,?alkali;?atrial,?embryonic? MYL4? 0.34?
Ubiquitin?specific?peptidase?12? USP12? 0.34?
folate?receptor?1?? FOLR1? 0.34?
Ring?finger?protein?39? RNF39? 0.34?
pseudouridylate?synthase?3?? PUS3? 0.33?
PTPRF?interacting?protein,?binding?protein?1?? PPFIBP1? 0.33? 0?
Wiskott?Aldrich?syndrome?? WAS? 0.33?
zinc?finger,?RAN?binding?domain?containing?2? ZRANB2? 0.33?
metallothionein?1F?? MT1F? 0.33? 0.07?
enhancer?of?zeste?homolog?1?? EZH1? 0.33?
Mannosidase,?alpha,?class?1A,?member?1? MAN1A1? 0.33?
hypothetical?protein?LOC283012? LOC283012? 0.33?
myeloid?cell?leukemia?sequence?1?? MCL1? 0.33? 0.22?
butyrophilin?like?9? BTNL9? 0.33?
hypothetical?gene?supported?by?BC019009? LOC283902? 0.33?
hypothetical?protein?FLJ40125? FLJ40125? 0.33?
BCL2?associated?athanogene?2? BAG2? 0.33?
prefoldin?subunit?4? PFDN4? 0.33?
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intraflagellar?transport?80?homolog?? IFT80? 0.33?
tripartite?motif?containing?5? TRIM5? 0.33?
zinc?finger?protein?236? ZNF236? 0.33?
runt?related?transcription?factor?3? RUNX3? 0.33? 0.02?
TatD?DNase?domain?containing?1? TATDN1? 0.33?
KIAA0143?protein? KIAA0143? 0.33? 0.01?
cysteine?and?glycine?rich?protein?1? CSRP1? 0.33?
cytokine?inducible?SH2?containing?protein? CISH? 0.33? 0.08?
lipoyltransferase?1? LIPT1? 0.33?
DPH3,?KTI11?homolog? DPH3? 0.32?
single?stranded?DNA?binding?protein?4?? SSBP4?? 0.32? 0.04?
WAP?four?disulfide?core?domain?2? WFDC2? 0.32?
caspase?1?dominant?negative?inhibitor?pseudo?ICE? COP1? 0.32?
RAB18,?member?RAS?oncogene?family? RAB18? 0.32? 0.06?
sorbin?and?SH3?domain?containing?3? SORBS3? 0.32?
Tsukushin? TSKU? 0.32?
similar?to?CG3558?PA,?isoform?A?? LOC729830?? 0.32?
methyl?CpG?binding?domain?protein?4? MBD4? 0.32?
Sterile?alpha?motif?domain?containing?4A? SAMD4A? 0.32?
Hedgehog?acyltransferase? HHAT? 0.32?
ubiquitin?conjugating?enzyme?E2B?? UBE2B? 0.32?
hypothetical?protein?BC017488? LOC124446? 0.32?
endothelial?differentiation,?lysophosphatidic?acid?G?protein?coupled?receptor,?
2? EDG2? 0.32? ?
ubiquitin?specific?peptidase?42? USP42? 0.32? 0.05?
Thioredoxin? TXN? 0.32?
sialic?acid?binding?Ig?like?lectin?1,?sialoadhesin? SIGLEC1? 0.32?
transcription?factor?AP?2?alpha?? TFAP2A? 0.32?
oncostatin?M?receptor? OSMR? 0.32? 0.03?
SCY1?like?3?? SCYL3? 0.31?
CDC42?effector?protein?(Rho?GTPase?binding)?4? CDC42EP4? 0.31?
transmembrane?protein?49? TMEM49? 0.31?
golgi?associated,???adaptin?ear?containing,?ARF?binding?protein?3? GGA3? 0.31?
Src?like?adaptor? SLA? 0.31?
B?cell?CLL/lymphoma?3? BCL3? 0.31?
epiplakin?1?? EPPK1? 0.31?
golgi?autoantigen,?golgin?subfamily?a,?3? GOLGA3? 0.31?
DTW?domain?containing?1? DTWD1? 0.31?
GTP?cyclohydrolase?1?? GCH1? 0.31?
protein?tyrosine?phosphatase?type?2? PTPN2? 0.31? 0.02?
ring?finger?protein?149?? RNF149?? 0.31?
Major?histocompatibility?complex,?class?I,?C? HLA?C? 0.31?
MYC?associated?zinc?finger?protein?? MAZ? 0.31?
zinc?finger?CCCH?type?containing?11A? ZC3H11A? 0.31?
Cullin?3? CUL3? 0.31?
Mps?One?Binder?kinase?activator?like?1B?? MOBK1B? 0.31? 0.05?
serine/threonine?kinase?3?? STK3? 0.31? 0.05?
CCAAT/enhancer?binding?protein?(C/EBP),?beta? CEBPB? 0.31?
melanoma?antigen?family?A,?9?? MAGEA9?? 0.31?
MAP/microtubule?affinity?regulating?kinase?4? MARK4? 0.31?
Multiple?C2?domains,?transmembrane?2? MCTP2? 0.31?
solute?carrier?family?22?member?15? SLC22A15? 0.31?
phosphatidylinositol?glycan?anchor?biosynthesis,?class?L? PIGL? 0.31?
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proteasome?maturation?protein? POMP? 0.3?
kinesin?family?member?9? KIF9? 0.3? 0.02?
F?box?protein?7? FBXO7? 0.3? 0.04?
lectin,?galactoside?binding,?soluble,?8?? LGALS8? 0.3?
mucin?13? MUC13? 0.3?
fibromodulin? FMOD? 0.3?
oxidative?stress?induced?growth?inhibitor?family?member?2? OSGIN2? 0.3?
IKAROS?family?zinc?finger?1?? IKZF1? 0.3?
annexin?A3? ANXA3? 0.3?
complement?component?1,?r?subcomponent?like? C1RL? 0.3?
candidate?tumor?suppressor?in?ovarian?cancer?2? OVCA2? 0.3?
hexose?6?phosphate?dehydrogenase?? H6PD? 0.3?
cofactor?required?for?Sp1?transcriptional?activation,?subunit?9,?33kDa? CRSP9? 0.3?
chromosome?1?open?reading?frame?41?? C1orf41?? 0.3?
NADH?dehydrogenase?1???subcomplex?3? NDUFB3? 0.3?
kinesin?heavy?chain?member?2A? KIF2A? 0.3? 0.05?
proteasome?subunit?beta?4? PSMB2? 0.3?
Ras?like?without?CAAX?1? RIT1? 0.3?
OK/SW?cl.16? LOC440552? 0.3? 0.01?
RNA?binding?motif?protein?3? RBM3? 0.3?
Hypothetical?LOC440900? LOC440900? 0.3?
syntaxin?17? STX17? 0.3? 0.01?
PI?3?kinase?related?kinase?SMG?1?pseudogene? LOC595101? 0.3?
Hypothetical?protein?FLJ32569? FLJ32569? 0.3?
keratin?17? KRT17? 0.29? 0.02?
Structural?maintenance?of?chromosomes?5? SMC5? 0.29?
chromosome?8?open?reading?frame?59? C8orf59? 0.29?
major?facilitator?superfamily?domain?containing?7? MFSD7? 0.29?
homolog?of?rat?pragma?of?Rnd2? DKFZp761P0423? 0.29?
establishment?of?cohesion?1?homolog?2?? ESCO2? 0.29?
GTP?binding?protein?1? GTPBP1? 0.29?
centaurin,?delta?1? CENTD1? 0.29?
zinc?finger,?RAN?binding?domain?containing?3? ZRANB3? 0.29?
chromosome?12?open?reading?frame?44? C12orf44? 0.29?
Solute?carrier?family?24?member?3? SLC24A3? 0.29?
Chromosome?X?open?reading?frame?45? CXorf45? 0.29?
Ribosomal?protein?S10? RPS10? 0.29? 0.01?
solute?carrier?family?27?member?1? SLC27A1? 0.29?
vacuolar?protein?sorting?54?homolog?? VPS54? 0.29? 0?
retinitis?pigmentosa?2?? RP2? 0.29?
Eukaryotic?translation?elongation?factor?1?epsilon?1? EEF1E1? 0.29?
proteasome?subunit?alpha?5? PSMA5? 0.29? 0.01?
putative?homeodomain?transcription?factor?2? PHTF2? 0.29?
mucosa?associated?lymphoid?tissue?lymphoma?translocation?gene?1? MALT1? 0.29?
Desmoplakin? DSP? 0.29?
Ubiquitin?binding?protein?homolog? UBPH? 0.29?
bromodomain?adjacent?to?zinc?finger?domain,?2A? BAZ2A? 0.29?
C1GALT1?specific?chaperone?1? C1GALT1C1? 0.29?
development?and?differentiation?enhancing?factor?like?1? DDEFL1? 0.29?
non?imprinted?in?Prader?Willi/Angelman?syndrome?1? NIPA1? 0.29?
chromosome?7?open?reading?frame?28A?? C7orf28A?? 0.29?
RAB6?interacting?protein?1? RAB6IP1? 0.29?
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Unc?51?like?kinase?4?? ULK4? 0.29?
zinc?finger?protein?582? ZNF582? 0.29?
polymerase?(RNA)?II?polypeptide?K,?7.0kDa? POLR2K? 0.29?
KIAA0256?gene?product? KIAA0256? 0.29?
sema,?immunoglobulin,?transmembrane?and?short?cytoplasmic?domain?4F? SEMA4F? 0.29?
phosphodiesterase?4D,?cAMP?specific?? PDE4D? 0.29?
solute?carrier?family?26,?member?11? SLC26A11? 0.29?
endothelin?receptor?type?A? EDNRA? 0.28? 0.02?
oxoglutarate?dehydrogenase? OGDH? 0.28?
selenoprotein?I? SELI? 0.28?
F?box?protein?3? FBXO3? 0.28?
hypothetical?protein?FLJ12355? FLJ12355? 0.28?
CD22?molecule?? CD22?? 0.28?
PTK2?protein?tyrosine?kinase?2? PTK2? 0.28?
follicular?lymphoma?variant?translocation?1? FVT1? 0.28?
integrin,?alpha?6? ITGA6? 0.28?
ubiquitin?activating?enzyme?E1?like?2? UBE1L2? 0.28? 0.03?
major?histocompatibility?complex,?class?I,?F? HLA?F? 0.28? 0.01?
dystrophia?myotonica?containing?WD?repeat?motif? DMWD? 0.28?
nucleoporin?160kDa? NUP160? 0.28?
chromosome?22?open?reading?frame?27? C22orf27? 0.28?
cathepsin?L?like?3? CTSLL3? 0.28?
sorting?nexin?13? SNX13? 0.28?
tetratricopeptide?repeat?domain?35? TTC35? 0.28?
hypothetical?protein?MGC46336? MGC46336? 0.28? 0.02?
transmembrane?channel?like?5? TMC5? 0.28?
transducer?of?ERBB2,?1? TOB1? 0.28?
major?histocompatibility?complex,?class?II,?DO?alpha? HLA?DOA? 0.28?
Cullin?4A? CUL4A? 0.28? 0?
chromosome?14?open?reading?frame?11? C14orf11? 0.28?
B?cell?CLL/lymphoma?10? BCL10? 0.28?
PHD?finger?protein?15? PHF15? 0.28?
F?box?and?leucine?rich?repeat?protein?5? FBXL5? 0.28? 0?
chromosome?5?open?reading?frame?4? C5orf4? 0.28?
similar?to?CG9643?PA? LOC399818? 0.28?
BCL2?like?11?? BCL2L11? 0.28?
scotin? SCOTIN? 0.28?
MCF.2?cell?line?derived?transforming?sequence?like? MCF2L? 0.28?
Tetratricopeptide?repeat?domain?7A? TTC7A? 0.28?
Sorbin?and?SH3?domain?containing?2? SORBS2? 0.27?
Nedd4?family?interacting?protein?1? NDFIP1? 0.27? 0.01?
similar?to?ATP?binding?cassette,?sub?family?C,?member?6? LOC730013? 0.27?
HORMA?domain?containing?1? HORMAD1? 0.27?
Heat?shock?protein?90kDa?beta?member?1? HSP90B1? 0.27? 0?
hypothetical?protein?FLJ35429? RP3?377H14.5? 0.27?
ESF1,?nucleolar?pre?rRNA?processing?protein,?homolog?? ESF1? 0.27?
transgelin? TAGLN? 0.27?
zinc?finger?CCCH?type?containing?5? ZC3H5? 0.27?
hemoglobin,?alpha?1?? HBA1? 0.27?
Chromosome?1?open?reading?frame?75? C1orf75? 0.27?
hairy?and?enhancer?of?split?4?? HES4? 0.27?
oligonucleotide/oligosaccharide?binding?fold?containing?2A? OBFC2A? 0.27?
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Protein?tyrosine?phosphatase?domain?containing?1? PTPDC1? 0.27?
ubiquitin?B?? UBB?? 0.27?
Myosin?regulatory?light?chain?MRCL3? MRCL3? 0.27?
GA?binding?protein?transcription?factor,???subunit?2? GABPB2? 0.27?
butyrophilin,?subfamily?2,?member?A2? BTN2A2? 0.27?
solute?carrier?family?30?member?5? SLC30A5? 0.27?
Tax1?binding?protein?3? TAX1BP3? 0.27?
AT?rich?interactive?domain?1B?? ARID1B? 0.27?
cell?division?cycle?26?homolog?? CDC26? 0.27?
zinc?finger?protein?364? ZNF364? 0.27?
CDC5?cell?division?cycle?5?like?? CDC5L? 0.27?
inhibin,?beta?C? INHBC? 0.27?
chromosome?20?open?reading?frame?160? C20orf160? 0.27?
hypothetical?LOC389362? RP11?506K6.3? 0.27?
golgi?transport?1?homolog?B?? GOLT1B? 0.27?
transcription?factor?20?? TCF20? 0.27?
DnaJ?(Hsp40)?homolog,?subfamily?B,?member?1? DNAJB1? 0.27?
HIV?1?Rev?binding?protein? HRB? 0.27?
Eukaryotic?translation?initiation?factor?3,?subunit?5?epsilon,?47kDa? EIF3S5? 0.27?
NADH?dehydrogenase?Fe?S?protein?1,?75kDa?? NDUFS1? 0.27?
chromosome?22?open?reading?frame?13? C22orf13? 0.27?
zinc?finger,?CDGSH?type?domain?2? ZCD2? 0.27?
MYC?associated?factor?X? MAX? 0.27?
family?with?sequence?similarity?80,?member?A? FAM80A? 0.27?
chromatin?modifying?protein?5? CHMP5? 0.27?
chromosome?9?open?reading?frame?46? C9orf46? 0.27?
voltage?dependent?anion?channel?1? VDAC1? 0.27?
interleukin?17?receptor?B? IL17RB? 0.27?
ribosomal?protein?S27?like? RPS27L? 0.27? 0.07?
Myosin?X? MYO10? 0.27?
DnaJ?(Hsp40)?homolog,?subfamily?A,?member?1? DNAJA1? 0.26? 0.07?
fibroblast?growth?factor?receptor?1?? FGFR1? 0.26?
hypothetical?protein?LOC729556?? LOC729556?? 0.26?
PHD?finger?protein?7? PHF7? 0.26?
caspase?8? CASP8? 0.26?
prominin?2? PROM2? 0.26?
carbonic?anhydrase?XI? CA11? 0.26?
zinc?finger?and?BTB?domain?containing?24? ZBTB24? 0.26?
Hypothetical?protein?LOC730096? LOC730096? 0.26?
NIK?and?IKK??binding?protein? NIBP? 0.26?
Tyrosylprotein?sulfotransferase?1? TPST1? 0.26?
OCIA?domain?containing?1? OCIAD1? 0.26?
Sterile?alpha?motif?domain?containing?4B? SAMD4B? 0.26?
SERTA?domain?containing?1? SERTAD1? 0.26?
Glyceraldehyde?3?phosphate?dehydrogenase,?spermatogenic? GAPDHS? 0.26?
zinc?finger?protein?219? ZNF219? 0.26?
proline?rich?3? PRR3? 0.26?
poly?(ADP?ribose)?polymerase?family,?member?8? PARP8? 0.26?
coiled?coil?alpha?helical?rod?protein?1? CCHCR1? 0.26?
ADP?ribosylation?factor?6? ARF6? 0.26?
putative?nucleic?acid?binding?protein?RY?1? RY1? 0.26?
Family?with?sequence?similarity?125,?member?A? FAM125A? 0.26?
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ADP?ribosylation?factor?3?? ARF3? 0.26?
Vacuolar?protein?sorting?8?homolog?? VPS8? 0.26?
mixed?lineage?kinase?domain?like? MLKL? 0.26?
Cell?division?cycle?42?? CDC42? 0.26?
vesicle?associated?membrane?protein?8?? VAMP8? 0.26?
NECAP?endocytosis?associated?1? NECAP1? 0.26?
bromodomain?adjacent?to?zinc?finger?domain,?1A? BAZ1A? 0.26?
gelsolin?? GSN? 0.26?
SH2B?adaptor?protein?2? SH2B2? 0.26?
TP53RK?binding?protein? TPRKB? 0.26?
microtubule?associated?protein?tau? MAPT? 0.26?
lysosomal?associated?multispanning?membrane?protein?5? LAPTM5? 0.26?
sorting?nexin?6? SNX6? 0.26?
protein?phosphatase?1,?regulatory?subunit?11? PPP1R11? 0.26?
peroxiredoxin?3? PRDX3? 0.26?
opioid?growth?factor?receptor?like?1? OGFRL1? 0.26?
annexin?A7? ANXA7? 0.26?
serine?peptidase?inhibitor,?Kazal?type?6? SPINK6? 0.26?
RUN?and?FYVE?domain?containing?2? RUFY2? 0.26?
mitochondrial?ribosomal?protein?L14? MRPL14? 0.26?
Atrophin?1? ATN1? 0.26?
Similar?to?60S?ribosomal?protein?L26?like?1? LOC653147? 0.26?
OAF?homolog? OAF? 0.26?
La?ribonucleoprotein?domain?family,?member?4? LARP4? 0.26?
hypothetical?protein?LOC222070? LOC222070? 0.26?
ribosomal?protein?L14? RPL14? 0.17? 0.28?
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